{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "bf53710b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mFirst, I need to take a screenshot of the website.\n",
      "Action: TakeScreenshotOfCompendium\n",
      "Action Input: output_path='compendium_screenshot.png'\u001b[0m"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\selenium\\webdriver\\remote\\webdriver.py:994: UserWarning: name used for saved screenshot does not match file type. It should end with a `.png` extension\n",
      "  return self.get_screenshot_as_file(filename)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3moutput_path='compendium_screenshot.png'\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mNow that I have the screenshot, I need to extract the text from it.\n",
      "Action: ExtractTextFromImage\n",
      "Action Input: image_path='compendium_screenshot.png'\u001b[0m"
     ]
    },
    {
     "ename": "FileNotFoundError",
     "evalue": "[Errno 2] No such file or directory: \"image_path='compendium_screenshot.png'\"",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mFileNotFoundError\u001b[39m                         Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[10]\u001b[39m\u001b[32m, line 92\u001b[39m\n\u001b[32m     84\u001b[39m agent = initialize_agent(\n\u001b[32m     85\u001b[39m     tools=tools,\n\u001b[32m     86\u001b[39m     llm=llm,\n\u001b[32m     87\u001b[39m     agent=AgentType.ZERO_SHOT_REACT_DESCRIPTION,\n\u001b[32m     88\u001b[39m     verbose=\u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[32m     89\u001b[39m )\n\u001b[32m     91\u001b[39m \u001b[38;5;66;03m# Run the workflow\u001b[39;00m\n\u001b[32m---> \u001b[39m\u001b[32m92\u001b[39m result = \u001b[43magent\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mTake a screenshot of compendium.ch, extract text from it, and tell me what action to take.\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[32m     93\u001b[39m \u001b[38;5;28mprint\u001b[39m(result)\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\_api\\deprecation.py:188\u001b[39m, in \u001b[36mdeprecated.<locals>.deprecate.<locals>.warning_emitting_wrapper\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m    186\u001b[39m     warned = \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[32m    187\u001b[39m     emit_warning()\n\u001b[32m--> \u001b[39m\u001b[32m188\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mwrapped\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\chains\\base.py:606\u001b[39m, in \u001b[36mChain.run\u001b[39m\u001b[34m(self, callbacks, tags, metadata, *args, **kwargs)\u001b[39m\n\u001b[32m    604\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(args) != \u001b[32m1\u001b[39m:\n\u001b[32m    605\u001b[39m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[33m\"\u001b[39m\u001b[33m`run` supports only one positional argument.\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m--> \u001b[39m\u001b[32m606\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43margs\u001b[49m\u001b[43m[\u001b[49m\u001b[32;43m0\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mcallbacks\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcallbacks\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtags\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtags\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m)\u001b[49m[\n\u001b[32m    607\u001b[39m         _output_key\n\u001b[32m    608\u001b[39m     ]\n\u001b[32m    610\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m kwargs \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m args:\n\u001b[32m    611\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m(kwargs, callbacks=callbacks, tags=tags, metadata=metadata)[\n\u001b[32m    612\u001b[39m         _output_key\n\u001b[32m    613\u001b[39m     ]\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\_api\\deprecation.py:188\u001b[39m, in \u001b[36mdeprecated.<locals>.deprecate.<locals>.warning_emitting_wrapper\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m    186\u001b[39m     warned = \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[32m    187\u001b[39m     emit_warning()\n\u001b[32m--> \u001b[39m\u001b[32m188\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mwrapped\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\chains\\base.py:389\u001b[39m, in \u001b[36mChain.__call__\u001b[39m\u001b[34m(self, inputs, return_only_outputs, callbacks, tags, metadata, run_name, include_run_info)\u001b[39m\n\u001b[32m    357\u001b[39m \u001b[38;5;250m\u001b[39m\u001b[33;03m\"\"\"Execute the chain.\u001b[39;00m\n\u001b[32m    358\u001b[39m \n\u001b[32m    359\u001b[39m \u001b[33;03mArgs:\u001b[39;00m\n\u001b[32m   (...)\u001b[39m\u001b[32m    380\u001b[39m \u001b[33;03m        `Chain.output_keys`.\u001b[39;00m\n\u001b[32m    381\u001b[39m \u001b[33;03m\"\"\"\u001b[39;00m\n\u001b[32m    382\u001b[39m config = {\n\u001b[32m    383\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mcallbacks\u001b[39m\u001b[33m\"\u001b[39m: callbacks,\n\u001b[32m    384\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mtags\u001b[39m\u001b[33m\"\u001b[39m: tags,\n\u001b[32m    385\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mmetadata\u001b[39m\u001b[33m\"\u001b[39m: metadata,\n\u001b[32m    386\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mrun_name\u001b[39m\u001b[33m\"\u001b[39m: run_name,\n\u001b[32m    387\u001b[39m }\n\u001b[32m--> \u001b[39m\u001b[32m389\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43minvoke\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    390\u001b[39m \u001b[43m    \u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    391\u001b[39m \u001b[43m    \u001b[49m\u001b[43mcast\u001b[49m\u001b[43m(\u001b[49m\u001b[43mRunnableConfig\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[43mk\u001b[49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mv\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mk\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mv\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m.\u001b[49m\u001b[43mitems\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mv\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mis\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mnot\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m}\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    392\u001b[39m \u001b[43m    \u001b[49m\u001b[43mreturn_only_outputs\u001b[49m\u001b[43m=\u001b[49m\u001b[43mreturn_only_outputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    393\u001b[39m \u001b[43m    \u001b[49m\u001b[43minclude_run_info\u001b[49m\u001b[43m=\u001b[49m\u001b[43minclude_run_info\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    394\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\chains\\base.py:170\u001b[39m, in \u001b[36mChain.invoke\u001b[39m\u001b[34m(self, input, config, **kwargs)\u001b[39m\n\u001b[32m    168\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[32m    169\u001b[39m     run_manager.on_chain_error(e)\n\u001b[32m--> \u001b[39m\u001b[32m170\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m e\n\u001b[32m    171\u001b[39m run_manager.on_chain_end(outputs)\n\u001b[32m    173\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m include_run_info:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\chains\\base.py:160\u001b[39m, in \u001b[36mChain.invoke\u001b[39m\u001b[34m(self, input, config, **kwargs)\u001b[39m\n\u001b[32m    157\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m    158\u001b[39m     \u001b[38;5;28mself\u001b[39m._validate_inputs(inputs)\n\u001b[32m    159\u001b[39m     outputs = (\n\u001b[32m--> \u001b[39m\u001b[32m160\u001b[39m         \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_call\u001b[49m\u001b[43m(\u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    161\u001b[39m         \u001b[38;5;28;01mif\u001b[39;00m new_arg_supported\n\u001b[32m    162\u001b[39m         \u001b[38;5;28;01melse\u001b[39;00m \u001b[38;5;28mself\u001b[39m._call(inputs)\n\u001b[32m    163\u001b[39m     )\n\u001b[32m    165\u001b[39m     final_outputs: Dict[\u001b[38;5;28mstr\u001b[39m, Any] = \u001b[38;5;28mself\u001b[39m.prep_outputs(\n\u001b[32m    166\u001b[39m         inputs, outputs, return_only_outputs\n\u001b[32m    167\u001b[39m     )\n\u001b[32m    168\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1624\u001b[39m, in \u001b[36mAgentExecutor._call\u001b[39m\u001b[34m(self, inputs, run_manager)\u001b[39m\n\u001b[32m   1622\u001b[39m \u001b[38;5;66;03m# We now enter the agent loop (until it returns something).\u001b[39;00m\n\u001b[32m   1623\u001b[39m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28mself\u001b[39m._should_continue(iterations, time_elapsed):\n\u001b[32m-> \u001b[39m\u001b[32m1624\u001b[39m     next_step_output = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_take_next_step\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1625\u001b[39m \u001b[43m        \u001b[49m\u001b[43mname_to_tool_map\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1626\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcolor_mapping\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1627\u001b[39m \u001b[43m        \u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1628\u001b[39m \u001b[43m        \u001b[49m\u001b[43mintermediate_steps\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1629\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1630\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1631\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(next_step_output, AgentFinish):\n\u001b[32m   1632\u001b[39m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m._return(\n\u001b[32m   1633\u001b[39m             next_step_output, intermediate_steps, run_manager=run_manager\n\u001b[32m   1634\u001b[39m         )\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1330\u001b[39m, in \u001b[36mAgentExecutor._take_next_step\u001b[39m\u001b[34m(self, name_to_tool_map, color_mapping, inputs, intermediate_steps, run_manager)\u001b[39m\n\u001b[32m   1321\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m_take_next_step\u001b[39m(\n\u001b[32m   1322\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   1323\u001b[39m     name_to_tool_map: Dict[\u001b[38;5;28mstr\u001b[39m, BaseTool],\n\u001b[32m   (...)\u001b[39m\u001b[32m   1327\u001b[39m     run_manager: Optional[CallbackManagerForChainRun] = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m   1328\u001b[39m ) -> Union[AgentFinish, List[Tuple[AgentAction, \u001b[38;5;28mstr\u001b[39m]]]:\n\u001b[32m   1329\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m._consume_next_step(\n\u001b[32m-> \u001b[39m\u001b[32m1330\u001b[39m         \u001b[43m[\u001b[49m\n\u001b[32m   1331\u001b[39m \u001b[43m            \u001b[49m\u001b[43ma\u001b[49m\n\u001b[32m   1332\u001b[39m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43ma\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_iter_next_step\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1333\u001b[39m \u001b[43m                \u001b[49m\u001b[43mname_to_tool_map\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1334\u001b[39m \u001b[43m                \u001b[49m\u001b[43mcolor_mapping\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1335\u001b[39m \u001b[43m                \u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1336\u001b[39m \u001b[43m                \u001b[49m\u001b[43mintermediate_steps\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1337\u001b[39m \u001b[43m                \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1338\u001b[39m \u001b[43m            \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1339\u001b[39m \u001b[43m        \u001b[49m\u001b[43m]\u001b[49m\n\u001b[32m   1340\u001b[39m     )\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1330\u001b[39m, in \u001b[36m<listcomp>\u001b[39m\u001b[34m(.0)\u001b[39m\n\u001b[32m   1321\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m_take_next_step\u001b[39m(\n\u001b[32m   1322\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   1323\u001b[39m     name_to_tool_map: Dict[\u001b[38;5;28mstr\u001b[39m, BaseTool],\n\u001b[32m   (...)\u001b[39m\u001b[32m   1327\u001b[39m     run_manager: Optional[CallbackManagerForChainRun] = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m   1328\u001b[39m ) -> Union[AgentFinish, List[Tuple[AgentAction, \u001b[38;5;28mstr\u001b[39m]]]:\n\u001b[32m   1329\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m._consume_next_step(\n\u001b[32m-> \u001b[39m\u001b[32m1330\u001b[39m         \u001b[43m[\u001b[49m\n\u001b[32m   1331\u001b[39m \u001b[43m            \u001b[49m\u001b[43ma\u001b[49m\n\u001b[32m   1332\u001b[39m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43ma\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_iter_next_step\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1333\u001b[39m \u001b[43m                \u001b[49m\u001b[43mname_to_tool_map\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1334\u001b[39m \u001b[43m                \u001b[49m\u001b[43mcolor_mapping\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1335\u001b[39m \u001b[43m                \u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1336\u001b[39m \u001b[43m                \u001b[49m\u001b[43mintermediate_steps\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1337\u001b[39m \u001b[43m                \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1338\u001b[39m \u001b[43m            \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1339\u001b[39m \u001b[43m        \u001b[49m\u001b[43m]\u001b[49m\n\u001b[32m   1340\u001b[39m     )\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1415\u001b[39m, in \u001b[36mAgentExecutor._iter_next_step\u001b[39m\u001b[34m(self, name_to_tool_map, color_mapping, inputs, intermediate_steps, run_manager)\u001b[39m\n\u001b[32m   1413\u001b[39m     \u001b[38;5;28;01myield\u001b[39;00m agent_action\n\u001b[32m   1414\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m agent_action \u001b[38;5;129;01min\u001b[39;00m actions:\n\u001b[32m-> \u001b[39m\u001b[32m1415\u001b[39m     \u001b[38;5;28;01myield\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_perform_agent_action\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1416\u001b[39m \u001b[43m        \u001b[49m\u001b[43mname_to_tool_map\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mcolor_mapping\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43magent_action\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mrun_manager\u001b[49m\n\u001b[32m   1417\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1437\u001b[39m, in \u001b[36mAgentExecutor._perform_agent_action\u001b[39m\u001b[34m(self, name_to_tool_map, color_mapping, agent_action, run_manager)\u001b[39m\n\u001b[32m   1435\u001b[39m         tool_run_kwargs[\u001b[33m\"\u001b[39m\u001b[33mllm_prefix\u001b[39m\u001b[33m\"\u001b[39m] = \u001b[33m\"\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m   1436\u001b[39m     \u001b[38;5;66;03m# We then call the tool on the tool input to get an observation\u001b[39;00m\n\u001b[32m-> \u001b[39m\u001b[32m1437\u001b[39m     observation = \u001b[43mtool\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1438\u001b[39m \u001b[43m        \u001b[49m\u001b[43magent_action\u001b[49m\u001b[43m.\u001b[49m\u001b[43mtool_input\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1439\u001b[39m \u001b[43m        \u001b[49m\u001b[43mverbose\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mverbose\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1440\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcolor\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcolor\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1441\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcallbacks\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m.\u001b[49m\u001b[43mget_child\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01melse\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[32m   1442\u001b[39m \u001b[43m        \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mtool_run_kwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1443\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1444\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m   1445\u001b[39m     tool_run_kwargs = \u001b[38;5;28mself\u001b[39m._action_agent.tool_run_logging_kwargs()\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\tools\\base.py:775\u001b[39m, in \u001b[36mBaseTool.run\u001b[39m\u001b[34m(self, tool_input, verbose, start_color, color, callbacks, tags, metadata, run_name, run_id, config, tool_call_id, **kwargs)\u001b[39m\n\u001b[32m    773\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m error_to_raise:\n\u001b[32m    774\u001b[39m     run_manager.on_tool_error(error_to_raise)\n\u001b[32m--> \u001b[39m\u001b[32m775\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m error_to_raise\n\u001b[32m    776\u001b[39m output = _format_output(content, artifact, tool_call_id, \u001b[38;5;28mself\u001b[39m.name, status)\n\u001b[32m    777\u001b[39m run_manager.on_tool_end(output, color=color, name=\u001b[38;5;28mself\u001b[39m.name, **kwargs)\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\tools\\base.py:744\u001b[39m, in \u001b[36mBaseTool.run\u001b[39m\u001b[34m(self, tool_input, verbose, start_color, color, callbacks, tags, metadata, run_name, run_id, config, tool_call_id, **kwargs)\u001b[39m\n\u001b[32m    742\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m config_param := _get_runnable_config_param(\u001b[38;5;28mself\u001b[39m._run):\n\u001b[32m    743\u001b[39m         tool_kwargs = tool_kwargs | {config_param: config}\n\u001b[32m--> \u001b[39m\u001b[32m744\u001b[39m     response = \u001b[43mcontext\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_run\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43mtool_args\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mtool_kwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    745\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m.response_format == \u001b[33m\"\u001b[39m\u001b[33mcontent_and_artifact\u001b[39m\u001b[33m\"\u001b[39m:\n\u001b[32m    746\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(response, \u001b[38;5;28mtuple\u001b[39m) \u001b[38;5;129;01mor\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(response) != \u001b[32m2\u001b[39m:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\tools\\simple.py:105\u001b[39m, in \u001b[36mTool._run\u001b[39m\u001b[34m(self, config, run_manager, *args, **kwargs)\u001b[39m\n\u001b[32m    103\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m config_param := _get_runnable_config_param(\u001b[38;5;28mself\u001b[39m.func):\n\u001b[32m    104\u001b[39m         kwargs[config_param] = config\n\u001b[32m--> \u001b[39m\u001b[32m105\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mfunc\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    106\u001b[39m msg = \u001b[33m\"\u001b[39m\u001b[33mTool does not support sync invocation.\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m    107\u001b[39m \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mNotImplementedError\u001b[39;00m(msg)\n",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[10]\u001b[39m\u001b[32m, line 38\u001b[39m, in \u001b[36mextract_text_from_image\u001b[39m\u001b[34m(image_path)\u001b[39m\n\u001b[32m     37\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mextract_text_from_image\u001b[39m(image_path):\n\u001b[32m---> \u001b[39m\u001b[32m38\u001b[39m     image = \u001b[43mImage\u001b[49m\u001b[43m.\u001b[49m\u001b[43mopen\u001b[49m\u001b[43m(\u001b[49m\u001b[43mimage_path\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     39\u001b[39m     text = pytesseract.image_to_string(image)\n\u001b[32m     40\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m text\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\PIL\\Image.py:3505\u001b[39m, in \u001b[36mopen\u001b[39m\u001b[34m(fp, mode, formats)\u001b[39m\n\u001b[32m   3502\u001b[39m     filename = os.fspath(fp)\n\u001b[32m   3504\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m filename:\n\u001b[32m-> \u001b[39m\u001b[32m3505\u001b[39m     fp = builtins.open(filename, \u001b[33m\"\u001b[39m\u001b[33mrb\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m   3506\u001b[39m     exclusive_fp = \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[32m   3507\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n",
      "\u001b[31mFileNotFoundError\u001b[39m: [Errno 2] No such file or directory: \"image_path='compendium_screenshot.png'\""
     ]
    }
   ],
   "source": [
    "# Setup\n",
    "from langchain.chat_models import ChatOpenAI\n",
    "from langchain.agents import Tool, initialize_agent, AgentType\n",
    "from PIL import Image\n",
    "import pytesseract\n",
    "import os\n",
    "from dotenv import load_dotenv\n",
    "from selenium import webdriver\n",
    "from selenium.webdriver.chrome.options import Options\n",
    "import time\n",
    "\n",
    "# Load env variables\n",
    "load_dotenv()\n",
    "\n",
    "# Set tesseract path\n",
    "pytesseract.pytesseract.tesseract_cmd = r\"C:\\Users\\FahRe\\AppData\\Local\\Programs\\Tesseract-OCR\\tesseract.exe\"\n",
    "\n",
    "# LangSmith setup (optional)\n",
    "os.environ[\"LANGCHAIN_TRACING_V2\"] = \"true\"\n",
    "os.environ[\"LANGCHAIN_PROJECT\"] = \"ReAct-Demo\"\n",
    "\n",
    "# Define a constant for the screenshot path\n",
    "SCREENSHOT_PATH = \"compendium_screenshot.png\"\n",
    "\n",
    "# Function to open compendium.ch and take screenshot\n",
    "def take_screenshot_of_compendium(output_path=SCREENSHOT_PATH):\n",
    "    chrome_options = Options()\n",
    "    chrome_options.add_argument(\"--headless\")  # comment this out if you want to see the browser\n",
    "    driver = webdriver.Chrome(options=chrome_options)\n",
    "    driver.get(\"https://compendium.ch\")\n",
    "    time.sleep(3)  # wait for page to load\n",
    "    driver.save_screenshot(output_path)\n",
    "    driver.quit()\n",
    "    return output_path\n",
    "\n",
    "# OCR function\n",
    "def extract_text_from_image(image_path):\n",
    "    image = Image.open(image_path)\n",
    "    text = pytesseract.image_to_string(image)\n",
    "    return text\n",
    "\n",
    "# --- New function: type into search field ---\n",
    "def type_into_search_field(search_term=\"Dafalgan EXTRA\"):\n",
    "    chrome_options = Options()\n",
    "    chrome_options.add_argument(\"--headless\")  # Optional: remove if you want to see it\n",
    "    driver = webdriver.Chrome(options=chrome_options)\n",
    "    driver.get(\"https://compendium.ch\")\n",
    "    time.sleep(3)\n",
    "\n",
    "    search_input = driver.find_element(\"css selector\", \"input[placeholder*='Suche']\")\n",
    "    search_input.send_keys(search_term)\n",
    "    search_input.submit()\n",
    "\n",
    "    time.sleep(3)\n",
    "    screenshot_path = \"search_result.png\"\n",
    "    driver.save_screenshot(screenshot_path)\n",
    "    driver.quit()\n",
    "    return f\"Typed '{search_term}' into search. Screenshot saved as {screenshot_path}\"\n",
    "\n",
    "\n",
    "# LLM setup\n",
    "llm = ChatOpenAI(temperature=0, model=\"gpt-4\", openai_api_key=os.getenv(\"OPENAI_KEY\"))\n",
    "\n",
    "# Tools for the agent\n",
    "tools = [\n",
    "    Tool(\n",
    "        name=\"TakeScreenshotOfCompendium\",\n",
    "        func=take_screenshot_of_compendium,\n",
    "        description=\"Use this to take a screenshot of compendium.ch\"\n",
    "    ),\n",
    "    Tool(\n",
    "        name=\"ExtractTextFromImage\",\n",
    "        func=extract_text_from_image,\n",
    "        description=\"Use this to read text from a screenshot\"\n",
    "    ),\n",
    "    Tool(\n",
    "            name=\"TypeIntoSearch\",\n",
    "            func=type_into_search_field,\n",
    "            description=\"Use this to type 'Dafalgan EXTRA' into the website's search bar\"\n",
    "        )\n",
    "]\n",
    "\n",
    "# Initialize the agent\n",
    "agent = initialize_agent(\n",
    "    tools=tools,\n",
    "    llm=llm,\n",
    "    agent=AgentType.ZERO_SHOT_REACT_DESCRIPTION,\n",
    "    verbose=True\n",
    ")\n",
    "\n",
    "# Run the workflow\n",
    "result = agent.run(\"Take a screenshot of compendium.ch, extract text from it, and tell me what action to take.\")\n",
    "print(result)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "66c12563",
   "metadata": {},
   "outputs": [],
   "source": [
    "# === ðŸ§± SETUP ===\n",
    "from langchain.chat_models import ChatOpenAI\n",
    "from langchain.agents import Tool, initialize_agent, AgentType\n",
    "from PIL import Image\n",
    "import pytesseract\n",
    "from selenium import webdriver\n",
    "from selenium.webdriver.chrome.options import Options\n",
    "import time\n",
    "import os\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "# Load environment variables\n",
    "load_dotenv()\n",
    "\n",
    "# Setup LangSmith (optional)\n",
    "os.environ[\"LANGCHAIN_TRACING_V2\"] = \"true\"\n",
    "os.environ[\"LANGCHAIN_PROJECT\"] = \"ReAct-HCI-Agent\"\n",
    "\n",
    "# Point Tesseract to the installed path\n",
    "pytesseract.pytesseract.tesseract_cmd = r\"C:\\Users\\FahRe\\AppData\\Local\\Programs\\Tesseract-OCR\\tesseract.exe\"\n",
    "\n",
    "# Screenshot file path constant\n",
    "SCREENSHOT_PATH = \"compendium_screenshot.png\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "ab8fd282",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Take screenshot of compendium.ch\n",
    "def take_screenshot_of_compendium(output_path=SCREENSHOT_PATH):\n",
    "    chrome_options = Options()\n",
    "    chrome_options.add_argument(\"--headless\")\n",
    "    driver = webdriver.Chrome(options=chrome_options)\n",
    "    driver.get(\"https://compendium.ch\")\n",
    "    time.sleep(3)\n",
    "    driver.save_screenshot(output_path)\n",
    "    driver.quit()\n",
    "    return f\"Screenshot saved to {output_path}\"\n",
    "\n",
    "# OCR from screenshot\n",
    "def extract_text_from_image(image_path=SCREENSHOT_PATH):\n",
    "    image = Image.open(image_path)\n",
    "    text = pytesseract.image_to_string(image)\n",
    "    return text\n",
    "\n",
    "# Type into the search bar\n",
    "def type_into_search_field(search_term=\"Dafalgan EXTRA\"):\n",
    "    chrome_options = Options()\n",
    "    chrome_options.add_argument(\"--headless\")\n",
    "    driver = webdriver.Chrome(options=chrome_options)\n",
    "    driver.get(\"https://compendium.ch\")\n",
    "    time.sleep(3)\n",
    "\n",
    "    # Locate search input and enter term\n",
    "    search_input = driver.find_element(\"css selector\", \"input[placeholder*='Suche']\")\n",
    "    search_input.send_keys(search_term)\n",
    "    search_input.submit()\n",
    "\n",
    "    time.sleep(3)\n",
    "    screenshot_path = \"search_result.png\"\n",
    "    driver.save_screenshot(screenshot_path)\n",
    "    driver.quit()\n",
    "    return f\"Searched for '{search_term}'. Screenshot saved as {screenshot_path}\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "899f9c96",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load your LLM\n",
    "llm = ChatOpenAI(temperature=0, model=\"gpt-4\", openai_api_key=os.getenv(\"OPENAI_KEY\"))\n",
    "\n",
    "# Define tools\n",
    "tools = [\n",
    "    Tool(\n",
    "        name=\"TakeScreenshotOfCompendium\",\n",
    "        func=take_screenshot_of_compendium,\n",
    "        description=\"Takes a screenshot of the compendium.ch homepage.\"\n",
    "    ),\n",
    "    Tool(\n",
    "        name=\"ExtractTextFromImage\",\n",
    "        func=extract_text_from_image,\n",
    "        description=\"Extracts visible text from a screenshot using OCR.\"\n",
    "    ),\n",
    "    Tool(\n",
    "        name=\"TypeIntoSearchField\",\n",
    "        func=type_into_search_field,\n",
    "        description=\"Types 'Dafalgan EXTRA' into the search bar and returns new screenshot.\"\n",
    "    )\n",
    "]\n",
    "\n",
    "# Initialize ReAct agent\n",
    "agent = initialize_agent(\n",
    "    tools=tools,\n",
    "    llm=llm,\n",
    "    agent=AgentType.ZERO_SHOT_REACT_DESCRIPTION,\n",
    "    verbose=True\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "d3a5bd44",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "ðŸ” Step 1 ----------------------------\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mFirst, I need to take a screenshot of the compendium.ch homepage.\n",
      "\n",
      "Action: \n",
      "TakeScreenshotOfCompendium\n",
      "\n",
      "Action Input: \n",
      "output_path='compendium_screenshot.png'\n",
      "\u001b[0m"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\selenium\\webdriver\\remote\\webdriver.py:994: UserWarning: name used for saved screenshot does not match file type. It should end with a `.png` extension\n",
      "  return self.get_screenshot_as_file(filename)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mScreenshot saved to output_path='compendium_screenshot.png'\n",
      "\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mNow I need to extract the visible text from the screenshot.\n",
      "\n",
      "Action: \n",
      "ExtractTextFromImage\n",
      "\n",
      "Action Input: \n",
      "image_path='compendium_screenshot.png'\n",
      "\u001b[0m"
     ]
    },
    {
     "ename": "OSError",
     "evalue": "[Errno 22] Invalid argument: \"image_path='compendium_screenshot.png'\\n\"",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mOSError\u001b[39m                                   Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[15]\u001b[39m\u001b[32m, line 10\u001b[39m\n\u001b[32m      8\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m step \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mrange\u001b[39m(\u001b[32m3\u001b[39m):\n\u001b[32m      9\u001b[39m     \u001b[38;5;28mprint\u001b[39m(\u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[33mðŸ” Step \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mstep\u001b[38;5;250m \u001b[39m+\u001b[38;5;250m \u001b[39m\u001b[32m1\u001b[39m\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m ----------------------------\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m---> \u001b[39m\u001b[32m10\u001b[39m     result = \u001b[43magent\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\u001b[43mgoal\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     11\u001b[39m     \u001b[38;5;28mprint\u001b[39m(\u001b[33m\"\u001b[39m\u001b[33mðŸ“Œ Agent output:\u001b[39m\u001b[33m\"\u001b[39m, result)\n\u001b[32m     13\u001b[39m     \u001b[38;5;66;03m# Optional: Break early if successful\u001b[39;00m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\_api\\deprecation.py:188\u001b[39m, in \u001b[36mdeprecated.<locals>.deprecate.<locals>.warning_emitting_wrapper\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m    186\u001b[39m     warned = \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[32m    187\u001b[39m     emit_warning()\n\u001b[32m--> \u001b[39m\u001b[32m188\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mwrapped\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\chains\\base.py:606\u001b[39m, in \u001b[36mChain.run\u001b[39m\u001b[34m(self, callbacks, tags, metadata, *args, **kwargs)\u001b[39m\n\u001b[32m    604\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(args) != \u001b[32m1\u001b[39m:\n\u001b[32m    605\u001b[39m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[33m\"\u001b[39m\u001b[33m`run` supports only one positional argument.\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m--> \u001b[39m\u001b[32m606\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43margs\u001b[49m\u001b[43m[\u001b[49m\u001b[32;43m0\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mcallbacks\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcallbacks\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtags\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtags\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m)\u001b[49m[\n\u001b[32m    607\u001b[39m         _output_key\n\u001b[32m    608\u001b[39m     ]\n\u001b[32m    610\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m kwargs \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m args:\n\u001b[32m    611\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m(kwargs, callbacks=callbacks, tags=tags, metadata=metadata)[\n\u001b[32m    612\u001b[39m         _output_key\n\u001b[32m    613\u001b[39m     ]\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\_api\\deprecation.py:188\u001b[39m, in \u001b[36mdeprecated.<locals>.deprecate.<locals>.warning_emitting_wrapper\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m    186\u001b[39m     warned = \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[32m    187\u001b[39m     emit_warning()\n\u001b[32m--> \u001b[39m\u001b[32m188\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mwrapped\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\chains\\base.py:389\u001b[39m, in \u001b[36mChain.__call__\u001b[39m\u001b[34m(self, inputs, return_only_outputs, callbacks, tags, metadata, run_name, include_run_info)\u001b[39m\n\u001b[32m    357\u001b[39m \u001b[38;5;250m\u001b[39m\u001b[33;03m\"\"\"Execute the chain.\u001b[39;00m\n\u001b[32m    358\u001b[39m \n\u001b[32m    359\u001b[39m \u001b[33;03mArgs:\u001b[39;00m\n\u001b[32m   (...)\u001b[39m\u001b[32m    380\u001b[39m \u001b[33;03m        `Chain.output_keys`.\u001b[39;00m\n\u001b[32m    381\u001b[39m \u001b[33;03m\"\"\"\u001b[39;00m\n\u001b[32m    382\u001b[39m config = {\n\u001b[32m    383\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mcallbacks\u001b[39m\u001b[33m\"\u001b[39m: callbacks,\n\u001b[32m    384\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mtags\u001b[39m\u001b[33m\"\u001b[39m: tags,\n\u001b[32m    385\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mmetadata\u001b[39m\u001b[33m\"\u001b[39m: metadata,\n\u001b[32m    386\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mrun_name\u001b[39m\u001b[33m\"\u001b[39m: run_name,\n\u001b[32m    387\u001b[39m }\n\u001b[32m--> \u001b[39m\u001b[32m389\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43minvoke\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    390\u001b[39m \u001b[43m    \u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    391\u001b[39m \u001b[43m    \u001b[49m\u001b[43mcast\u001b[49m\u001b[43m(\u001b[49m\u001b[43mRunnableConfig\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[43mk\u001b[49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mv\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mk\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mv\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m.\u001b[49m\u001b[43mitems\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mv\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mis\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mnot\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m}\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    392\u001b[39m \u001b[43m    \u001b[49m\u001b[43mreturn_only_outputs\u001b[49m\u001b[43m=\u001b[49m\u001b[43mreturn_only_outputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    393\u001b[39m \u001b[43m    \u001b[49m\u001b[43minclude_run_info\u001b[49m\u001b[43m=\u001b[49m\u001b[43minclude_run_info\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    394\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\chains\\base.py:170\u001b[39m, in \u001b[36mChain.invoke\u001b[39m\u001b[34m(self, input, config, **kwargs)\u001b[39m\n\u001b[32m    168\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[32m    169\u001b[39m     run_manager.on_chain_error(e)\n\u001b[32m--> \u001b[39m\u001b[32m170\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m e\n\u001b[32m    171\u001b[39m run_manager.on_chain_end(outputs)\n\u001b[32m    173\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m include_run_info:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\chains\\base.py:160\u001b[39m, in \u001b[36mChain.invoke\u001b[39m\u001b[34m(self, input, config, **kwargs)\u001b[39m\n\u001b[32m    157\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m    158\u001b[39m     \u001b[38;5;28mself\u001b[39m._validate_inputs(inputs)\n\u001b[32m    159\u001b[39m     outputs = (\n\u001b[32m--> \u001b[39m\u001b[32m160\u001b[39m         \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_call\u001b[49m\u001b[43m(\u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    161\u001b[39m         \u001b[38;5;28;01mif\u001b[39;00m new_arg_supported\n\u001b[32m    162\u001b[39m         \u001b[38;5;28;01melse\u001b[39;00m \u001b[38;5;28mself\u001b[39m._call(inputs)\n\u001b[32m    163\u001b[39m     )\n\u001b[32m    165\u001b[39m     final_outputs: Dict[\u001b[38;5;28mstr\u001b[39m, Any] = \u001b[38;5;28mself\u001b[39m.prep_outputs(\n\u001b[32m    166\u001b[39m         inputs, outputs, return_only_outputs\n\u001b[32m    167\u001b[39m     )\n\u001b[32m    168\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1624\u001b[39m, in \u001b[36mAgentExecutor._call\u001b[39m\u001b[34m(self, inputs, run_manager)\u001b[39m\n\u001b[32m   1622\u001b[39m \u001b[38;5;66;03m# We now enter the agent loop (until it returns something).\u001b[39;00m\n\u001b[32m   1623\u001b[39m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28mself\u001b[39m._should_continue(iterations, time_elapsed):\n\u001b[32m-> \u001b[39m\u001b[32m1624\u001b[39m     next_step_output = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_take_next_step\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1625\u001b[39m \u001b[43m        \u001b[49m\u001b[43mname_to_tool_map\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1626\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcolor_mapping\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1627\u001b[39m \u001b[43m        \u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1628\u001b[39m \u001b[43m        \u001b[49m\u001b[43mintermediate_steps\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1629\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1630\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1631\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(next_step_output, AgentFinish):\n\u001b[32m   1632\u001b[39m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m._return(\n\u001b[32m   1633\u001b[39m             next_step_output, intermediate_steps, run_manager=run_manager\n\u001b[32m   1634\u001b[39m         )\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1330\u001b[39m, in \u001b[36mAgentExecutor._take_next_step\u001b[39m\u001b[34m(self, name_to_tool_map, color_mapping, inputs, intermediate_steps, run_manager)\u001b[39m\n\u001b[32m   1321\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m_take_next_step\u001b[39m(\n\u001b[32m   1322\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   1323\u001b[39m     name_to_tool_map: Dict[\u001b[38;5;28mstr\u001b[39m, BaseTool],\n\u001b[32m   (...)\u001b[39m\u001b[32m   1327\u001b[39m     run_manager: Optional[CallbackManagerForChainRun] = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m   1328\u001b[39m ) -> Union[AgentFinish, List[Tuple[AgentAction, \u001b[38;5;28mstr\u001b[39m]]]:\n\u001b[32m   1329\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m._consume_next_step(\n\u001b[32m-> \u001b[39m\u001b[32m1330\u001b[39m         \u001b[43m[\u001b[49m\n\u001b[32m   1331\u001b[39m \u001b[43m            \u001b[49m\u001b[43ma\u001b[49m\n\u001b[32m   1332\u001b[39m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43ma\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_iter_next_step\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1333\u001b[39m \u001b[43m                \u001b[49m\u001b[43mname_to_tool_map\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1334\u001b[39m \u001b[43m                \u001b[49m\u001b[43mcolor_mapping\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1335\u001b[39m \u001b[43m                \u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1336\u001b[39m \u001b[43m                \u001b[49m\u001b[43mintermediate_steps\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1337\u001b[39m \u001b[43m                \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1338\u001b[39m \u001b[43m            \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1339\u001b[39m \u001b[43m        \u001b[49m\u001b[43m]\u001b[49m\n\u001b[32m   1340\u001b[39m     )\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1330\u001b[39m, in \u001b[36m<listcomp>\u001b[39m\u001b[34m(.0)\u001b[39m\n\u001b[32m   1321\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m_take_next_step\u001b[39m(\n\u001b[32m   1322\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   1323\u001b[39m     name_to_tool_map: Dict[\u001b[38;5;28mstr\u001b[39m, BaseTool],\n\u001b[32m   (...)\u001b[39m\u001b[32m   1327\u001b[39m     run_manager: Optional[CallbackManagerForChainRun] = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m   1328\u001b[39m ) -> Union[AgentFinish, List[Tuple[AgentAction, \u001b[38;5;28mstr\u001b[39m]]]:\n\u001b[32m   1329\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m._consume_next_step(\n\u001b[32m-> \u001b[39m\u001b[32m1330\u001b[39m         \u001b[43m[\u001b[49m\n\u001b[32m   1331\u001b[39m \u001b[43m            \u001b[49m\u001b[43ma\u001b[49m\n\u001b[32m   1332\u001b[39m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43ma\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_iter_next_step\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1333\u001b[39m \u001b[43m                \u001b[49m\u001b[43mname_to_tool_map\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1334\u001b[39m \u001b[43m                \u001b[49m\u001b[43mcolor_mapping\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1335\u001b[39m \u001b[43m                \u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1336\u001b[39m \u001b[43m                \u001b[49m\u001b[43mintermediate_steps\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1337\u001b[39m \u001b[43m                \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1338\u001b[39m \u001b[43m            \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1339\u001b[39m \u001b[43m        \u001b[49m\u001b[43m]\u001b[49m\n\u001b[32m   1340\u001b[39m     )\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1415\u001b[39m, in \u001b[36mAgentExecutor._iter_next_step\u001b[39m\u001b[34m(self, name_to_tool_map, color_mapping, inputs, intermediate_steps, run_manager)\u001b[39m\n\u001b[32m   1413\u001b[39m     \u001b[38;5;28;01myield\u001b[39;00m agent_action\n\u001b[32m   1414\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m agent_action \u001b[38;5;129;01min\u001b[39;00m actions:\n\u001b[32m-> \u001b[39m\u001b[32m1415\u001b[39m     \u001b[38;5;28;01myield\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_perform_agent_action\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1416\u001b[39m \u001b[43m        \u001b[49m\u001b[43mname_to_tool_map\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mcolor_mapping\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43magent_action\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mrun_manager\u001b[49m\n\u001b[32m   1417\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1437\u001b[39m, in \u001b[36mAgentExecutor._perform_agent_action\u001b[39m\u001b[34m(self, name_to_tool_map, color_mapping, agent_action, run_manager)\u001b[39m\n\u001b[32m   1435\u001b[39m         tool_run_kwargs[\u001b[33m\"\u001b[39m\u001b[33mllm_prefix\u001b[39m\u001b[33m\"\u001b[39m] = \u001b[33m\"\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m   1436\u001b[39m     \u001b[38;5;66;03m# We then call the tool on the tool input to get an observation\u001b[39;00m\n\u001b[32m-> \u001b[39m\u001b[32m1437\u001b[39m     observation = \u001b[43mtool\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1438\u001b[39m \u001b[43m        \u001b[49m\u001b[43magent_action\u001b[49m\u001b[43m.\u001b[49m\u001b[43mtool_input\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1439\u001b[39m \u001b[43m        \u001b[49m\u001b[43mverbose\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mverbose\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1440\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcolor\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcolor\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1441\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcallbacks\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m.\u001b[49m\u001b[43mget_child\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01melse\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[32m   1442\u001b[39m \u001b[43m        \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mtool_run_kwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1443\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1444\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m   1445\u001b[39m     tool_run_kwargs = \u001b[38;5;28mself\u001b[39m._action_agent.tool_run_logging_kwargs()\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\tools\\base.py:775\u001b[39m, in \u001b[36mBaseTool.run\u001b[39m\u001b[34m(self, tool_input, verbose, start_color, color, callbacks, tags, metadata, run_name, run_id, config, tool_call_id, **kwargs)\u001b[39m\n\u001b[32m    773\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m error_to_raise:\n\u001b[32m    774\u001b[39m     run_manager.on_tool_error(error_to_raise)\n\u001b[32m--> \u001b[39m\u001b[32m775\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m error_to_raise\n\u001b[32m    776\u001b[39m output = _format_output(content, artifact, tool_call_id, \u001b[38;5;28mself\u001b[39m.name, status)\n\u001b[32m    777\u001b[39m run_manager.on_tool_end(output, color=color, name=\u001b[38;5;28mself\u001b[39m.name, **kwargs)\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\tools\\base.py:744\u001b[39m, in \u001b[36mBaseTool.run\u001b[39m\u001b[34m(self, tool_input, verbose, start_color, color, callbacks, tags, metadata, run_name, run_id, config, tool_call_id, **kwargs)\u001b[39m\n\u001b[32m    742\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m config_param := _get_runnable_config_param(\u001b[38;5;28mself\u001b[39m._run):\n\u001b[32m    743\u001b[39m         tool_kwargs = tool_kwargs | {config_param: config}\n\u001b[32m--> \u001b[39m\u001b[32m744\u001b[39m     response = \u001b[43mcontext\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_run\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43mtool_args\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mtool_kwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    745\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m.response_format == \u001b[33m\"\u001b[39m\u001b[33mcontent_and_artifact\u001b[39m\u001b[33m\"\u001b[39m:\n\u001b[32m    746\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(response, \u001b[38;5;28mtuple\u001b[39m) \u001b[38;5;129;01mor\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(response) != \u001b[32m2\u001b[39m:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\tools\\simple.py:105\u001b[39m, in \u001b[36mTool._run\u001b[39m\u001b[34m(self, config, run_manager, *args, **kwargs)\u001b[39m\n\u001b[32m    103\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m config_param := _get_runnable_config_param(\u001b[38;5;28mself\u001b[39m.func):\n\u001b[32m    104\u001b[39m         kwargs[config_param] = config\n\u001b[32m--> \u001b[39m\u001b[32m105\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mfunc\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    106\u001b[39m msg = \u001b[33m\"\u001b[39m\u001b[33mTool does not support sync invocation.\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m    107\u001b[39m \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mNotImplementedError\u001b[39;00m(msg)\n",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[13]\u001b[39m\u001b[32m, line 14\u001b[39m, in \u001b[36mextract_text_from_image\u001b[39m\u001b[34m(image_path)\u001b[39m\n\u001b[32m     13\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mextract_text_from_image\u001b[39m(image_path=SCREENSHOT_PATH):\n\u001b[32m---> \u001b[39m\u001b[32m14\u001b[39m     image = \u001b[43mImage\u001b[49m\u001b[43m.\u001b[49m\u001b[43mopen\u001b[49m\u001b[43m(\u001b[49m\u001b[43mimage_path\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     15\u001b[39m     text = pytesseract.image_to_string(image)\n\u001b[32m     16\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m text\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\PIL\\Image.py:3505\u001b[39m, in \u001b[36mopen\u001b[39m\u001b[34m(fp, mode, formats)\u001b[39m\n\u001b[32m   3502\u001b[39m     filename = os.fspath(fp)\n\u001b[32m   3504\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m filename:\n\u001b[32m-> \u001b[39m\u001b[32m3505\u001b[39m     fp = builtins.open(filename, \u001b[33m\"\u001b[39m\u001b[33mrb\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m   3506\u001b[39m     exclusive_fp = \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[32m   3507\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n",
      "\u001b[31mOSError\u001b[39m: [Errno 22] Invalid argument: \"image_path='compendium_screenshot.png'\\n\""
     ]
    }
   ],
   "source": [
    "# Set a goal and run the agent multiple times\n",
    "goal = \"\"\"\n",
    "Visit https://compendium.ch, extract what is visible, and search for 'Dafalgan EXTRA'.\n",
    "Repeat until you have found the search results.\n",
    "\"\"\"\n",
    "\n",
    "# Loop over steps, simulating ReAct-style behavior\n",
    "for step in range(3):\n",
    "    print(f\"\\nðŸ” Step {step + 1} ----------------------------\")\n",
    "    result = agent.run(goal)\n",
    "    print(\"ðŸ“Œ Agent output:\", result)\n",
    "\n",
    "    # Optional: Break early if successful\n",
    "    if \"500/65 mg\" in result or \"Filmtabl\" in result:\n",
    "        print(\"\\nâœ… Goal achieved: Found product info.\")\n",
    "        break\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3da0ede1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mUm die Wirkung von Dafalgan EXTRA zu ermitteln, muss ich die Informationen aus dem Compendium abrufen.\n",
      "Action: get_compendium_info\n",
      "Action Input: Dafalgan EXTRA\u001b[0m\n",
      "Observation: \u001b[36;1m\u001b[1;3m**Info fÃ¼r 'Dafalgan EXTRA':**\n",
      "\n",
      "Dafalgan Extra is a paracetamol-based analgesic with caffeine, manufactured by UPSA Switzerland AG, used for mild to moderate pain relief. It is available in film-coated tablet form. The product is registered under ATC code N02BE51.\n",
      "\n",
      "Links:\n",
      "- https://compendium.ch/fr/product/1450988-dafalgan-extra-cpr-pell-500-65-mg/mpro\n",
      "- https://compendium.ch/it/register/atc/N02BE51\n",
      "- https://compendium.ch/search/all/Paracetamol/startwith/de\n",
      "\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mIch habe jetzt die Informationen Ã¼ber Dafalgan EXTRA. Es ist ein auf Paracetamol basierendes Schmerzmittel mit Koffein, das zur Linderung von leichtem bis mÃ¤ÃŸigem Schmerz verwendet wird.\n",
      "Final Answer: Dafalgan EXTRA ist ein auf Paracetamol basierendes Schmerzmittel mit Koffein, das zur Linderung von leichtem bis mÃ¤ÃŸigem Schmerz verwendet wird.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Dafalgan EXTRA ist ein auf Paracetamol basierendes Schmerzmittel mit Koffein, das zur Linderung von leichtem bis mÃ¤ÃŸigem Schmerz verwendet wird.\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "fc9fee1b1f874014bfb5ac3184eb908f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Dropdown(description='Fragetyp:', options=('ðŸ’Š Wirkung', 'ðŸ“¦ Lagerung', 'ðŸ’¥ Interaktionen', 'ðŸ’‰ Dosierung', 'ðŸ§ª Inhâ€¦"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b7e0b133038441bab4e8aef8eaac979a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Dropdown(description='Art der Eingabe:', options=('ðŸ§ª Wirkstoff', 'ðŸ’Š Medikament'), style=DescriptionStyle(descrâ€¦"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e75e0c92c36748e784f842d80a4e4e9e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Text(value='', description='Name:', placeholder='z.\\u202fB. Dafalgan oder Paracetamol', style=TextStyle(descriâ€¦"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b3337d6bb6784939b7f2a31dd6c8b63d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Button(button_style='success', description='ðŸš€ Frage stellen', style=ButtonStyle())"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "34b98e52dbf241a79d7675c764fafe97",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Output()"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "load_dotenv()\n",
    "from tavily import TavilyClient\n",
    "from langchain.chat_models import ChatOpenAI\n",
    "from langchain.agents import initialize_agent, AgentType\n",
    "from langchain.tools import Tool\n",
    "from langchain.agents import AgentExecutor\n",
    "from langchain.agents import AgentType\n",
    "from langchain.agents import create_openai_functions_agent\n",
    "from langchain.prompts import MessagesPlaceholder\n",
    "from langchain.prompts import ChatPromptTemplate, HumanMessagePromptTemplate, SystemMessagePromptTemplate\n",
    "from langchain.prompts import MessagesPlaceholder\n",
    "\n",
    "import ipywidgets as widgets\n",
    "from IPython.display import display, clear_output\n",
    "\n",
    "client = TavilyClient(api_key=os.getenv(\"TAVILY_API_KEY\"))\n",
    "\n",
    "def get_compendium_info(medication: str) -> str:\n",
    "    query = f\"site:compendium.ch {medication}\"\n",
    "    results = client.search(query=query, search_depth=\"advanced\", include_answer=True)\n",
    "    answer = results.get(\"answer\")\n",
    "    urls = [r[\"url\"] for r in results.get(\"results\", [])]\n",
    "    if not answer:\n",
    "        return f\"âš ï¸ Keine direkte Antwort gefunden fÃ¼r: '{medication}' â€“ du solltest die Links Ã¼berprÃ¼fen oder gezielter nach z.B. 'Lagerung' oder 'Dosierung' suchen.\\n\\nðŸ”— Links:\\n\" + \"\\n\".join(f\"- {url}\" for url in urls[:3])\n",
    "    response = f\"**Info fÃ¼r '{medication}':**\\n\\n{answer}\\n\\nLinks:\\n\"\n",
    "    for url in urls[:3]:\n",
    "        response += f\"- {url}\\n\"\n",
    "    return response\n",
    "\n",
    "compendium_tool = Tool(name=\"get_compendium_info\",func=get_compendium_info,description=\"Use this to get medication information from compendium.ch. Input should be the medication name, like 'Dafalgan EXTRA'.\")\n",
    "\n",
    "llm = ChatOpenAI(\n",
    "    model=\"gpt-4\",\n",
    "    openai_api_key=os.getenv(\"OPENAI_KEY\"),\n",
    "    temperature=0.2,\n",
    "    streaming=True,\n",
    ")\n",
    "\n",
    "agent = initialize_agent(\n",
    "    tools=[compendium_tool],\n",
    "    llm=llm,\n",
    "    agent=AgentType.ZERO_SHOT_REACT_DESCRIPTION,\n",
    "    verbose=True,\n",
    "    agent_kwargs={\n",
    "        \"system_message\": \"Du bist ein medizinischer Assistent. Antworte immer auf Deutsch und mÃ¶glichst prÃ¤zise. Wenn Informationen fehlen, erklÃ¤re das dem Nutzer klar.\"\n",
    "    }\n",
    ")\n",
    "question = \"Was ist die Wirkung von Dafalgan EXTRA?\"\n",
    "response = agent.run(question)\n",
    "print(response)\n",
    "\n",
    "question_types = {\n",
    "    \"ðŸ’Š Wirkung\": \"Was ist die Wirkung von\",\n",
    "    \"ðŸ“¦ Lagerung\": \"Wie sollte man lagern\",\n",
    "    \"ðŸ’¥ Interaktionen\": \"Welche Interaktionen gibt es bei\",\n",
    "    \"ðŸ’‰ Dosierung\": \"Wie lautet die empfohlene Dosierung von\",\n",
    "    \"ðŸ§ª Inhaltsstoffe\": \"Welche Wirkstoffe enthÃ¤lt\",\n",
    "    \"ðŸŒ¡ï¸ Haltbarkeit ohne KÃ¼hlung\": \"Wie lange ist haltbar ohne KÃ¼hlung\",\n",
    "    \"ðŸŒ Interaktionen mit auslÃ¤ndischen Medis\": \"Gibt es bekannte Interaktionen mit internationalen Medikamenten fÃ¼r\"\n",
    "}\n",
    "\n",
    "input_type_options = {\n",
    "    \"ðŸ§ª Wirkstoff\": \"Wirkstoff\",\n",
    "    \"ðŸ’Š Medikament\": \"Medikament\"}\n",
    "\n",
    "question_dropdown = widgets.Dropdown(\n",
    "    options=list(question_types.keys()),\n",
    "    description='Fragetyp:',\n",
    "    style={'description_width': 'initial'})\n",
    "\n",
    "input_type_dropdown = widgets.Dropdown(\n",
    "    options=list(input_type_options.keys()),\n",
    "    description='Art der Eingabe:',\n",
    "    style={'description_width': 'initial'})\n",
    "\n",
    "name_input = widgets.Text(\n",
    "    description='Name:',\n",
    "    placeholder='z.â€¯B. Dafalgan oder Paracetamol',\n",
    "    style={'description_width': 'initial'})\n",
    "\n",
    "run_button = widgets.Button(\n",
    "    description='ðŸš€ Frage stellen',\n",
    "    button_style='success')\n",
    "output = widgets.Output()\n",
    "def run_agent_question(_):\n",
    "    output.clear_output()\n",
    "    with output:\n",
    "        question_type = question_dropdown.value\n",
    "        query_prefix = question_types[question_type]\n",
    "\n",
    "        name = name_input.value.strip()\n",
    "        if not name:\n",
    "            print(\"â— Bitte gib den Namen eines Medikaments oder Wirkstoffs ein.\")\n",
    "            return\n",
    "        input_type = input_type_options[input_type_dropdown.value]\n",
    "        full_prompt = f\"{query_prefix} {name}? ({input_type})\"\n",
    "        print(f\"ðŸ§  Frage-Formulierung: {full_prompt}\")\n",
    "        try:\n",
    "            response = agent.run(full_prompt)\n",
    "        except Exception as e:\n",
    "            response = f\"âŒ Fehler beim AusfÃ¼hren des Agenten:\\n{e}\"\n",
    "        print(\"âœ… Antwort:\")\n",
    "        print(response)\n",
    "\n",
    "run_button.on_click(run_agent_question)\n",
    "\n",
    "display(question_dropdown, input_type_dropdown, name_input, run_button, output)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a3d8b3f3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "fdecc52f89eb41658e16a6b4fae28125",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Dropdown(description='Fragetyp:', options=('ðŸ’Š Wirkung', 'ðŸ“¦ Lagerung', 'ðŸ’¥ Interaktionen', 'ðŸ’‰ Dosierung', 'ðŸ§ª Inhâ€¦"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b926f5fb58674d9bbd6aab2b552caaed",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Dropdown(description='Art der Eingabe:', options=('ðŸ§ª Wirkstoff', 'ðŸ’Š Medikament'), style=DescriptionStyle(descrâ€¦"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b37bdb1a1dbf4c2782dd5b99abadd8db",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Text(value='', description='Name:', placeholder='z.\\u202fB. Dafalgan oder Paracetamol', style=TextStyle(descriâ€¦"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "854d518cb273423784bf2f9d9e09f66a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Button(button_style='success', description='ðŸš€ Frage stellen', style=ButtonStyle())"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f514c299f7244d45a6871ed889119731",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Output()"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "3c32c2e4",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\FahRe\\AppData\\Local\\Temp\\ipykernel_31352\\2082307243.py:47: LangChainDeprecationWarning: The class `ChatOpenAI` was deprecated in LangChain 0.0.10 and will be removed in 1.0. An updated version of the class exists in the :class:`~langchain-openai package and should be used instead. To use it run `pip install -U :class:`~langchain-openai` and import as `from :class:`~langchain_openai import ChatOpenAI``.\n",
      "  llm = ChatOpenAI(\n",
      "C:\\Users\\FahRe\\AppData\\Local\\Temp\\ipykernel_31352\\2082307243.py:55: LangChainDeprecationWarning: LangChain agents will continue to be supported, but it is recommended for new use cases to be built with LangGraph. LangGraph offers a more flexible and full-featured framework for building agents, including support for tool-calling, persistence of state, and human-in-the-loop workflows. For details, refer to the `LangGraph documentation <https://langchain-ai.github.io/langgraph/>`_ as well as guides for `Migrating from AgentExecutor <https://python.langchain.com/docs/how_to/migrate_agent/>`_ and LangGraph's `Pre-built ReAct agent <https://langchain-ai.github.io/langgraph/how-tos/create-react-agent/>`_.\n",
      "  agent = initialize_agent(\n",
      "C:\\Users\\FahRe\\AppData\\Local\\Temp\\ipykernel_31352\\2082307243.py:70: LangChainDeprecationWarning: The method `Chain.run` was deprecated in langchain 0.1.0 and will be removed in 1.0. Use :meth:`~invoke` instead.\n",
      "  example_response = agent.run(example_question)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mUm diese Frage zu beantworten, muss ich Informationen Ã¼ber das Medikament Dafalgan EXTRA abrufen.\n",
      "Action: get_compendium_info\n",
      "Action Input: Dafalgan EXTRA\u001b[0m\n",
      "Observation: \u001b[36;1m\u001b[1;3m**Info fÃ¼r 'Dafalgan EXTRA':**\n",
      "\n",
      "Dafalgan Extra is a paracetamol-based analgesic with caffeine, manufactured by UPSA Switzerland AG, used for mild to moderate pain relief. It is available in film-coated tablet form. The product is registered under ATC code N02BE51.\n",
      "\n",
      "ðŸ”— Links:\n",
      "- https://compendium.ch/fr/product/1450988-dafalgan-extra-cpr-pell-500-65-mg/mpro\n",
      "- https://compendium.ch/it/register/atc/N02BE51\n",
      "- https://compendium.ch/search/all/Paracetamol/startwith/de\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mIch habe jetzt Informationen Ã¼ber Dafalgan EXTRA. Es ist ein auf Paracetamol basierendes Schmerzmittel mit Koffein, das zur Linderung von leichtem bis mÃ¤ÃŸigem Schmerz verwendet wird.\n",
      "Final Answer: Dafalgan EXTRA ist ein auf Paracetamol basierendes Schmerzmittel mit Koffein, das zur Linderung von leichtem bis mÃ¤ÃŸigem Schmerz verwendet wird.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "Dafalgan EXTRA ist ein auf Paracetamol basierendes Schmerzmittel mit Koffein, das zur Linderung von leichtem bis mÃ¤ÃŸigem Schmerz verwendet wird.\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e94f683501984b6eaa59df72e843ab45",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Dropdown(description='Fragetyp:', options=('ðŸ’Š Wirkung', 'ðŸ“¦ Lagerung', 'ðŸ’¥ Interaktionen', 'ðŸ’‰ Dosierung', 'ðŸ§ª Inhâ€¦"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "69fe8e76d2b04323add9a41a7f27f816",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Dropdown(description='Art der Eingabe:', options=('ðŸ§ª Wirkstoff', 'ðŸ’Š Medikament'), style=DescriptionStyle(descrâ€¦"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "1225785b5cc148f391711eb5e00c9d0c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Text(value='', description='Name:', placeholder='z.\\u202fB. Dafalgan oder Paracetamol', style=TextStyle(descriâ€¦"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "cc6db120e4ff4f07ada13394fca75bbe",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Button(button_style='success', description='ðŸš€ Frage stellen', style=ButtonStyle())"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "956f0bc2b987458eb9b31c2872ddb4d8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Output()"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# === Environment & API Setup ===\n",
    "from dotenv import load_dotenv\n",
    "import os\n",
    "load_dotenv()\n",
    "from langchain_community.tools.tavily_search import TavilySearchResults\n",
    "from tavily import TavilyClient\n",
    "from langchain.chat_models import ChatOpenAI\n",
    "from langchain.agents import initialize_agent, AgentType\n",
    "from langchain.tools import Tool\n",
    "\n",
    "\n",
    "# === Prompt and UI Setup ===\n",
    "from langchain.prompts import ChatPromptTemplate, HumanMessagePromptTemplate, SystemMessagePromptTemplate, MessagesPlaceholder\n",
    "\n",
    "import ipywidgets as widgets\n",
    "from IPython.display import display, clear_output\n",
    "\n",
    "# === Tavily Client ===\n",
    "client = TavilyClient(api_key=os.getenv(\"TAVILY_API_KEY\"))\n",
    "\n",
    "# === Tool Function ===\n",
    "def get_compendium_info(medication: str) -> str:\n",
    "    query = f\"site:compendium.ch {medication}\"\n",
    "    results = client.search(query=query, search_depth=\"advanced\", include_answer=True)\n",
    "\n",
    "    answer = results.get(\"answer\")\n",
    "    urls = [r[\"url\"] for r in results.get(\"results\", [])]\n",
    "\n",
    "    if not answer:\n",
    "        return (\n",
    "            f\"âš ï¸ Keine direkte Antwort gefunden fÃ¼r: '{medication}' â€“ \"\n",
    "            \"du solltest die Links Ã¼berprÃ¼fen oder gezielter nach z.â€¯B. 'Lagerung' oder 'Dosierung' suchen.\\n\\n\"\n",
    "            \"ðŸ”— Links:\\n\" + \"\\n\".join(f\"- {url}\" for url in urls[:3])\n",
    "        )\n",
    "    \n",
    "    response = f\"**Info fÃ¼r '{medication}':**\\n\\n{answer}\\n\\nðŸ”— Links:\\n\"\n",
    "    response += \"\\n\".join(f\"- {url}\" for url in urls[:3])\n",
    "    return response\n",
    "\n",
    "compendium_tool = Tool(\n",
    "    name=\"get_compendium_info\",\n",
    "    func=get_compendium_info,\n",
    "    description=\"Nutze dieses Tool, um Informationen Ã¼ber Medikamente von compendium.ch abzurufen. Eingabe ist der Medikamentenname, z.â€¯B. 'Dafalgan EXTRA'.\"\n",
    ")\n",
    "\n",
    "# === LLM Setup ===\n",
    "llm = ChatOpenAI(\n",
    "    model=\"gpt-4\",\n",
    "    openai_api_key=os.getenv(\"OPENAI_KEY\"),\n",
    "    temperature=0.2,\n",
    "    streaming=True,\n",
    ")\n",
    "\n",
    "# === Agent Setup ===\n",
    "agent = initialize_agent(\n",
    "    tools=[compendium_tool],\n",
    "    llm=llm,\n",
    "    agent=AgentType.ZERO_SHOT_REACT_DESCRIPTION,\n",
    "    verbose=True,\n",
    "    agent_kwargs={\n",
    "        \"system_message\": (\n",
    "            \"Du bist ein medizinischer Assistent. Antworte immer auf Deutsch und mÃ¶glichst prÃ¤zise. \"\n",
    "            \"Wenn Informationen fehlen, erklÃ¤re das dem Nutzer klar.\"\n",
    "        )\n",
    "    }\n",
    ")\n",
    "\n",
    "# === Default Prompt Example ===\n",
    "example_question = \"Was ist die Wirkung von Dafalgan EXTRA?\"\n",
    "example_response = agent.run(example_question)\n",
    "print(example_response)\n",
    "\n",
    "# === UI Logic ===\n",
    "question_types = {\n",
    "    \"ðŸ’Š Wirkung\": \"Was ist die Wirkung von\",\n",
    "    \"ðŸ“¦ Lagerung\": \"Wie sollte man lagern\",\n",
    "    \"ðŸ’¥ Interaktionen\": \"Welche Interaktionen gibt es bei\",\n",
    "    \"ðŸ’‰ Dosierung\": \"Wie lautet die empfohlene Dosierung von\",\n",
    "    \"ðŸ§ª Inhaltsstoffe\": \"Welche Wirkstoffe enthÃ¤lt\",\n",
    "    \"ðŸŒ¡ï¸ Haltbarkeit ohne KÃ¼hlung\": \"Wie lange ist haltbar ohne KÃ¼hlung\",\n",
    "    \"ðŸŒ Interaktionen mit auslÃ¤ndischen Medis\": \"Gibt es bekannte Interaktionen mit internationalen Medikamenten fÃ¼r\"\n",
    "}\n",
    "\n",
    "input_type_options = {\n",
    "    \"ðŸ§ª Wirkstoff\": \"Wirkstoff\",\n",
    "    \"ðŸ’Š Medikament\": \"Medikament\"\n",
    "}\n",
    "\n",
    "question_dropdown = widgets.Dropdown(\n",
    "    options=list(question_types.keys()),\n",
    "    description='Fragetyp:',\n",
    "    style={'description_width': 'initial'}\n",
    ")\n",
    "\n",
    "input_type_dropdown = widgets.Dropdown(\n",
    "    options=list(input_type_options.keys()),\n",
    "    description='Art der Eingabe:',\n",
    "    style={'description_width': 'initial'}\n",
    ")\n",
    "\n",
    "name_input = widgets.Text(\n",
    "    description='Name:',\n",
    "    placeholder='z.â€¯B. Dafalgan oder Paracetamol',\n",
    "    style={'description_width': 'initial'}\n",
    ")\n",
    "\n",
    "run_button = widgets.Button(\n",
    "    description='ðŸš€ Frage stellen',\n",
    "    button_style='success'\n",
    ")\n",
    "\n",
    "output = widgets.Output()\n",
    "\n",
    "# === Callback ===\n",
    "def run_agent_question(_):\n",
    "    output.clear_output()\n",
    "    with output:\n",
    "        question_type = question_dropdown.value\n",
    "        query_prefix = question_types[question_type]\n",
    "        name = name_input.value.strip()\n",
    "\n",
    "        if not name:\n",
    "            print(\"â— Bitte gib den Namen eines Medikaments oder Wirkstoffs ein.\")\n",
    "            return\n",
    "\n",
    "        input_type = input_type_options[input_type_dropdown.value]\n",
    "        full_prompt = f\"{query_prefix} {name}? ({input_type})\"\n",
    "        print(f\"ðŸ§  Frage-Formulierung: {full_prompt}\")\n",
    "\n",
    "        try:\n",
    "            response = agent.run(full_prompt)\n",
    "        except Exception as e:\n",
    "            response = f\"âŒ Fehler beim AusfÃ¼hren des Agenten:\\n{e}\"\n",
    "        \n",
    "        print(\"âœ… Antwort:\")\n",
    "        print(response)\n",
    "\n",
    "run_button.on_click(run_agent_question)\n",
    "\n",
    "# === Display UI ===\n",
    "display(question_dropdown, input_type_dropdown, name_input, run_button, output)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "409a8933",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "HIGHLIGHTS OF PRESCRIBING INFORMATION \n",
      "These highlights do not include all th e information needed to use AZMIRO \n",
      "safely and effectively. See full prescribing information for AZMIRO. \n",
      "AZMIRO (testosterone cypionate) inje ction, for intramuscular use, CIII \n",
      "Initial U.S. Approval: 1953 \n",
      "------------------------------INDICATIONS AND USAGE---------------------------\n",
      "AZMIRO is an androgen indicated for testosterone replacement therapy in males \n",
      "for conditions associated with a deficiency or absence of endogenous testosterone \n",
      "(1). \n",
      "Limitations of Use: \n",
      "ï‚· Safety and efficacy of AZMIRO in men with â€œage- related hypogonadismâ€ \n",
      "(also referred to as â€œlate-onset hypogonadismâ€) have not been established (1). \n",
      "ï‚· Safety and effectiveness in pediatric patients below the age of 12 years have \n",
      "not been established (8.4). \n",
      "------------------------ DOSAGE AND ADMINISTRATION------------------------\n",
      "ï‚· Injectable testosterone products may have different doses, strengths, or \n",
      "administration instructions and they are not substitutable on a milligram-per-\n",
      "milligram basis.  Administer AZMIRO by deep gluteal intramuscular injection \n",
      "only (2.1). \n",
      "ï‚· Prior to initiating AZMIRO, confirm the diagnosis of hypogonadism by \n",
      "ensuring that serum testosterone concen trations have been measured in the \n",
      "morning on at least two separate days and that these serum concentrations are \n",
      "below the normal range (2.2). \n",
      "ï‚· Recommended dosage is 50 mg to 400 mg administered every two to four \n",
      "weeks as a deep intramuscular injection in the gluteal muscle. Individualize \n",
      "the dose and schedule based on the patie ntâ€™s age, diagnosis, response to \n",
      "treatment, and the appearance of adverse reactions (2.3). \n",
      "ï‚· The prefilled syringe should be administer ed as an intramuscular injection by \n",
      "a healthcare professional only. \n",
      "-----------------------DOSAGE FORMS AND STRENGTHS-----------------------\n",
      "Injection: 200 mg/mL in a single-dose vial (3) \n",
      " 200 mg/mL in a single-dose prefilled syringe (3) \n",
      "-------------------------------CONTRAINDICATIONS--------------------------------\n",
      "ï‚· Known hypersensitivity to AZMIRO or  any of its components, skin \n",
      "manifestations and anaphylactoid reactions have been reported (4) \n",
      "ï‚· Men with carcinoma of the breast or known or suspected carcinoma of the \n",
      "prostate (4). \n",
      "ï‚· Women who are pregnant. Testosterone may cause fetal harm (4). \n",
      "-----------------------WARNINGS AND PRECAUTIONS--------------------------\n",
      "ï‚· Polycythemia: Monitor hematocrit periodically during treatment. Discontinue \n",
      "AZMIRO, if necessary (5.1). \n",
      "ï‚· Cardiovascular Risk: AZMIRO may in crease the risk of major adverse \n",
      "cardiovascular events (MACE). Inform patients of this risk when deciding \n",
      "whether to use or to continue treatment (5.2). \n",
      "ï‚· Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of \n",
      "Prostate Cancer: Monitor patients with  benign prostatic hyperplasia (BPH) for \n",
      "worsening of signs and symptoms of BPH.  Evaluate patients for prostate cancer, \n",
      "including monitoring prostate specific antigen (PSA) prior to initiating and during \n",
      "treatment with androgens (5.3). \n",
      "ï‚· Venous thromboembolism (VTE) : VTE, including deep vein thrombosis (DVT) \n",
      "and pulmonary embolism (PE) have been reported in patients using testosterone \n",
      "products. Discontinue AZMIRO  if VTE is suspected and initiate appropriate \n",
      "workup and management (5.4). \n",
      "ï‚· Abuse of Testosterone and Monitoring of Serum Testosterone: If testosterone use \n",
      "at doses higher than recommended for the approved indication and in combination \n",
      "with other anabolic androgenic steroids is suspected, check serum testosterone \n",
      "concentration (5.5). \n",
      "ï‚· Potential for Adverse Effects on Spermatogenesis: AZMIRO may cause \n",
      "azoospermia (5.7, 8.3). \n",
      "ï‚· Edema: Edema, with or without conges tive heart failure (CHF), may occur in \n",
      "patients with pre-existing cardiac, renal, or hepatic disease. Discontinue AZMIRO \n",
      "and initiate appropriate workup (5.9). \n",
      "ï‚· Sleep Apnea: AZMIRO may potentiate sleep apnea in those with risk factors \n",
      "(5.10). \n",
      "ï‚· Lipid Changes: Testosterone may affect serum lipid profile.  Monitor patient lipid \n",
      "concentrations; if necessary, adjust dosage of lipid lowering drug(s) or discontinue \n",
      "AZMIRO (5.12). \n",
      "ï‚· Adverse Effects on Bone Maturation: Testosterone may result in acceleration of \n",
      "bone age and premature closure of epiphyses in pediatric patients which may result \n",
      "in compromised adult stature. Monitor the effect on bone maturation by assessing \n",
      "bone age of the wrist and hand every 6 months. \n",
      "----------------------------------ADVERSE REACTIONS----------------------------------\n",
      "Common adverse reactions (incidence â‰¥4%) are injection site erythema and injection \n",
      "site reaction (6.1). \n",
      "Other adverse reactions include: polyc ythemia, gynecomastia, headache, and \n",
      "depression (6.2). \n",
      "To report SUSPECTED ADVERSE REACTIONS, contact Slayback Pharma at \n",
      "1-844-566-2505 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch \n",
      "----------------------------------DRUG INTERACTIONS----------------------------------\n",
      "ï‚· Insulin: In patients with diabetes, concomitant use with AZMIRO may decrease \n",
      "blood glucose and insulin requirements (7.1). \n",
      "ï‚· Oral Anticoagulants: Concomitant use with AZMIRO may cause changes in \n",
      "anticoagulant activity. Monitor International Normalized Ratio and prothrombin \n",
      "time frequently (7.2). \n",
      "ï‚· Corticosteroids: Concomitant use with AZMIRO may result in increased fluid \n",
      "retention. Use with caution, particularly in patients with cardiac, renal, or hepatic \n",
      "disease (7.3). \n",
      "----------------------------USE IN SPECIFIC POPULATIONS--------------------------\n",
      "Geriatric Patients: Geriatric patients treated with androgens may also be at risk for \n",
      "worsening of signs and symptoms of BPH and prostatic carcinoma (8.5). \n",
      "See 17 for PATIENT COUNSELING INFORMATION. \n",
      "Revised: 2/2024 \n",
      "FULL PRESCRIBING INFORMATION: CONTENTS*  \n",
      "1 INDICATIONS AND USAGE 6 ADVERSE REACTIONS \n",
      "2 DOSAGE AND ADMINISTRATION 6.1 Clinical Trial Experience \n",
      "2.1 Important Dosage Information 6.2 Other Adverse Reactions \n",
      "2.2 Confirmation of Hypogonadism before Initiation of AZMIRO 7 DRUG INTERACTIONS \n",
      "2.3 Recommended Dosage 7.1 Insulin \n",
      "2.4 Administration Instructions for AZMIRO Single-dose Vial 7.2 Oral Anticoagulants \n",
      "2.5 Important Administration Information and Administration 7.3 Corticosteroids \n",
      "Instructions for AZMIRO Prefilled Syringe 8 USE IN SPECIFIC POPULATIONS \n",
      "3 DOSAGE FORMS AND STRENGTHS 8.1 Pregnancy \n",
      "4 CONTRAINDICATIONS 8.2 Lactation \n",
      "5 WARNINGS AND PRECAUTIONS 8.3 Females and Males of Reproductive Potential \n",
      "5.1 Polycythemia 8.4 Pediatric Use \n",
      "5.2 Cardiovascular Risk 8.5 Geriatric Use \n",
      "5.3 Worsening of Benign Prostatic Hyperplasia (BPH) and Potential 9 DRUG ABUSE AND DEPENDENCE \n",
      "Risk of Prostate Cancer 9.1 Controlled Substance \n",
      "5.4 Venous Thromboembolism (VTE) 9.2 Abuse \n",
      "5.5 Abuse of Testosterone and Monitoring of Serum Testosterone 9.3 Dependence \n",
      "Concentrations 10 OVERDOSAGE \n",
      "5.6 Not for Use in Women 11 DESCRIPTION \n",
      "5.7 Potential for Adverse Effects on Spermatogenesis 12 CLINICAL PHARMACOLOGY \n",
      "5.8 Hepatic Adverse Effects 12.1 Mechanism of Action \n",
      "5.9 Edema 12.2 Pharmacodynamics \n",
      "5.10 Sleep Apnea 12.3 Pharmacokinetics \n",
      "5.11 Gynecomastia 13 NONCLINICAL TOXICOLOGY \n",
      "5.12 Lipid Changes 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility \n",
      "5.13 Hypercalcemia 16 HOW SUPPLIED/STORAGE AND HANDLING \n",
      "5.14 Decreased Thyroxine-binding Globulin 17 PATIENT COUNSELING INFORMATION \n",
      "5.15 Increases in Prolactin *Sections or subsections omitted from the full prescribing information are not \n",
      "5.16 Adverse Effects on Bone Maturation listed. \n",
      "Reference ID: 5321225 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfdaReference ID:FULL PRESCRIBING INFORMATION \n",
      "1. INDICATIONS AND USAGE \n",
      "AZMIRO is indicated for testosterone replacement therapy in males in conditions associated with a \n",
      "deficiency or absence of endogenous testosterone: \n",
      "ï‚· Primary hypogonadism (congenital or  acquired): testicular failur e due to conditions such as \n",
      "cryptorchidism, bilateral tors ion, orchitis, vanishing tes tis syndrome; or orchiectomy, \n",
      "Klinefelterâ€™s syndrome, or toxi c damage from alcohol or heavy metals, ch emotherapy, or toxic \n",
      "damage from alcohol or heavy metals. Thes e men usually have low serum testosterone \n",
      "concentrations and gonadotropins (follicle s timulating hormone (FSH),  luteinizing hormone \n",
      "(LH)) above the normal range [see Dosage and Administration (2.2)]. \n",
      "ï‚· Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing \n",
      "hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, \n",
      "trauma, or radiation.  These men have low testosterone serum concentrations but have \n",
      "gonadotropins in the normal or low range [see Dosage and Administration (2.2)]. \n",
      "Limitations of Use \n",
      "ï‚· Safety and efficacy of AZMIRO in men with â€œage- relate d hypogonadismâ€ (also referred to \n",
      "as â€œlate-onset hypogonadismâ€) have not been established. \n",
      "ï‚· Safety and efficacy of AZMIRO in pediatric patients below the age of 12 years have not been \n",
      "established [see Use in Specific Populations (8.4)]. \n",
      "2. DOSAGE AND ADMINISTRATION \n",
      "2.1 Important Dosage Information \n",
      "ï‚· Injectable testosterone products may have different doses, strengths, or administration \n",
      "instructions and they are not substitutable on a milligram-per-milligram basis. \n",
      "ï‚· Administer AZMIRO by deep gluteal intramuscular injection only. \n",
      "2.2 Confirmation of Hypogonadism before Initiation of AZMIRO \n",
      "Prior to initiating AZMIRO, confirm the diagnosis of hypogonadism by ensuring that serum \n",
      "testosterone concentrations have been measured in the morning on at least two separate days and \n",
      "that these serum testosterone concentrations are below the normal range. \n",
      "2.3 Recommended Dosage  \n",
      "The recommended dosage of AZMIRO is 50 mg to 400 mg administered every two to four weeks as \n",
      "a deep intramuscular injection in the gluteal muscle. \n",
      "Individualize the dose and schedule of AZMIRO based on the patientâ€™s age, diagnosis, response to \n",
      "treatment, and the appearan\n"
     ]
    }
   ],
   "source": [
    "from langchain_community.document_loaders import PyPDFLoader\n",
    "file_path = r\"C:\\Users\\FahRe\\Downloads\\Medication Guides.pdf\" \n",
    "file_path = r\"C:\\Users\\FahRe\\Downloads\\test.pdf\" \n",
    "loader = PyPDFLoader(file_path, mode=\"single\",pages_delimiter=\"Reference ID:\")\n",
    "docs = loader.load()\n",
    "print(docs[0].page_content[:10000])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "43aacbe2",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Processing PDFs: 100%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ| 978/978 [39:14<00:00,  2.41s/it]  \n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "âœ… Valid documents for vectorstore: 0\n"
     ]
    },
    {
     "ename": "IndexError",
     "evalue": "list index out of range",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mIndexError\u001b[39m                                Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[37]\u001b[39m\u001b[32m, line 87\u001b[39m\n\u001b[32m     84\u001b[39m \u001b[38;5;28mprint\u001b[39m(\u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[33mâœ… Valid documents for vectorstore: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mlen\u001b[39m(docs)\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m\"\u001b[39m)\n\u001b[32m     86\u001b[39m embedding_model = OpenAIEmbeddings(openai_api_key=os.getenv(\u001b[33m\"\u001b[39m\u001b[33mOPENAI_KEY\u001b[39m\u001b[33m\"\u001b[39m))\n\u001b[32m---> \u001b[39m\u001b[32m87\u001b[39m vectorstore = \u001b[43mFAISS\u001b[49m\u001b[43m.\u001b[49m\u001b[43mfrom_documents\u001b[49m\u001b[43m(\u001b[49m\u001b[43mdocs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43membedding_model\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     88\u001b[39m vectorstore.save_local(\u001b[33m\"\u001b[39m\u001b[33mmeds_vector_db\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m     89\u001b[39m \u001b[38;5;28mprint\u001b[39m(\u001b[33m\"\u001b[39m\u001b[33mâœ… Vectorstore saved: meds_vector_db\u001b[39m\u001b[33m\"\u001b[39m)\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\vectorstores\\base.py:848\u001b[39m, in \u001b[36mVectorStore.from_documents\u001b[39m\u001b[34m(cls, documents, embedding, **kwargs)\u001b[39m\n\u001b[32m    845\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28many\u001b[39m(ids):\n\u001b[32m    846\u001b[39m         kwargs[\u001b[33m\"\u001b[39m\u001b[33mids\u001b[39m\u001b[33m\"\u001b[39m] = ids\n\u001b[32m--> \u001b[39m\u001b[32m848\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mcls\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mfrom_texts\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtexts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43membedding\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadatas\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmetadatas\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_community\\vectorstores\\faiss.py:1044\u001b[39m, in \u001b[36mFAISS.from_texts\u001b[39m\u001b[34m(cls, texts, embedding, metadatas, ids, **kwargs)\u001b[39m\n\u001b[32m   1025\u001b[39m \u001b[38;5;250m\u001b[39m\u001b[33;03m\"\"\"Construct FAISS wrapper from raw documents.\u001b[39;00m\n\u001b[32m   1026\u001b[39m \n\u001b[32m   1027\u001b[39m \u001b[33;03mThis is a user friendly interface that:\u001b[39;00m\n\u001b[32m   (...)\u001b[39m\u001b[32m   1041\u001b[39m \u001b[33;03m        faiss = FAISS.from_texts(texts, embeddings)\u001b[39;00m\n\u001b[32m   1042\u001b[39m \u001b[33;03m\"\"\"\u001b[39;00m\n\u001b[32m   1043\u001b[39m embeddings = embedding.embed_documents(texts)\n\u001b[32m-> \u001b[39m\u001b[32m1044\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mcls\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m__from\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1045\u001b[39m \u001b[43m    \u001b[49m\u001b[43mtexts\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1046\u001b[39m \u001b[43m    \u001b[49m\u001b[43membeddings\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1047\u001b[39m \u001b[43m    \u001b[49m\u001b[43membedding\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1048\u001b[39m \u001b[43m    \u001b[49m\u001b[43mmetadatas\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmetadatas\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1049\u001b[39m \u001b[43m    \u001b[49m\u001b[43mids\u001b[49m\u001b[43m=\u001b[49m\u001b[43mids\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1050\u001b[39m \u001b[43m    \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1051\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_community\\vectorstores\\faiss.py:1001\u001b[39m, in \u001b[36mFAISS.__from\u001b[39m\u001b[34m(cls, texts, embeddings, embedding, metadatas, ids, normalize_L2, distance_strategy, **kwargs)\u001b[39m\n\u001b[32m    998\u001b[39m     index = faiss.IndexFlatIP(\u001b[38;5;28mlen\u001b[39m(embeddings[\u001b[32m0\u001b[39m]))\n\u001b[32m    999\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m   1000\u001b[39m     \u001b[38;5;66;03m# Default to L2, currently other metric types not initialized.\u001b[39;00m\n\u001b[32m-> \u001b[39m\u001b[32m1001\u001b[39m     index = faiss.IndexFlatL2(\u001b[38;5;28mlen\u001b[39m(\u001b[43membeddings\u001b[49m\u001b[43m[\u001b[49m\u001b[32;43m0\u001b[39;49m\u001b[43m]\u001b[49m))\n\u001b[32m   1002\u001b[39m docstore = kwargs.pop(\u001b[33m\"\u001b[39m\u001b[33mdocstore\u001b[39m\u001b[33m\"\u001b[39m, InMemoryDocstore())\n\u001b[32m   1003\u001b[39m index_to_docstore_id = kwargs.pop(\u001b[33m\"\u001b[39m\u001b[33mindex_to_docstore_id\u001b[39m\u001b[33m\"\u001b[39m, {})\n",
      "\u001b[31mIndexError\u001b[39m: list index out of range"
     ]
    }
   ],
   "source": [
    "# opne csv \n",
    "import pandas as pd\n",
    "import requests\n",
    "from PyPDF2 import PdfReader\n",
    "import os\n",
    "from tqdm import tqdm\n",
    "from langchain.embeddings import OpenAIEmbeddings\n",
    "from langchain.vectorstores import FAISS\n",
    "from langchain.docstore.document import Document\n",
    "df = pd.read_csv(r\"C:\\Users\\FahRe\\Downloads\\Medication Guides.csv\")\n",
    "\n",
    "\n",
    "\n",
    "def extract_text_from_pdf_url(url, ):\n",
    "    try:\n",
    "        if \"#page=\" in url:\n",
    "            url = url.split(\"#\")[0]\n",
    "\n",
    "        headers = {\"User-Agent\": \"Mozilla/5.0\"}\n",
    "        response = requests.get(url, headers=headers, timeout=20)\n",
    "        response.raise_for_status()\n",
    "\n",
    "\n",
    "        text = \"\\n\".join([\n",
    "            p.extract_text() or \"\" for p in reader.pages\n",
    "        ]).strip()\n",
    "\n",
    "        if text:\n",
    "            return text\n",
    "\n",
    "        return \"[Empty PDF]\"\n",
    "\n",
    "    except Exception as e:\n",
    "        return f\"[Error: {e}]\"\n",
    "\n",
    "os.makedirs(\"pdfs\", exist_ok=True)\n",
    "os.makedirs(\"texts\", exist_ok=True)\n",
    "\n",
    "#entries = df.to_dict(orient=\"records\")\n",
    "for entry in tqdm(df.to_dict(orient=\"records\"), desc=\"Processing PDFs\"):\n",
    "    try:\n",
    "        url = entry[\"URL\"]\n",
    "        appl_no = str(entry[\"Appl. No.\"])\n",
    "        text = extract_text_from_pdf_url(url)\n",
    "        with open(f\"texts/{appl_no}.txt\", \"w\", encoding=\"utf-8\") as f:\n",
    "            f.write(text)\n",
    "\n",
    "        entry[\"pdf_text\"] = text\n",
    "\n",
    "    except Exception as e:\n",
    "        print(f\"Error processing {entry['Drug Name']} - {e}\")\n",
    "        entry[\"pdf_text\"] = f\"[Error: {e}]\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "9c52b803",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import requests\n",
    "import pandas as pd\n",
    "from tqdm import tqdm\n",
    "from langchain_community.document_loaders import PyPDFLoader\n",
    "\n",
    "csv_path = r\"C:\\Users\\FahRe\\Downloads\\Medication Guides.csv\"\n",
    "pdf_dir = \"pdfs\"\n",
    "txt_dir = \"texts\"\n",
    "os.makedirs(pdf_dir, exist_ok=True)\n",
    "os.makedirs(txt_dir, exist_ok=True)\n",
    "df = pd.read_csv(csv_path)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3e7c45a7",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "ðŸ“„ Processing PDFs:  10%|â–‰         | 97/978 [04:37<1:04:45,  4.41s/it]"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import requests\n",
    "import pandas as pd\n",
    "from tqdm import tqdm\n",
    "from langchain_community.document_loaders import PyPDFLoader\n",
    "\n",
    "csv_path = r\"C:\\Users\\FahRe\\Downloads\\Medication Guides.csv\"\n",
    "pdf_dir = \"pdfs\"\n",
    "txt_dir = \"texts\"\n",
    "os.makedirs(pdf_dir, exist_ok=True)\n",
    "os.makedirs(txt_dir, exist_ok=True)\n",
    "df = pd.read_csv(csv_path)\n",
    "\n",
    "def download_pdf(url, appl_no):\n",
    "    try:\n",
    "        url = url.split(\"#\")[0]\n",
    "        headers = {\"User-Agent\": \"Mozilla/5.0\"}\n",
    "        response = requests.get(url, headers=headers, timeout=30)\n",
    "        response.raise_for_status()\n",
    "        local_path = os.path.join(pdf_dir, f\"{appl_no}.pdf\")\n",
    "        with open(local_path, \"wb\") as f:\n",
    "            f.write(response.content)\n",
    "        return local_path\n",
    "    except Exception as e:\n",
    "        return f\"[Error: Download failed - {e}]\"\n",
    "\n",
    "\n",
    "def extract_text_with_langchain(pdf_path):\n",
    "    try:\n",
    "        loader = PyPDFLoader(pdf_path, mode=\"single\", pages_delimiter=\"Reference ID:\")\n",
    "        docs = loader.load()\n",
    "        full_text = \"\\n\\n\".join(doc.page_content.strip() for doc in docs if doc.page_content)\n",
    "        return full_text if full_text.strip() else \"[Empty PDF]\"\n",
    "    except Exception as e:\n",
    "        return f\"[Error: Extraction failed - {e}]\"\n",
    "text_results = []\n",
    "\n",
    "for idx, row in tqdm(df.iterrows(), total=len(df), desc=\"ðŸ“„ Processing PDFs\"):\n",
    "    appl_no = row['Appl. No.']\n",
    "    url = row['URL']\n",
    "    pdf_path = download_pdf(url, appl_no)\n",
    "    extracted_text = extract_text_with_langchain(pdf_path)\n",
    "    txt_file_path = os.path.join(txt_dir, f\"{appl_no}.txt\")\n",
    "    with open(txt_file_path, \"w\", encoding=\"utf-8\") as f:\n",
    "        f.write(extracted_text)\n",
    "    text_results.append({\"appl_no\": appl_no, \"text\": extracted_text})\n",
    "\n",
    "print(\"\\nâœ… All Medication Guide PDFs processed and saved.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "fe5555db",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Drug Name</th>\n",
       "      <th>Active Ingredient</th>\n",
       "      <th>Form; Route</th>\n",
       "      <th>Appl. No.</th>\n",
       "      <th>Company</th>\n",
       "      <th>Date</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ABACAVIR and LAMIVUDINE</td>\n",
       "      <td>ABACAVIR SULFATE;LAMIVUDINE</td>\n",
       "      <td>TABLET;ORAL</td>\n",
       "      <td>204311</td>\n",
       "      <td>MYLAN LABORATORIES LIMITED</td>\n",
       "      <td>12/22/2023</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ABILIFY</td>\n",
       "      <td>ARIPIPRAZOLE</td>\n",
       "      <td>SOLUTION;ORAL</td>\n",
       "      <td>21713</td>\n",
       "      <td>OTSUKA</td>\n",
       "      <td>02/05/2020</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ABILIFY</td>\n",
       "      <td>ARIPIPRAZOLE</td>\n",
       "      <td>TABLET, ORALLY DISINTEGRATING;ORAL</td>\n",
       "      <td>21729</td>\n",
       "      <td>OTSUKA</td>\n",
       "      <td>02/05/2020</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ABILIFY</td>\n",
       "      <td>ARIPIPRAZOLE</td>\n",
       "      <td>TABLET;ORAL</td>\n",
       "      <td>21436</td>\n",
       "      <td>OTSUKA</td>\n",
       "      <td>01/22/2025</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ABILIFY</td>\n",
       "      <td>ARIPIPRAZOLE</td>\n",
       "      <td>INJECTABLE;INTRAMUSCULAR</td>\n",
       "      <td>21866</td>\n",
       "      <td>OTSUKA</td>\n",
       "      <td>02/05/2020</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>973</th>\n",
       "      <td>ZYNYZ</td>\n",
       "      <td>RETIFANLIMAB-DLWR</td>\n",
       "      <td>INJECTABLE;INTRAVENOUS</td>\n",
       "      <td>761334</td>\n",
       "      <td>INCYTE</td>\n",
       "      <td>04/22/2024</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>974</th>\n",
       "      <td>ZYPREXA</td>\n",
       "      <td>OLANZAPINE</td>\n",
       "      <td>TABLET;ORAL</td>\n",
       "      <td>20592</td>\n",
       "      <td>LILLY</td>\n",
       "      <td>01/22/2025</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>975</th>\n",
       "      <td>ZYPREXA</td>\n",
       "      <td>OLANZAPINE</td>\n",
       "      <td>INJECTABLE;INTRAMUSCULAR</td>\n",
       "      <td>21253</td>\n",
       "      <td>LILLY</td>\n",
       "      <td>01/22/2025</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>976</th>\n",
       "      <td>ZYPREXA RELPREVV</td>\n",
       "      <td>OLANZAPINE PAMOATE</td>\n",
       "      <td>SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR</td>\n",
       "      <td>22173</td>\n",
       "      <td>ELI LILLY CO</td>\n",
       "      <td>01/22/2025</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>977</th>\n",
       "      <td>ZYPREXA ZYDIS</td>\n",
       "      <td>OLANZAPINE</td>\n",
       "      <td>TABLET, ORALLY DISINTEGRATING;ORAL</td>\n",
       "      <td>21086</td>\n",
       "      <td>LILLY</td>\n",
       "      <td>01/22/2025</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>978 rows Ã— 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                   Drug Name            Active Ingredient  \\\n",
       "0    ABACAVIR and LAMIVUDINE  ABACAVIR SULFATE;LAMIVUDINE   \n",
       "1                    ABILIFY                 ARIPIPRAZOLE   \n",
       "2                    ABILIFY                 ARIPIPRAZOLE   \n",
       "3                    ABILIFY                 ARIPIPRAZOLE   \n",
       "4                    ABILIFY                 ARIPIPRAZOLE   \n",
       "..                       ...                          ...   \n",
       "973                    ZYNYZ            RETIFANLIMAB-DLWR   \n",
       "974                  ZYPREXA                   OLANZAPINE   \n",
       "975                  ZYPREXA                   OLANZAPINE   \n",
       "976         ZYPREXA RELPREVV           OLANZAPINE PAMOATE   \n",
       "977            ZYPREXA ZYDIS                   OLANZAPINE   \n",
       "\n",
       "                                    Form; Route Appl. No.  \\\n",
       "0                                   TABLET;ORAL    204311   \n",
       "1                                 SOLUTION;ORAL     21713   \n",
       "2            TABLET, ORALLY DISINTEGRATING;ORAL     21729   \n",
       "3                                   TABLET;ORAL     21436   \n",
       "4                      INJECTABLE;INTRAMUSCULAR     21866   \n",
       "..                                          ...       ...   \n",
       "973                      INJECTABLE;INTRAVENOUS    761334   \n",
       "974                                 TABLET;ORAL     20592   \n",
       "975                    INJECTABLE;INTRAMUSCULAR     21253   \n",
       "976  SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR     22173   \n",
       "977          TABLET, ORALLY DISINTEGRATING;ORAL     21086   \n",
       "\n",
       "                        Company        Date  \\\n",
       "0    MYLAN LABORATORIES LIMITED  12/22/2023   \n",
       "1                        OTSUKA  02/05/2020   \n",
       "2                        OTSUKA  02/05/2020   \n",
       "3                        OTSUKA  01/22/2025   \n",
       "4                        OTSUKA  02/05/2020   \n",
       "..                          ...         ...   \n",
       "973                      INCYTE  04/22/2024   \n",
       "974                       LILLY  01/22/2025   \n",
       "975                       LILLY  01/22/2025   \n",
       "976                ELI LILLY CO  01/22/2025   \n",
       "977                       LILLY  01/22/2025   \n",
       "\n",
       "                                                   URL  \n",
       "0    https://www.accessdata.fda.gov/drugsatfda_docs...  \n",
       "1    https://www.accessdata.fda.gov/drugsatfda_docs...  \n",
       "2    https://www.accessdata.fda.gov/drugsatfda_docs...  \n",
       "3    https://www.accessdata.fda.gov/drugsatfda_docs...  \n",
       "4    https://www.accessdata.fda.gov/drugsatfda_docs...  \n",
       "..                                                 ...  \n",
       "973  https://www.accessdata.fda.gov/drugsatfda_docs...  \n",
       "974  https://www.accessdata.fda.gov/drugsatfda_docs...  \n",
       "975  https://www.accessdata.fda.gov/drugsatfda_docs...  \n",
       "976  https://www.accessdata.fda.gov/drugsatfda_docs...  \n",
       "977  https://www.accessdata.fda.gov/drugsatfda_docs...  \n",
       "\n",
       "[978 rows x 7 columns]"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "45669d7e",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "ðŸ“„ Processing PDFs:   0%|          | 0/978 [00:00<?, ?it/s]\n"
     ]
    },
    {
     "ename": "AttributeError",
     "evalue": "'Pandas' object has no attribute 'Appl. No.'",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mAttributeError\u001b[39m                            Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[62]\u001b[39m\u001b[32m, line 2\u001b[39m\n\u001b[32m      1\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m row \u001b[38;5;129;01min\u001b[39;00m tqdm(df.itertuples(index=\u001b[38;5;28;01mFalse\u001b[39;00m), total=\u001b[38;5;28mlen\u001b[39m(df), desc=\u001b[33m\"\u001b[39m\u001b[33mðŸ“„ Processing PDFs\u001b[39m\u001b[33m\"\u001b[39m):\n\u001b[32m----> \u001b[39m\u001b[32m2\u001b[39m     appl_no = \u001b[38;5;28;43mgetattr\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mrow\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mAppl. No.\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[32m      3\u001b[39m     url = \u001b[38;5;28mgetattr\u001b[39m(row, \u001b[33m\"\u001b[39m\u001b[33mURL\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m      5\u001b[39m     \u001b[38;5;66;03m# === Step 1: Download PDF ===\u001b[39;00m\n",
      "\u001b[31mAttributeError\u001b[39m: 'Pandas' object has no attribute 'Appl. No.'"
     ]
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a58bb7c0",
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "\n",
    "def clean_text(raw):\n",
    "    # Remove page headers/footers\n",
    "    text = re.sub(r\"Reference ID: \\d+\", \"\", raw)\n",
    "    text = re.sub(r\"(?i)This label may not be the latest.*?drugsatfda\", \"\", text)\n",
    "    # Normalize spaces and line breaks\n",
    "    text = re.sub(r\"\\n{2,}\", \"\\n\\n\", text)  # Keep paragraph breaks\n",
    "    text = re.sub(r\"[ \\t]+\", \" \", text)     # Remove weird spacing\n",
    "    text = re.sub(r\"â€“+\", \"-\", text)         # Fix dashes\n",
    "\n",
    "    return text.strip()\n",
    "sections = [\n",
    "    r\"(?i)^INDICATIONS AND USAGE\",\n",
    "    r\"(?i)^DOSAGE AND ADMINISTRATION\",\n",
    "    r\"(?i)^STORAGE AND HANDLING\",\n",
    "    r\"(?i)^ADVERSE REACTIONS\",\n",
    "    r\"(?i)^WARNINGS AND PRECAUTIONS\",\n",
    "]\n",
    "\n",
    "for sec in sections:\n",
    "    raw = re.sub(sec, f\"\\n\\n### {sec.upper()} ###\\n\\n\", raw)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "e54f9837",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ðŸ“‚ Processing 916 medication files...\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "ðŸ“„ Chunking files: 100%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ| 916/916 [00:07<00:00, 114.82it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "âœ… Total document chunks prepared: 109795\n",
      "ðŸ§  Embedding documents into vector space...\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mHTTPStatusError\u001b[39m                           Traceback (most recent call last)",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\openai\\_base_client.py:1007\u001b[39m, in \u001b[36mSyncAPIClient._request\u001b[39m\u001b[34m(self, cast_to, options, retries_taken, stream, stream_cls)\u001b[39m\n\u001b[32m   1006\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m-> \u001b[39m\u001b[32m1007\u001b[39m     \u001b[43mresponse\u001b[49m\u001b[43m.\u001b[49m\u001b[43mraise_for_status\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1008\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m httpx.HTTPStatusError \u001b[38;5;28;01mas\u001b[39;00m err:  \u001b[38;5;66;03m# thrown on 4xx and 5xx status code\u001b[39;00m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\httpx\\_models.py:829\u001b[39m, in \u001b[36mResponse.raise_for_status\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m    828\u001b[39m message = message.format(\u001b[38;5;28mself\u001b[39m, error_type=error_type)\n\u001b[32m--> \u001b[39m\u001b[32m829\u001b[39m \u001b[38;5;28;01mraise\u001b[39;00m HTTPStatusError(message, request=request, response=\u001b[38;5;28mself\u001b[39m)\n",
      "\u001b[31mHTTPStatusError\u001b[39m: Client error '429 Too Many Requests' for url 'https://api.openai.com/v1/embeddings'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/429",
      "\nDuring handling of the above exception, another exception occurred:\n",
      "\u001b[31mKeyboardInterrupt\u001b[39m                         Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[44]\u001b[39m\u001b[32m, line 76\u001b[39m\n\u001b[32m     73\u001b[39m     \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34membed_query\u001b[39m(\u001b[38;5;28mself\u001b[39m, text):\n\u001b[32m     74\u001b[39m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m.base.embed_query(text)\n\u001b[32m---> \u001b[39m\u001b[32m76\u001b[39m vectorstore = \u001b[43mFAISS\u001b[49m\u001b[43m.\u001b[49m\u001b[43mfrom_documents\u001b[49m\u001b[43m(\u001b[49m\u001b[43mall_docs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mTqdmEmbedding\u001b[49m\u001b[43m(\u001b[49m\u001b[43membedding_model\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     77\u001b[39m vectorstore.save_local(\u001b[33m\"\u001b[39m\u001b[33mmeds_vector_db\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m     78\u001b[39m \u001b[38;5;28mprint\u001b[39m(\u001b[33m\"\u001b[39m\u001b[33mâœ… FAISS vector store saved to \u001b[39m\u001b[33m'\u001b[39m\u001b[33mmeds_vector_db\u001b[39m\u001b[33m'\u001b[39m\u001b[33m\"\u001b[39m)\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\vectorstores\\base.py:848\u001b[39m, in \u001b[36mVectorStore.from_documents\u001b[39m\u001b[34m(cls, documents, embedding, **kwargs)\u001b[39m\n\u001b[32m    845\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28many\u001b[39m(ids):\n\u001b[32m    846\u001b[39m         kwargs[\u001b[33m\"\u001b[39m\u001b[33mids\u001b[39m\u001b[33m\"\u001b[39m] = ids\n\u001b[32m--> \u001b[39m\u001b[32m848\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mcls\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mfrom_texts\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtexts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43membedding\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadatas\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmetadatas\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_community\\vectorstores\\faiss.py:1043\u001b[39m, in \u001b[36mFAISS.from_texts\u001b[39m\u001b[34m(cls, texts, embedding, metadatas, ids, **kwargs)\u001b[39m\n\u001b[32m   1016\u001b[39m \u001b[38;5;129m@classmethod\u001b[39m\n\u001b[32m   1017\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mfrom_texts\u001b[39m(\n\u001b[32m   1018\u001b[39m     \u001b[38;5;28mcls\u001b[39m,\n\u001b[32m   (...)\u001b[39m\u001b[32m   1023\u001b[39m     **kwargs: Any,\n\u001b[32m   1024\u001b[39m ) -> FAISS:\n\u001b[32m   1025\u001b[39m \u001b[38;5;250m    \u001b[39m\u001b[33;03m\"\"\"Construct FAISS wrapper from raw documents.\u001b[39;00m\n\u001b[32m   1026\u001b[39m \n\u001b[32m   1027\u001b[39m \u001b[33;03m    This is a user friendly interface that:\u001b[39;00m\n\u001b[32m   (...)\u001b[39m\u001b[32m   1041\u001b[39m \u001b[33;03m            faiss = FAISS.from_texts(texts, embeddings)\u001b[39;00m\n\u001b[32m   1042\u001b[39m \u001b[33;03m    \"\"\"\u001b[39;00m\n\u001b[32m-> \u001b[39m\u001b[32m1043\u001b[39m     embeddings = \u001b[43membedding\u001b[49m\u001b[43m.\u001b[49m\u001b[43membed_documents\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtexts\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1044\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mcls\u001b[39m.__from(\n\u001b[32m   1045\u001b[39m         texts,\n\u001b[32m   1046\u001b[39m         embeddings,\n\u001b[32m   (...)\u001b[39m\u001b[32m   1050\u001b[39m         **kwargs,\n\u001b[32m   1051\u001b[39m     )\n",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[44]\u001b[39m\u001b[32m, line 72\u001b[39m, in \u001b[36mTqdmEmbedding.embed_documents\u001b[39m\u001b[34m(self, texts)\u001b[39m\n\u001b[32m     71\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34membed_documents\u001b[39m(\u001b[38;5;28mself\u001b[39m, texts):\n\u001b[32m---> \u001b[39m\u001b[32m72\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mlist\u001b[39m(tqdm(\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mbase\u001b[49m\u001b[43m.\u001b[49m\u001b[43membed_documents\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtexts\u001b[49m\u001b[43m)\u001b[49m, desc=\u001b[33m\"\u001b[39m\u001b[33mðŸ”— Embedding chunks\u001b[39m\u001b[33m\"\u001b[39m))\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_community\\embeddings\\openai.py:671\u001b[39m, in \u001b[36mOpenAIEmbeddings.embed_documents\u001b[39m\u001b[34m(self, texts, chunk_size)\u001b[39m\n\u001b[32m    668\u001b[39m \u001b[38;5;66;03m# NOTE: to keep things simple, we assume the list may contain texts longer\u001b[39;00m\n\u001b[32m    669\u001b[39m \u001b[38;5;66;03m#       than the maximum context and use length-safe embedding function.\u001b[39;00m\n\u001b[32m    670\u001b[39m engine = cast(\u001b[38;5;28mstr\u001b[39m, \u001b[38;5;28mself\u001b[39m.deployment)\n\u001b[32m--> \u001b[39m\u001b[32m671\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_get_len_safe_embeddings\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtexts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mengine\u001b[49m\u001b[43m=\u001b[49m\u001b[43mengine\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_community\\embeddings\\openai.py:497\u001b[39m, in \u001b[36mOpenAIEmbeddings._get_len_safe_embeddings\u001b[39m\u001b[34m(self, texts, engine, chunk_size)\u001b[39m\n\u001b[32m    495\u001b[39m batched_embeddings: List[List[\u001b[38;5;28mfloat\u001b[39m]] = []\n\u001b[32m    496\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m i \u001b[38;5;129;01min\u001b[39;00m _iter:\n\u001b[32m--> \u001b[39m\u001b[32m497\u001b[39m     response = \u001b[43membed_with_retry\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    498\u001b[39m \u001b[43m        \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m    499\u001b[39m \u001b[43m        \u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[43m=\u001b[49m\u001b[43mtokens\u001b[49m\u001b[43m[\u001b[49m\u001b[43mi\u001b[49m\u001b[43m \u001b[49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mi\u001b[49m\u001b[43m \u001b[49m\u001b[43m+\u001b[49m\u001b[43m \u001b[49m\u001b[43m_chunk_size\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    500\u001b[39m \u001b[43m        \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_invocation_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    501\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    502\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(response, \u001b[38;5;28mdict\u001b[39m):\n\u001b[32m    503\u001b[39m         response = response.dict()\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_community\\embeddings\\openai.py:120\u001b[39m, in \u001b[36membed_with_retry\u001b[39m\u001b[34m(embeddings, **kwargs)\u001b[39m\n\u001b[32m    118\u001b[39m \u001b[38;5;250m\u001b[39m\u001b[33;03m\"\"\"Use tenacity to retry the embedding call.\"\"\"\u001b[39;00m\n\u001b[32m    119\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m is_openai_v1():\n\u001b[32m--> \u001b[39m\u001b[32m120\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43membeddings\u001b[49m\u001b[43m.\u001b[49m\u001b[43mclient\u001b[49m\u001b[43m.\u001b[49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    121\u001b[39m retry_decorator = _create_retry_decorator(embeddings)\n\u001b[32m    123\u001b[39m \u001b[38;5;129m@retry_decorator\u001b[39m\n\u001b[32m    124\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m_embed_with_retry\u001b[39m(**kwargs: Any) -> Any:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\openai\\resources\\embeddings.py:128\u001b[39m, in \u001b[36mEmbeddings.create\u001b[39m\u001b[34m(self, input, model, dimensions, encoding_format, user, extra_headers, extra_query, extra_body, timeout)\u001b[39m\n\u001b[32m    122\u001b[39m             embedding.embedding = np.frombuffer(  \u001b[38;5;66;03m# type: ignore[no-untyped-call]\u001b[39;00m\n\u001b[32m    123\u001b[39m                 base64.b64decode(data), dtype=\u001b[33m\"\u001b[39m\u001b[33mfloat32\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m    124\u001b[39m             ).tolist()\n\u001b[32m    126\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m obj\n\u001b[32m--> \u001b[39m\u001b[32m128\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    129\u001b[39m \u001b[43m    \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43m/embeddings\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m    130\u001b[39m \u001b[43m    \u001b[49m\u001b[43mbody\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\u001b[43mparams\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43membedding_create_params\u001b[49m\u001b[43m.\u001b[49m\u001b[43mEmbeddingCreateParams\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    131\u001b[39m \u001b[43m    \u001b[49m\u001b[43moptions\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    132\u001b[39m \u001b[43m        \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[43m=\u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    133\u001b[39m \u001b[43m        \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[43m=\u001b[49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    134\u001b[39m \u001b[43m        \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[43m=\u001b[49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    135\u001b[39m \u001b[43m        \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    136\u001b[39m \u001b[43m        \u001b[49m\u001b[43mpost_parser\u001b[49m\u001b[43m=\u001b[49m\u001b[43mparser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    137\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    138\u001b[39m \u001b[43m    \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m=\u001b[49m\u001b[43mCreateEmbeddingResponse\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    139\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\openai\\_base_client.py:1247\u001b[39m, in \u001b[36mSyncAPIClient.post\u001b[39m\u001b[34m(self, path, cast_to, body, options, files, stream, stream_cls)\u001b[39m\n\u001b[32m   1233\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mpost\u001b[39m(\n\u001b[32m   1234\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   1235\u001b[39m     path: \u001b[38;5;28mstr\u001b[39m,\n\u001b[32m   (...)\u001b[39m\u001b[32m   1242\u001b[39m     stream_cls: \u001b[38;5;28mtype\u001b[39m[_StreamT] | \u001b[38;5;28;01mNone\u001b[39;00m = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m   1243\u001b[39m ) -> ResponseT | _StreamT:\n\u001b[32m   1244\u001b[39m     opts = FinalRequestOptions.construct(\n\u001b[32m   1245\u001b[39m         method=\u001b[33m\"\u001b[39m\u001b[33mpost\u001b[39m\u001b[33m\"\u001b[39m, url=path, json_data=body, files=to_httpx_files(files), **options\n\u001b[32m   1246\u001b[39m     )\n\u001b[32m-> \u001b[39m\u001b[32m1247\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\openai\\_base_client.py:920\u001b[39m, in \u001b[36mSyncAPIClient.request\u001b[39m\u001b[34m(self, cast_to, options, remaining_retries, stream, stream_cls)\u001b[39m\n\u001b[32m    917\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m    918\u001b[39m     retries_taken = \u001b[32m0\u001b[39m\n\u001b[32m--> \u001b[39m\u001b[32m920\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_request\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    921\u001b[39m \u001b[43m    \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    922\u001b[39m \u001b[43m    \u001b[49m\u001b[43moptions\u001b[49m\u001b[43m=\u001b[49m\u001b[43moptions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    923\u001b[39m \u001b[43m    \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    924\u001b[39m \u001b[43m    \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    925\u001b[39m \u001b[43m    \u001b[49m\u001b[43mretries_taken\u001b[49m\u001b[43m=\u001b[49m\u001b[43mretries_taken\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    926\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\openai\\_base_client.py:1013\u001b[39m, in \u001b[36mSyncAPIClient._request\u001b[39m\u001b[34m(self, cast_to, options, retries_taken, stream, stream_cls)\u001b[39m\n\u001b[32m   1011\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m remaining_retries > \u001b[32m0\u001b[39m \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28mself\u001b[39m._should_retry(err.response):\n\u001b[32m   1012\u001b[39m     err.response.close()\n\u001b[32m-> \u001b[39m\u001b[32m1013\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_retry_request\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1014\u001b[39m \u001b[43m        \u001b[49m\u001b[43minput_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1015\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1016\u001b[39m \u001b[43m        \u001b[49m\u001b[43mretries_taken\u001b[49m\u001b[43m=\u001b[49m\u001b[43mretries_taken\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1017\u001b[39m \u001b[43m        \u001b[49m\u001b[43mresponse_headers\u001b[49m\u001b[43m=\u001b[49m\u001b[43merr\u001b[49m\u001b[43m.\u001b[49m\u001b[43mresponse\u001b[49m\u001b[43m.\u001b[49m\u001b[43mheaders\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1018\u001b[39m \u001b[43m        \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1019\u001b[39m \u001b[43m        \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1020\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1022\u001b[39m \u001b[38;5;66;03m# If the response is streamed then we need to explicitly read the response\u001b[39;00m\n\u001b[32m   1023\u001b[39m \u001b[38;5;66;03m# to completion before attempting to access the response text.\u001b[39;00m\n\u001b[32m   1024\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m err.response.is_closed:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\openai\\_base_client.py:1060\u001b[39m, in \u001b[36mSyncAPIClient._retry_request\u001b[39m\u001b[34m(self, options, cast_to, retries_taken, response_headers, stream, stream_cls)\u001b[39m\n\u001b[32m   1056\u001b[39m log.info(\u001b[33m\"\u001b[39m\u001b[33mRetrying request to \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[33m in \u001b[39m\u001b[38;5;132;01m%f\u001b[39;00m\u001b[33m seconds\u001b[39m\u001b[33m\"\u001b[39m, options.url, timeout)\n\u001b[32m   1058\u001b[39m \u001b[38;5;66;03m# In a synchronous context we are blocking the entire thread. Up to the library user to run the client in a\u001b[39;00m\n\u001b[32m   1059\u001b[39m \u001b[38;5;66;03m# different thread if necessary.\u001b[39;00m\n\u001b[32m-> \u001b[39m\u001b[32m1060\u001b[39m time.sleep(timeout)\n\u001b[32m   1062\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m._request(\n\u001b[32m   1063\u001b[39m     options=options,\n\u001b[32m   1064\u001b[39m     cast_to=cast_to,\n\u001b[32m   (...)\u001b[39m\u001b[32m   1067\u001b[39m     stream_cls=stream_cls,\n\u001b[32m   1068\u001b[39m )\n",
      "\u001b[31mKeyboardInterrupt\u001b[39m: "
     ]
    }
   ],
   "source": [
    "import os\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain.docstore.document import Document\n",
    "from langchain.embeddings import OpenAIEmbeddings\n",
    "from langchain.vectorstores import FAISS\n",
    "from tqdm import tqdm  # âœ… make sure you're using tqdm.tqdm\n",
    "\n",
    "import pandas as pd\n",
    "\n",
    "# Load your CSV for metadata\n",
    "df = pd.read_csv(r\"C:\\Users\\FahRe\\Downloads\\Medication Guides.csv\")\n",
    "df = df.set_index(\"Appl. No.\")\n",
    "\n",
    "# === Chunker ===\n",
    "splitter = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=1000,\n",
    "    chunk_overlap=200,\n",
    "    separators=[\"\\n\\n\", \"\\n\", \".\", \" \"]\n",
    ")\n",
    "\n",
    "# === Build documents from text files + metadata ===\n",
    "all_docs = []\n",
    "text_files = [f for f in os.listdir(\"texts\") if f.endswith(\".txt\")]\n",
    "\n",
    "print(f\"ðŸ“‚ Processing {len(text_files)} medication files...\\n\")\n",
    "for fname in tqdm(text_files, desc=\"ðŸ“„ Chunking files\"):\n",
    "    appl_no = fname.replace(\".txt\", \"\")\n",
    "    path = os.path.join(\"texts\", fname)\n",
    "\n",
    "    try:\n",
    "        with open(path, \"r\", encoding=\"utf-8\") as f:\n",
    "            full_text = f.read()\n",
    "\n",
    "        if not full_text.strip() or full_text.startswith(\"[Error\"):\n",
    "            continue\n",
    "\n",
    "        # Use the metadata from the CSV\n",
    "        row = df.loc[int(appl_no)]\n",
    "        chunks = splitter.split_text(full_text)\n",
    "\n",
    "        for chunk in chunks:\n",
    "            all_docs.append(Document(\n",
    "                page_content=chunk,\n",
    "                metadata={\n",
    "                    \"application_no\": appl_no,\n",
    "                    \"drug_name\": row[\"Drug Name\"],\n",
    "                    \"active_ingredient\": row[\"Active Ingredient\"],\n",
    "                    \"form\": row[\"Form; Route\"],\n",
    "                    \"company\": row[\"Company\"],\n",
    "                    \"date\": row[\"Date\"],\n",
    "                    \"url\": row[\"URL\"],\n",
    "                }\n",
    "            ))\n",
    "\n",
    "    except Exception as e:\n",
    "        print(f\"âš ï¸ Skipped {fname}: {e}\")\n",
    "\n",
    "print(f\"\\nâœ… Total document chunks prepared: {len(all_docs)}\")\n",
    "\n",
    "# === Embed and store ===\n",
    "print(\"ðŸ§  Embedding documents into vector space...\")\n",
    "embedding_model = OpenAIEmbeddings(openai_api_key=os.getenv(\"OPENAI_KEY\"))\n",
    "\n",
    "# Wrap the embedding process in a tqdm progress bar manually\n",
    "from langchain.embeddings.base import Embeddings\n",
    "\n",
    "# Patch to show progress inside FAISS\n",
    "class TqdmEmbedding(Embeddings):\n",
    "    def __init__(self, base):\n",
    "        self.base = base\n",
    "    def embed_documents(self, texts):\n",
    "        return list(tqdm(self.base.embed_documents(texts), desc=\"ðŸ”— Embedding chunks\"))\n",
    "    def embed_query(self, text):\n",
    "        return self.base.embed_query(text)\n",
    "\n",
    "vectorstore = FAISS.from_documents(all_docs, TqdmEmbedding(embedding_model))\n",
    "vectorstore.save_local(\"meds_vector_db\")\n",
    "print(\"âœ… FAISS vector store saved to 'meds_vector_db'\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e6b7cb92",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "print(f\"\\nâœ… Valid documents for vectorstore: {len(docs)}\")\n",
    "\n",
    "embedding_model = OpenAIEmbeddings(openai_api_key=os.getenv(\"OPENAI_KEY\"))\n",
    "vectorstore = FAISS.from_documents(docs, embedding_model)\n",
    "vectorstore.save_local(\"meds_vector_db\")\n",
    "print(\"âœ… Vectorstore saved: meds_vector_db\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "92de637d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Extracted Text:\n",
      " HIGHLIGHTS OF PRESCRIBING INFORMATION \n",
      "These highlights do not include all the information needed to u se \n",
      "ZOHYDROÂ® ER safely and effectively. See full prescribing information \n",
      "for ZOHYDROÂ® ER. \n",
      "ZOHYDROÂ® ER (hydrocodone bitartrate) extended-release capsules, for \n",
      "oral use, CII Initial U.S. Approval: 1943 \n",
      "WARNING: ADDICTION, ABUSE, AND MISUSE; RISK \n",
      "EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-\n",
      "THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL\n",
      "\t\n",
      "INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and \n",
      "CYTOCHROME P450 3A4 IN TERACTION; RISKS FROM \n",
      "CONCOMITANT USE WITH BENZODIAZEPINES AND OTHER CNS \n",
      "DEPRESSANT; INTERACTION WITH ALCOHOL \n",
      "See full prescribing information for complete boxed warning. \n",
      "ï‚·\t ZOHYDRO ER exposes users to risks of addiction, abuse, and misu se, \n",
      "which can lead to overdose and death. Assess patientâ€™s risk before prescribing, and monitor regular ly for these behaviors and cond itions. \n",
      "(5.1) \n",
      "ï‚·\t To ensure that the benetfits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, th e Food and Drug Administration \n",
      "(FDA) has required a Risk Evalua tion and Mitigation Strategy (REMS) \n",
      "for these products. (5.2) \n",
      "ï‚·\t Serious, life-threatening, or fatal respiratory depression may occur. \n",
      "Monitor closely, especially upon initiation or following a dose  increase. \n",
      "Instruct patients to swallow ZOHYDRO ER whole to avoid exposure  to \n",
      "a potentially fatal dose of hydrocodone. (5.3) \n",
      "ï‚·\t Accidental ingestion of ZOHYDRO ER, especially in children, can result in a fatal overdose of hydrocodone. (5.3) \n",
      "ï‚·\t Prolonged use of ZOHYDRO ER during pregnancy can result in neonatal opioid withdrawal syndr ome, which may be life-threaten ing if \n",
      "not recognized and treated. If prolonged opioid use is required  in a \n",
      "pregnant woman, advise the patie nt of the risk of neonatal opio id \n",
      "withdrawal syndrome and ensure t hat appropriate treatment will be \n",
      "available. (5.4) \n",
      "ï‚·\t Concomitant use with CYP3A4 inhi bitors (or discontinuation of \n",
      "CYP3A4 inducers) can result in a f atal overdose of hydrocodone. (5.5) \n",
      "ï‚·\t Concomitant use of opioids with benzodiazepines or other centra l \n",
      "nervous system (CNS) depressants, including alcohol, may result  in \n",
      "profound sedation, respiratory d epression, coma, and death.  Re serve \n",
      "concomitant prescribing for use in patients for whom alternativ e \n",
      "treatment options are inadequate; limit dosages and durations t o the \n",
      "minimum required; and follow pati ents for signs and symptoms of \n",
      "respiratory depression and sedation. (5.6, 7) \n",
      "ï‚·\t Instruct patients not to consume alcohol or any products contai ning \n",
      "alcohol while taking ZOHYDRO ER b ecause co-ingestion can result  in \n",
      "fatal plasma hydrocodone levels. (5.6) \n",
      "----------------------------RECENT MAJOR CHANGES --------------------------\n",
      "Dosage and Administration (2.2) 03/2021 \n",
      "Warnings and Precautions (5.1, 5.3, 5.6) 03/2021 \n",
      "--------------------------- INDICATIONS AND USAGE ----------------------------\n",
      "ZOHYDRO ER is an opioid agonist indicated for the management of pain \n",
      "severe enough to require daily, around-the-clock, long-term opi oid treatment \n",
      "and for which alternative treatment options are inadequate. (1) \n",
      "Limitations of Use \n",
      "â€¢\t\tBecause of the risks of addicti on, abuse, and misuse with opioi ds, even \n",
      "at recommended doses, and because  of the greater risks of overd ose and \n",
      "death with extended-release opioid formulations, reserve \n",
      "ZOHYDRO ER for use in patients for whom alternative treatment \n",
      "options (e.g., non-opioid analgesics or immediate-release opioi ds) are \n",
      "ineffective, not tolerated, or w ould be otherwise inadequate to provide \n",
      "sufficient management of pain. (1) \n",
      "â€¢\t\tZOHYDRO ER is not indicated as an as-needed (prn) analgesic. (1) \n",
      "----------------------- DOSAGE AND ADMINISTRATION -----------------------\n",
      "â€¢\t\tTo be prescribed only by healthcare providers knowledgeable in use of \n",
      "potent opioids for management of chronic pain \n",
      "â€¢\t\tDaily doses of ZOHYDRO ER, a sing le dose greater than 40 mg, or  a \n",
      "total daily dose greate r than 80 mg are only for use in patient s in whom \n",
      "tolerance to an opioid of comparable potency has been establish ed. (2.1) \n",
      "â€¢\t\tPatients considered opioid-tole rant are those taking, for one w eek or \n",
      "longer, at least 60 mg oral morphine per day, 25 mcg transderma l \n",
      "fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral \n",
      "hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg or al \n",
      "hydrocodone per day, or an equian algesic dose of another opioid . (2.1) â€¢\t\tUse the lowest effective dosage fo r the shortest duration consi stent with \n",
      "individual patient treatment goals. (2.1) \n",
      "â€¢\t\tIndividualize dosing based on se verity of pain, patient respons e, prior \n",
      "analgesic experience, and risk f actors for addiction, abuse, an d misuse. \n",
      "(2.1) \n",
      "â€¢\t\tInstruct patients to swallow Z OHYDRO ER intact and not to cut, break, \n",
      "chew, crush, or dissolv e the capsules (risk of potentially fata l overdose). \n",
      "(2.1, 5.1) \n",
      "â€¢\t\tDiscuss availability of naloxone  with the patient and caregiver and \n",
      "assess each patientâ€™s need for access to naloxone, both when initiating \n",
      "and renewing treatment with ZO HYDRO ER. Consider prescribing \n",
      "naloxone based on the patientâ€™s risk factors for overdose. (2.2 , 5.1, 5.3, \n",
      "5.6) \n",
      "â€¢\t\tFor opioid-naÃ¯ve and opioid non-tolerant patients, initiate wit h 10 mg \n",
      "capsules orally every 12 hours. (2.3) \n",
      "â€¢\t\tTo convert to ZOHYDRO ER from a nother opioid, use available \n",
      "conversion factors to obtain estimated dose. (2.3) \n",
      "â€¢\t\tDose titration of ZOHYDRO ER may o ccur every 3 to 7 days, using \n",
      "increments of 10 mg every 12 hours (i.e., 20 mg per day). (2.4) \n",
      "â€¢\t\tPatients with Severe Hepatic Impairment: Initiate dosing with 1 0 mg \n",
      "every 12 hours and titr ate carefully, while monitoring for resp iratory \n",
      "depression, sedation, and hypotension.  No adjustment in starti ng dose \n",
      "with ZOHYDRO ER is required in p atients with mild or moderate \n",
      "hepatic impairment. (2.5) \n",
      "â€¢\t\tDo not abruptly discontinue ZOHYD RO ER in a physically dependen t \n",
      "patient. (2.6) \n",
      "---------------------- DOSAGE FORMS AND STRENGTHS -------------------- -\n",
      "Extended-release capsules: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, a nd 50 mg (3) \n",
      "------------------------------- CONTRAINDICATIONS ----------------------------- -\n",
      "â€¢\t\tSignificant respiratory depression (4) \n",
      "â€¢\t\tAcute or severe bronchial asthma in an unmonitored setting or i n the \n",
      "absence of resuscitative equipment (4) \n",
      "â€¢\t\tKnown or suspected gastrointestinal obstruction, including para lytic \n",
      "ileus (4) \n",
      "â€¢\t\tHypersensitivity to hydrocodone o r to any other components of \n",
      "ZOHYDRO ER (4)\n",
      "\t\n",
      "----------------------- WARNINGS AND PRECAUTIONS ------------------------\n",
      "â€¢\t\tLife-Threatening Respiratory De pression in Patients with Chroni c \n",
      "Pulmonary Disease or in Elderly , Cachectic, or Debilitated Pati ents: \n",
      "Monitor closely, particularly during initiation and titration. (5.3) \n",
      "â€¢\t\tAdrenal Insufficiency:  If diagnosed, treat with physiologic re placement \n",
      "of corticosteroids, and wean pa tient off of the opioid. (5.8) \n",
      "â€¢\t\tSevere Hypotension: Monitor during dosage initiation and titrat ion. \n",
      "Avoid use of ZOHYDRO ER in patient s with circulatory shock. (5. 9) \n",
      "â€¢\t\tRisks of Use in Patients with Increased Intracranial Pressure, Brain \n",
      "Tumors, Head Injury, or Impaired Consciousness: Monitor for sed ation \n",
      "and respiratory depr ession. Avoid use of ZOHYDRO ER in patients \n",
      "with circulatory shock. (5.10) \n",
      "------------------------------- ADVERSE REACTIONS ------------------------------\n",
      "Adverse reactions in â‰¥2% of pa tients in placebo-controlled tria ls include \n",
      "constipation, nausea, somnolen ce, fatigue, headache, dizziness, dry mouth, \n",
      "vomiting, pruritus, abdominal pain, edema peripheral, upper res piratory tract \n",
      "infection, muscle spasms, urinary tract infection, back pain, a nd tremor. (6.1) \n",
      "To report SUSPECTED ADVERSE  REACTIONS, contact Currax \n",
      "Pharmaceuticals LLC at 1-800-793-2145 or FDA at 1-800-FDA-1088 or \n",
      "www.fda.gov/medwatch . \n",
      "------------------------------- DRUG INTERACTIONS ------------------------------\n",
      "â€¢\t\tSerotonergic Drugs: Concomitant use may result in serotonin sy ndrome. \n",
      "Discontinue ZOHYDRO ER if serotonin syndrome is suspected. (7) \n",
      "â€¢\t\tMonoamine Oxidase Inhibitors (MAOIs): Can potentiate the effect s of \n",
      "hydrocodone. Avoid concomitant use  in patients receiving MAOIs or \n",
      "within 14 days of stopping an MAOI. (7) \n",
      "â€¢\t\tMixed Agonists/Antagonists and Pa rtial Agonist Opioid Analgesic s: \n",
      "Avoid use with ZOHYDRO ER becau se they may reduce analgesic \n",
      "effect of ZOHYDRO ER or precipi tate withdrawal symptoms. (7) \n",
      "----------------------- USE IN SPECIFIC POPULATIONS ------------------------\n",
      "â€¢\t\tPregnancy: May cause fetal harm. (8.1) \n",
      "â€¢\t\tLactation: Not recommended. (8.2) \n",
      "See 17 for PATIENT COUNSELING INFORMATION and Medication \n",
      "Guide \n",
      "Revised: 03/2021 \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "    \n",
      "   \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      "    \n",
      "   \n",
      "   \n",
      "   \n",
      "   \n",
      "   \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      "   \n",
      "   \n",
      "    \n",
      " \n",
      "    \n",
      "   \n",
      "    \n",
      "    \n",
      "    \n",
      "   \n",
      "    \n",
      "      \n",
      "  \n",
      "  \n",
      "  \n",
      " \n",
      "  \n",
      "  \n",
      "   \n",
      "  \n",
      "  \n",
      "   \n",
      "   \n",
      "  \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      "       \n",
      "  \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "     FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: ADDICTION, ABUSE, AND MISUSE; RISK \n",
      "EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-\n",
      "THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOI D WITHDRAWAL SYNDROME; \n",
      "and CYTOCHROME P450 3A4 INTERACTION; RISKS FROM \n",
      "CONCOMITANT USE WITH BENZODIAZEPINES AND OTHER CNS DEPRESSANTS; and IN TERACTION WITH ALCOHOL;  \n",
      "1 INDICATIONS AND USAGE \n",
      "2 DOSAGE AND ADMINISTRATION \n",
      "2.1\t    Important Dosage and Administration Information \n",
      "2.2  \t Patient Access to Naloxone f or the Emergency Treatment of Opioid \n",
      "Overdose \n",
      "2.3  \t Initial Dosage \n",
      "2.4\t    Titration and Maintenance Therapy \n",
      "2.5\t    Dosage Modifications in Patients with Severe Hepatic Im pairment \n",
      "2.6  \t Safe Reduction or Discontinuation of ZOHYDRO ER \n",
      "3 DOSAGE FORMS AND STRENGTHS \n",
      "4 CONTRAINDICATIONS \n",
      "5 WARNINGS AND PRECAUTIONS \n",
      "5.1\t    Addiction, Abuse, and Misuse \n",
      "5.2  \t Opioid Analgesic Risk Evaluation and Mitigation Strateg y (REMS) \n",
      "5.3\t    Life-Threatening Respiratory Depression \n",
      "5.4  \t Neonatal Opioid Withdrawal Syndrome \n",
      "5.5\t    Risks from Concomitant Use or Discontinuation of Cytoch rome \n",
      "P450 3A4 Inhibitors and Inducers  \n",
      "5.6 \t Risks from Concomitant Use with Benzodiazepines or Other C NS \n",
      "Depressants \n",
      "5.7\t\t Risk of Life-Threatening Respiratory Depression in Patient s with \n",
      "Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilita ted \n",
      "Patients \n",
      "5.8 \t Adrenal Insufficiency \n",
      "5.9\t    Severe Hypotensive \n",
      "5.10 Risk of Use in Patients w ith Increased Intracranial Pres sure, Brain \n",
      "Tumors, Head Injury, or Impaired Consciousness \n",
      "5.11 Risk of Use in Patients with Gastrointestinal Conditions \n",
      "5.12  Increased Risks of Seizures in Patients with Seizure Dis orders \n",
      "5.13 Withdrawal \n",
      "5.14 Risks Driving and Operating Machinery 6 ADVERSE REACTIONS \n",
      "6.1\t    Clinical Trial Experience \n",
      "6.2\t\t Postmarketing Experience \n",
      "7 DRUG INTERACTIONS \n",
      "8 USE IN SPECIFIC POPULATIONS \n",
      "8.1\t    Pregnancy \n",
      "8.2\t    Lactation \n",
      "8.3  \t Females and Males of  Reproductive Potential \n",
      "8.4\t    Pediatric Use \n",
      "8.5\t    Geriatric Use \n",
      "8.6\t    Hepatic Impairment \n",
      "8.7\t    Renal Impairment \n",
      "9 DRUG ABUSE AND DEPENDENCE \n",
      "9.1\t    Controlled Substance \n",
      "9.2\t    Abuse \n",
      "9.3\t    Dependence \n",
      "10 OVERDOSAGE 11 DESCRIPTION \n",
      "12 CLINICAL PHARMACOLOGY \n",
      "12.1 Mechanism of Action \n",
      "12.2 Pharmacodynamics \n",
      "12.3 Pharmacokinetics \n",
      "13 NONCLINICAL TOXICOLOGY \n",
      "13.1 Carcinogenesis, Mutagene sis, Impairment of Fertility \n",
      "14 CLINICAL STUDIES \n",
      "14.1 Placebo-Controlled Study in Opioid-Experienced Subjects w ith   \n",
      "Moderate-to-Severe Chronic Lower Back Pain \n",
      "16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION \n",
      "*Sections or subsections omitted from the full Prescribing Information are not \n",
      "listed. \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      "Â \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " FULL PRESCRIBING INFORMATION \n",
      "WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITI GATION \n",
      "STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCID ENTAL \n",
      "INGESTION; NEONATAL OPIOID WITH DRAWAL SYNDROME; CYTOCHROME P450 3A4 \n",
      "INTERACTION; RISKS FROM CONCOMITA NT USE WITH BENZODIAZEPINES AN D OTHER \n",
      "CNS DEPRESSANTS; and INTE RACTION WITH ALCOHOL. \n",
      "Addiction, Abuse, and Misuse \n",
      "ZOHYDRO ER exposes patients and other users to the risks of opi oid addiction, abuse, and misuse, \n",
      "which can lead to overdose and death. Assess each patientâ€™s ris k prior to prescribing ZOHYDRO ER \n",
      "and monitor all patients regularly for the development of these  behaviors and conditions [see \n",
      "Warnings and Precautions (5.1)] . \n",
      "Opioid Analgesic Risk Evaluation  and Mitigation Strategy (REMS) : \n",
      "To ensure that the benefits of  opioid analgesics outweigh the risks of addiction, abuse, and misuse, the \n",
      "Food and Drug Administration (FDA) has required a REMS for thes e products [ see Warnings and \n",
      "Precautions (5.2)].  Under the requirements of the REMS, drug companies with approved opioid \n",
      "analgesic products must make REMS-compliant education programs available to healthcare \n",
      "providers. Healthcare providers  are strongly encouraged to \n",
      "ï‚· complete a REMS-compliant education program, \n",
      "ï‚· counsel patients and/or their caregivers, with every prescripti on, on safe use, serious risks, storage, \n",
      "and disposal of these products, \n",
      "ï‚· emphasize to patients and their ca regivers the importance of reading the Medication Guide every \n",
      "time it is provided by their pharmacist, and \n",
      "ï‚· consider other tools to improve  patient, household, and community safety. \n",
      "Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of ZOHYDRO ER. \n",
      "Monitor for respiratory depression, especially during initiatio n of ZOHYDRO ER or following a dose \n",
      "increase. Instruct patients to swallow ZOHYDRO ER capsules whole; crushin g, chewing, or \n",
      "dissolving ZOHYDRO ER capsules c an cause rapid release and abso rption of a potentially fatal dose \n",
      "of hydrocodone [see Warnings and Precautions (5.3)] . \n",
      "Accidental Ingestion Accidental ingestion of even on e dose of ZOHYDRO ER, especially  by children, can result in a fatal \n",
      "overdose of hydrocodone [see Warnings and Precautions (5.3)] . \n",
      "Neonatal Opioid Wi thdrawal Syndrome \n",
      "Prolonged use of ZOHYDRO ER during pregnancy can result in neon atal opioid withdrawal \n",
      "syndrome, which may be life-threatening if not recognized and t reated, and requires management \n",
      "according to protocols developed by neonatology experts. If opi oid use is required for a prolonged \n",
      "period in a pregnant woman, advi se the patient of the risk of n eonatal opioid withdrawal syndrome \n",
      "and ensure that appropriate treatment will be available  [see Warnings and Precautions (5.4)]. \n",
      "Cytochrome P450 3A4 Interaction The concomitant use of ZOHYDRO ER with a ll cytochrome P450 3A4 inhibitors may result in an \n",
      "increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal  respiratory depression. In addi tion, discontinuation of a \n",
      "concomitantly used cytochrome P450 3A4 inducer may result in an  increase in hydrocodone plasma \n",
      "concentration. Monitor patients receiving ZOHYDRO ER and any CY P3A4 inhibitor or inducer [see \n",
      "Warnings and Precautions (5.5) and Clinical Pharmacology (12.3)] . \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " Risks from Concomitant Use with Benzodiazepines or Other CNS De pressants \n",
      "Concomitant use of opioids with benzodiazepines or other centra l nervous system (CNS) depressants, \n",
      "including alcohol, may result in profound sedation, respiratory depression, coma, and death  [see \n",
      "Warnings and Precautions (5.6), Drug Interactions (7)] . \n",
      "ï‚· Reserve concomitant prescribin g of ZOHYDRO ER and benzodiazepin es or other CNS \n",
      "depressants for use in patients for whom alternative treatment options are inadequate.   \n",
      "ï‚· Limit dosages and durations  to the minimum required. \n",
      "ï‚· Follow patients for signs and symptoms of respiratory depressio n and sedation. \n",
      "Interaction with Alcohol \n",
      "Instruct patients not to consu me alcoholic beverages or use pre scription or non-prescription products \n",
      "that contain alcohol while taking ZOHYDRO ER.  The co-ingestion of alcohol with ZOHYDRO ER may result in increased plasma levels and a potentially fatal o verdose of hydrocodone [see Warnings \n",
      "and Precautions (5.6) and Clinical Pharmacology (12.3)] . \n",
      "1 INDICATIONS AND USAGE \n",
      "ZOHYDRO\n",
      "Â® ER (hydrocodone bitartrate) is ind icated for the management of  pain severe enough to require \n",
      "daily, around-the-clock, long-te rm opioid treatment and for which alternative treatment options are inadequate.  \n",
      "Limitations of Use \n",
      "ï‚·\t Because of the risks of addict ion, abuse, and misuse with opioids, even at recommended doses, and \n",
      "because of the greater risks of overdose and death with extende d-release opioid formulations [see \n",
      "Warnings and Precautions (5.1)] , reserve ZOHYDRO ER for use in pa tients for whom alternative \n",
      "treatment options (e.g., non-opioi d analgesics or immediate-rel ease opioids) are ineff ective, not tolerated, \n",
      "or would be otherwise i nadequate to provide sufficient manageme nt of pain. \n",
      "ï‚·\t ZOHYDRO ER is not indicated as an as-needed (prn) analgesic. \n",
      "2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Information \n",
      "ZOHYDRO ER should be prescribed only by healthcare professionals who are knowledgeable in the use of \n",
      "potent opioids for the management of chronic pain. \n",
      "Daily doses of ZOHYDRO ER, a si ngle dose of greater than 40 mg,  or a total daily dos e of greater than 80 mg, \n",
      "are only for use in patients i n whom tolerance to an opioid of comparable potency has b een established. Patients \n",
      "who are opioid tolerant are thos e receiving, for one week or lo nger, at least 60 mg oral morphine per day, 25 \n",
      "mcg transdermal fentanyl per  hour, 30 mg oral oxycodone per day , 8 mg oral hydromorphone per day, 25 mg \n",
      "oral oxymorphone per day, 60 mg oral  hydrocodone per day, or an  equianalgesic dose  of another opioid.  \n",
      "ï‚·\t Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals \n",
      "[see Warnings and Precautions (5)] . \n",
      "ï‚·\t Initiate the dosing regimen for each patient individually, taki ng into account the patient's severity of pain, \n",
      "patient response, prior analgesi c treatment experience, and ris k factors for addiction, abuse, and misuse \n",
      "[see Warnings and Precautions (5.1)] . \n",
      "ï‚·\t Monitor patients closely for re spiratory depression, especially  within the first 24- 72 hours of initiating \n",
      "therapy and following dosage incr eases with ZOHYDRO ER and adjust the dosage accordingly [see\n",
      " \n",
      "Warnings and Precautions (5.3)]. \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "Â \n",
      "Â \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  Instruct patients to swallow ZOHYDRO ER capsules whole [see Patient Counseling Information (17)] . \n",
      "Crushing, chewing, or dissolving the beads in ZOHYDRO ER capsul es will result in unc ontrolled delivery of \n",
      "hydrocodone and can lead to overdose or death [see Warnings and Precautions (5.1)] . \n",
      "ZOHYDRO ER is administered or ally twice daily (every 12 hours). \n",
      "2.2 Patient Access to Naloxone for the Emergency Treatment of O pioid Overdose \n",
      "Discuss the availability of nal oxone for the emergency treatment of opioid overdose with the patient and \n",
      "caregiver and assess the potential need for access to naloxone,  both when initiating and renewing treatment with \n",
      "ZOHYDRO ER [see Warnings and Precautions (5.3), Patient Counseling Information (17)]. \n",
      "Inform patients and caregivers a bout the various ways to obtain  naloxone as permitted by individual state \n",
      "naloxone dispensing and prescribi ng requirements or guidelines (e.g., by prescription, d irectly from a \n",
      "pharmacist, or as part of a community-based program). \n",
      "Consider prescribing naloxone, ba sed on the patientâ€™s risk factors for overdose, such as concomitant use of CNS \n",
      "depressants, a history of opioid use disorder, or prior opioid overdose. The presence of r isk factors for overdose \n",
      "should not prevent the proper management of pain in any given p atient [see Warnings and Precautions (5.1, \n",
      "5.3, 5.6)]. Consider prescribing naloxone if the patient has household memb ers (including children) or  other close contacts \n",
      "at risk for accidental ingestion or overdose . \n",
      "2.3 Initial Dosage \n",
      "Use of ZOHYDRO ER as the First Op ioid Analgesic (opioid-naÃ¯ve p atients) \n",
      "Initiate therapy with ZOHYDRO ER with one 10 mg capsule every 1 2 hours.   \n",
      "Use of ZOHYDRO ER in Patients Who Are Not Opioid Tolerant  \n",
      "The starting dose for patients  who are not opioid tolerant is Z OHYDRO ER 10 mg orally every 12 hours.  \n",
      "Use of higher starting doses in pa tients who are not opioid tol erant may cause fatal respiratory depression [see \n",
      "Warnings and Precautions (5.3)] . \n",
      "Conversion from Oral Hydrocodone  Formulations to ZOHYDRO ER \n",
      "Patients receiving other oral hydrocodone-containing formulatio ns may be converted to ZOHYDRO ER by \n",
      "dividing the patientâ€™s total daily oral hydrocodone dose in hal f and administrating as ZOHYDRO ER every 12 \n",
      "hours. \n",
      "Conversion from Other Oral Opioid to ZOHYDRO ER \n",
      "Discontinue all other around-th e-clock opioid drugs when ZOHYDR O ER therapy is initiated. \n",
      "There is inter-patient variabi lity in the relative potency of d ifferent opioid drugs and products. Therefore, a \n",
      "conservative approach is advised when determining the total dai ly dosage of ZOHYDRO E R. It is safer to \n",
      "underestimate a patientâ€™s 24- hour oral hydrocodone dosage and provide rescue medication (e.g., immediate-\n",
      "release opioid) than to overes timate the 24-hour oral hydrocodo ne dosage and manage an adverse reaction due \n",
      "to an overdose. \n",
      "In a ZOHYDRO ER clinical trial  with an open label titration per iod, patients were convert ed from their prior \n",
      "opioid to ZOHYDRO ER using Table 1 a s a guide for the initial Z OHYDRO ER dose. To obtain the initial \n",
      "ZOHDYRO ER dose, first use Tabl e 1 to convert the prior oral op ioids to a total hydrocodone daily dose and \n",
      "then reduce the calculated daily hydrocodone dose by 25% to account for interpatient var iability in relative \n",
      "potency of different opioids. \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "     \n",
      "  \n",
      "   \n",
      "   \n",
      " \n",
      " \n",
      "   \n",
      " \n",
      "  \n",
      " \n",
      "   \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " Consider the following when using the information in Table 1: \n",
      "ï‚· This is not a table of equianalgesic doses. \n",
      "ï‚· The conversion factors in this table are only for the conversion from one of the listed oral opioid \n",
      "analgesics  to ZOHYDRO ER. \n",
      "ï‚· The table  cannot be used to convert  from ZOHYDRO ER to another opioi d. Doing so will result in an \n",
      "over-estimation of the dose of the  new opioid and may result in  fatal overdose. \n",
      "Table 1. \n",
      "Conversion Factors to ZOHYDRO ER (Not Equianalgesic Doses) \n",
      "Prior Oral Opioid Oral Dose (mg) Approximate Oral \n",
      "Conversion Factor \n",
      "Hydrocodone 10 1 \n",
      "Oxycodone 10 1 \n",
      "Methadone 10 1 \n",
      "Oxymorphone 5 2 \n",
      "Hydromorphone 3.75 2.67 \n",
      "Morphine 15 0.67 \n",
      "Codeine 100 0.10 \n",
      "The conversion ratios in this table are only to be used for the  conversion \n",
      "from current opioid therapy to ZOHYDRO ER. \n",
      "To calculate the estimated da ily ZOHYDRO ER dose using Table 1: \n",
      "ï‚·\t For patients on a single opioi d, sum the current total daily do se of the opioid and then multiply the \n",
      "total daily dose by the approximate oral conversion factor to c alculate the approximate oral \n",
      "hydrocodone daily dose. Divide the  daily dose in half for admin istration every 12 hours. \n",
      "ï‚·\t For patients on a regimen of m ore than one opioid, calculate the approximate oral hydrocodone dose \n",
      "for each opioid and sum the totals to obtain approximate total hydrocodone daily dose. The daily \n",
      "dose should then be divided in half for administration every 12  hours.  \n",
      "ï‚·\t For patients on a regimen of f ixed-ratio opioid/non-opioid anal gesic products, use only the opioid \n",
      "component of these produc ts in the conversion. \n",
      "ï‚·\t Reduce the calculated dail y oral hydrocodone dose by 25% \n",
      "Always round the dose down, if nece ssary, to the nearest ZOHYDR O ER strength(s) available and initiate \n",
      "therapy with that dose .Â \n",
      "Example conversion from a si ngle opioid to ZOHYDRO ER \n",
      "Step 1: Sum the total daily dose  of the opioid (in this case, e xtended-release oxymorphone); 15 mg \n",
      "oxymorphone twice daily = 30 mg total daily dose of oxymorphone . \n",
      "Step 2: Calculate the approximate equivalent dose of oral hydro codone based on the total daily dose of the \n",
      "current opioid using Table 1; 30 m g total daily dose of oxymorp hone x 2 = 60 mg of oral hydrocodone \n",
      "daily. The daily dose should then be  divided in half for administration every 12 hours.   \n",
      "Step 3: Calculate the approxi mate starting dose which is 30 mg ZOHYDRO ER every 12 hours. Round down, if \n",
      "necessary, to the appropriate ZOHYDRO ER capsule strengths avai lable. Close observation and \n",
      "frequent titration are warrante d until pain management is stabl e on the new opioid. Monitor patients for \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      "Â   \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " signs and symptoms of opioid with drawal or for signs of over-se dation/toxicity after converting \n",
      "patients to ZOHYDRO ER. \n",
      "The dose of ZOHYDRO ER can be gr adually adjusted preferably at increments of 10 mg every 12 hours every \n",
      "3 to 7 days, until adequate pain relief and acceptable adverse reactions have been achieved. \n",
      "Conversion from Methadone to ZOHYDRO ER \n",
      "Close monitoring is of particular importance when converting from methadone to other opioid agonists. The \n",
      "ratio between methadone and other opioid agonists may vary widely as a function of previous dose exposure. \n",
      "Methadone has a long half-life a nd tends to accumulate in the p lasma. \n",
      "Conversion from Transderm al Fentanyl to ZOHYDRO ER \n",
      "ZOHYDRO ER treatment can be i nitiated 18 hours following the removal of the transdermal fentanyl patch. \n",
      "Although there has been no systema tic assessment of such conversion, a conservative hydrocodone dose, \n",
      "approximately 10 mg every 12 hours of  ZOHYDRO ER, should be initially substituted f or each 25 mcg/hr \n",
      "fentanyl transdermal patch. Follo w the patient closely during conversion from transdermal fentanyl to \n",
      "ZOHYDRO ER, as there is limited documented experience with this  conversion.  \n",
      "2.4 Titration and Maintenance of Therapy \n",
      "Individually titrate ZOHYDRO ER  to a dose that provides adequate analgesia and minimizes adverse reactions. \n",
      "Continually reevaluate patients receiving ZOHYDRO ER to assess the maintenance of pain control and the \n",
      "relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse \n",
      "[see Warnings and Precautions (5.1)] . Frequent communication is impor tant among the prescriber, oth er \n",
      "members of the healthcare team, the patient, and the caregiver/ family during periods of changing analgesic \n",
      "requirements, including initial titration. During chronic thera py, periodically reassess the continued need for \n",
      "opioid analgesics. \n",
      "Patients who experience breakthr ough pain may require a dosage adjustment of ZOHYDRO ER, or may need a \n",
      "rescue medication with an appropr iate dose of an immediate-rele ase analgesic. If the le vel of pain increases \n",
      "after dose stabilization, attempt to identify the source of increased pain before in creasing the ZOHYDRO ER \n",
      "dosage. Because steady-state plas ma concentrations are approxim ated within 3 days, ZOHYDRO ER dosage \n",
      "adjustments, preferably at increments of 10 mg every 12 hours, may be done every 3 to 7 days.  \n",
      "If unacceptable opioid-related adverse reactions are observed, consider reducing the dos age. Adjust the dosage \n",
      "to obtain an appropriate balance between management of pain and  opioid-related adverse reactions. \n",
      "2.5 Dosage Modifications in Patients with Severe Hepatic Impair ment \n",
      "Patients with severe hepatic imp airment may have higher plasma concentrations of hydrocodone than those with \n",
      "normal function.  Therefore, initiate therapy with 10 mg every 12 hours and titrate caref ully, while monitoring \n",
      "for respiratory depression, s edation, and hypotension. No adjus tment in starting dose with ZOHYDRO ER is \n",
      "required in patients with mild or  moderate hepatic impairment  [see Clinical Pharmacology (12.3)] . \n",
      "2.6 Safe Reduction or Disco ntinuation of ZOHYDRO ER \n",
      "Do not abruptly discontinue ZOHY DRO ER in patients who may be p hysically dependent on opioids.  Rapid \n",
      "discontinuation of opioid analgesics in patients who are physic ally dependent on opioids ha s resulted in serious \n",
      "withdrawal symptoms, uncontrolle d pain, and suicide. Rapid disc ontinuation has also been associated with \n",
      "attempts to find other sources of  opioid analgesics, which may be confused with drug-seeking for abuse. \n",
      "Patients may also attempt to tre at their pain or withdrawal sym ptoms with illicit opioids, such as heroin, and \n",
      "other substances. When a decision has been made to decrease the dose or discontin ue therapy in an opioid-dependent patient \n",
      "taking ZOHYDRO ER, there are a va riety of factors that should b e considered, including the dose of \n",
      "ZOHYDRO ER the patient has been taking, the duration of treatment, the type of pain being treated, and the \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  physical and psychological attri butes of the patient. It is imp ortant to ensure ongoing car e of the patient and to \n",
      "agree on an appropriate taperi ng schedule and follow-up plan so that patient and provider goals and \n",
      "expectations are clear and real istic. When opioid analgesics ar e being discontinued due t o a suspected substance \n",
      "use disorder, evaluate and treat  the patient, or refer for eval uation and treatment of the  substance use disorder. \n",
      "Treatment should include evidenc e-based approaches, such as medication assisted treatment of opioid use \n",
      "disorder. Complex patients wit h co- morbid pain and substance u se disorders may benefit from referral to a \n",
      "specialist. \n",
      "There are no standard opioid tap ering schedules that are suitab le for all patients. Good clin ical practice dictates \n",
      "a patient-specific plan to tape r the dose of the opioid gradually. For patients on ZOHYDRO ER who are \n",
      "physically opioid-dependent, in itiate the taper by a small enou gh increment (e.g., no great er than 10% to 25% of \n",
      "the total daily dose) to avoid w ithdrawal symptoms, and proceed  with dose-lowering at an interval of every 2 to \n",
      "4 weeks. Patients who have been t aking opioids for briefer periods of time may tolerate a more rapid taper. \n",
      "It may be necessary to provide the patient with lower dosage st rengths to accomplish a successful taper. \n",
      "Reassess the patient frequently t o manage pain and withdrawal symptoms, should they emerge. Common \n",
      "withdrawal symptoms include res tlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and \n",
      "mydriasis. Other signs and sym ptoms also may develop, including  irritability, anxiety, backache, joint pain, \n",
      "weakness, abdominal cramps, insomnia, nausea, anorexia, vomitin g, diarrhea, or increased blood pressure, \n",
      "respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period \n",
      "of time or raise the dose of the  opioid analgesic to the previo us dose, and then proceed with a slower taper. In \n",
      "addition, monitor patients for any changes in mood, emergence o f suicidal thoughts, or us e of other substances. \n",
      "When managing patients taking opioid analgesics, particularly t hose who have been treated for a long duration \n",
      "and/or with high doses for chronic pain, ensure that a multimod al approach to pain management, including \n",
      "mental health support (if needed), is in place prior to initiat ing an opioid analgesic taper. A multimodal \n",
      "approach to pain management ma y optimize the treatment of chron ic pain, as well as assi st with the successful \n",
      "tapering of the opioid analgesic [see Warnings and Precautions (5.13 ), Drug Abuse and Dependence (9.3)] . \n",
      "3 DOSAGE FORMS AND STRENGTHS \n",
      "10 mg White opaque â€œZ310 10 mgâ€ in \n",
      "black ink \n",
      "15 mg Light green and \n",
      "white opaque â€œZ315 15 mgâ€ in \n",
      "black ink \n",
      "20 mg Light green \n",
      "opaque â€œZ320 20 mgâ€ in \n",
      "black ink \n",
      "30 mg Dark blue and \n",
      "white opaque â€œZ330 30 mgâ€ in \n",
      "black ink \n",
      "40 mg Dark brown and \n",
      "white opaque â€œZ340 40 mgâ€ in \n",
      "black ink \n",
      "50 mg Dark brown \n",
      "opaque â€œZ350 50 mgâ€ in \n",
      "black ink \n",
      "4 CONTRAINDICATIONS \n",
      "ZOHYDRO ER is contraindi cated in patients with:  \n",
      "ï‚· Significant respiratory depression [see Warnings and Precautions (5.3)] \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      "  \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " ï‚· Acute or severe bronchial asthma in an unmonitored setting or i n the absence of resuscitative equipment \n",
      "[see Warnings and Precautions (5.7)] \n",
      "ï‚·\t Known or suspected gastrointes tional obstruction, including par alytic ileus [see Warnings and \n",
      "Precautions (5.11)] \n",
      "ï‚·\t Hypersensitivity (e.g., anaphyl axis) to hydrocodone or any othe r ingredients in ZOHYDRO ER \n",
      "5 WARNINGS AND PRECAUTIONS  \n",
      "5.1 Addiction, Abuse, and Misuse \n",
      "ZOHYDRO ER contains hydrocodone, a Schedule II controlled subst ance. As an opioid, ZOHYDRO ER \n",
      "exposes users to the risks of a ddiction, abuse, and misuse. Bec ause extended-release products such as \n",
      "ZOHYDRO ER deliver the opioid over an extended period of time, there is a greater ris k for overdose and death \n",
      "due to the larger amount of hydrocodone present [see Drug Abuse and Dependence (9.1)] . \n",
      "Although the risk of addiction i n any individual is unknown, it can occur in patients appropriately prescribed \n",
      "ZOHYDRO ER. Addiction can occur at recommended doses and if the drug is misused or abused.   \n",
      "Assess each patientâ€™s risk for opioid addiction, abuse, or misuse prior to prescribing ZOHYDRO ER, and \n",
      "monitor all patients receiving Z OHYDRO ER for the development o f these behaviors and conditions. Risks are \n",
      "increased in patients with a pe rsonal or family history of substance abuse (including drug or alcohol addiction \n",
      "or abuse) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent \n",
      "the prescribing of ZOHYDRO ER fo r the proper management of pain  in any given patient. Pa tients at increased \n",
      "risk may be prescribed opioids such as ZOHYDRO ER, but use in s uch patients necessitates intensive \n",
      "counseling about the risks and pr oper use of ZOHYDRO ER along w ith intensive monitoring for signs of \n",
      "addiction, abuse, and misuse.  C onsider prescribing naloxone fo r the emergency treatment of opioid overdose \n",
      "[see Dosage and Administration (2.2), Warnings and Precautions (5.3)] . \n",
      "Abuse or misuse of ZOHYDRO ER by crushing, chewing, snorting, o r injecting the disso lved product will \n",
      "result in the uncontrolled delivery of the hydrocodone and can result in overdose and death [see Drug Abuse \n",
      "and Dependence (9.1), Overdosage (10)] . \n",
      "Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. \n",
      "Consider these risks when prescribing or dispensing ZOHYDRO ER. Strategies to reduce these risks include prescribing the drug in the sma llest appropriate quantity and advising the patient on the  proper disposal of \n",
      "unused drug [see Patient Counseling Information (17)] . Contact local state professional licensing board or state \n",
      "controlled substances authorit y for information on how to preve nt and detect abuse or div ersion of this product. \n",
      "5.2 Opioid Analgesic Risk Evalua tion and Mitigation Strategy (R EMS) \n",
      "To ensure that the benefits of  opioid analgesics  outweigh the r isks of addiction, abuse, and misuse, the Food and \n",
      "Drug Administration (FDA) has re quired a Risk Evaluation and Mi tigation Strategy (REMS ) for these products. \n",
      "Under the requirements of the R EMS, drug companies with approved opioid analgesic products must make \n",
      "REMS-compliant education programs available to healthcare provi ders. Healthcare providers are strongly \n",
      "encouraged to do all of the following: \n",
      "ï‚·\t Complete a REMS-compliant educ ation program offered by an accre dited provider of continuing \n",
      "education (CE) or another educa tion program that includes all t he elements of the FDA Education \n",
      "Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain. \n",
      "ï‚·\t Discuss the safe use, serious risks, and proper storage and dis posal of opioid analgesics with patients \n",
      "and/or their caregivers every time these medicines are prescrib ed. The Patient Counseling Guide (PCG) \n",
      "can be obtained at this link:  www.fda.gov/OpioidAnalgesicREMSPCG . \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "   \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " ï‚·\t Emphasize to patients and their car egivers the importance of re ading the Medication Guide that they will \n",
      "receive from their pharmacist eve ry time an opioid analgesic is dispensed to them. \n",
      "ï‚·\t Consider using other tools to improve patient, household, and c ommunity safety, such as patient-\n",
      "prescriber agreements that reinfo rce patient-prescriber respons ibilities.\n",
      "\t\n",
      "To obtain further information on th e opioid analgesic REMS and for a list of accredited REMS CME/CE, call 1-\n",
      "800-503-0784, or log on to www.opioidanalgesicrems.com . The FDA Blueprint can be found at \n",
      "www.fda.gov/OpioidAnalgesicREMSBlueprint . \n",
      "5.3 Life-Threatening Respiratory Depression  \n",
      "Serious, life-threatening, or f atal respiratory depression has been reported with the use of opioids, even when \n",
      "used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to \n",
      "respiratory arrest and death. Manag ement of respiratory depress ion may include close observation, supportive \n",
      "measures, and use of opioid antagonists, depending on the patie ntâ€™s clinical status [see Overdosage (10)] . \n",
      "Carbon dioxide (CO 2) retention from opioid-induced r espiratory depression can exacerbate the sedating effects \n",
      "of opioids. \n",
      "While serious, life-threatening, o r fatal respiratory depressio n can occur at any time during the use of \n",
      "ZOHYDRO ER, the risk is greate st during the initiation of thera py or following a dosage increase. Monitor \n",
      "patients closely for respirato ry depression, especially within the first 24-72 hours of initiating therapy with \n",
      "and following dosage increases of ZOHYDRO ER. To reduce the risk of respira tory depression, proper dosing and titration of ZOHYDRO ER are essential [see \n",
      "Dosage and Administration (2.4)] . Overestimating the ZOHYDRO ER  dose when converting patients f rom \n",
      "another opioid product can result in fatal overdose with the fi rst dose.  \n",
      "Accidental ingestion of even one do se of ZOHYDRO ER, especially  by children, can result in respiratory \n",
      "depression and death due to an overdose of hydrocodone. Educate patients and caregivers  on how to recognize respiratory  depression and emphasize the importance of \n",
      "calling 911 or getting emergency med ical help right away in the event of a known or suspected overdose [see \n",
      "Patient Counseling Information (17)]. Opioids can cause sleep-relat ed breathing disorders including central sleep apnea (C SA) and sleep-related \n",
      "hypoxemia. Opioid use increases the risk of CSA in a dose-depen dent fashion. In patient s who present with \n",
      "CSA, consider decreasing the opi oid dosage using best practices  for opioid taper [see Dosage and \n",
      "Administration (2.6)] . \n",
      "Patient Access to Naloxone for the  Emergency Treatment of Opioid Overdose \n",
      "Discuss the availability of nal oxone for the emergency treatment of opioid overdose with the patient and \n",
      "caregiver and assess the potential need for access to naloxone,  both when initiating and renewing treatment with \n",
      "ZOHYDRO ER. Inform patients and caregivers about  the various wa ys to obtain naloxone as permitted by \n",
      "individual state naloxone dispen sing and prescribing requiremen ts or guidelines (e.g., by prescription, directly \n",
      "from a pharmacist, or as part of a community-based program). Ed ucate patients and caregivers on how to \n",
      "recognize respiratory depression and emphasize the importance o f calling 911 or getting emergency medical \n",
      "help, even if naloxone is administered [see Patient Counseling Information (17)]. \n",
      "Consider prescribing naloxone, ba sed on the patientâ€™s risk factors for overdose, such as concomitant use of CNS \n",
      "depressants, a history of opioid use disorder, or prior opioid overdose. The presence of r isk factors for overdose \n",
      "should not prevent the proper management of pain in any given p atient. Also consider  prescribing naloxone if \n",
      "the patient has household member s (including children) or other  close contacts at risk fo r accidental ingestion or \n",
      "overdose. If naloxone is prescr ibed, educate patients and caregivers on how to treat with naloxone. [see \n",
      "Warnings and Precautions (5.1, 5.6), Patient Counseling Information (17)]. \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " 5.4 Neonatal Opioid Withdrawal Syndrome \n",
      "Prolonged use of ZOHYDRO ER during pregnancy can result in with drawal in the neonate. Neonatal opioid \n",
      "withdrawal syndrome, unlike opio id withdrawal syndrome in adults, may be life-threatening if not recognized \n",
      "and treated, and requires management according to protocols dev eloped by neonatology experts. Observe \n",
      "newborns for signs of neonatal  opioid withdrawal syndrome and m ange accordingly.  Advise pregnant women \n",
      "using opioids for a prolonged peri od of the risk of neonatal op ioid withdrawal syndrome and ensure that \n",
      "appropriate treatment will be available [see Use in Specific Populations (8.1 ), Patient Counseling Information \n",
      "(17)] . \n",
      "5.5 Risks from Concomitant Use or  Discontinuation of Cytochrome  P450 3A4 Inhibitors and Inducers \n",
      "Concomitant use of ZOHYDRO ER with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., \n",
      "erythromycin), azole-antifungal agents (e.g., keto conazole), an d protease inhibitors ( e.g., ritonavir), may \n",
      "increase plasma concentrat ions of hydrocodone and prolong opioid adverse reactions, which may cause \n",
      "potentially fatal res piratory depression [see Warnings and Precautions (5.3)] , particularly whe n an inhibitor is \n",
      "added after a stable dose of  ZOHYDRO ER is achieved . Similarly, discontinuation of  a CYP3A4 inducer, such \n",
      "as rifampin, carbamazepine, and phenytoin, in ZOHYDRO ER-treate d patients may increase hydrocodone \n",
      "plasma concentrations and prolong o pioid adverse reactions. When using ZOHYDRO ER with CYP3A4 \n",
      "inhibitors or discontinuing CYP3A 4 inducers in ZOHYDRO ER-treat ed patients, monitor patients closely at \n",
      "frequent intervals and consider  dosage reduction of ZOHYDRO ER until stable drug effects are achieved [see \n",
      "Drug Interactions (7)]. \n",
      "Concomitant use of ZOHYDRO ER w ith CYP3A4 inducers or discontin uation of an CYP3A4 inhibitor could \n",
      "decrease hydrocodone plasma con centrations, decrease opioid eff icacy or, possibly, lea d to a withdrawal \n",
      "syndrome in a patient who had developed physical dependence to hydrocodone. When using ZOHYDRO ER \n",
      "with CYP3A4 inducers or discon tinuing CYP3A4 inhibitors, monito r patients closely at fr equent intervals and \n",
      "consider increasing the opioi d dosage if needed to maintain adequate analgesia or if symptoms of opioid \n",
      "withdrawal occur [see Drug Interactions (7)] . \n",
      "5.6 Risks from Concomitant Use wi th Benzodiazepines or Other CN S Depressants \n",
      "Profound sedation, respiratory d epression, coma, and death may result from the concomitant use of ZOHYDRO \n",
      "ER with benzodiazepines or other CNS depressants (e.g., non-ben zodiazepine sedatives/hypnotics, anxiolytics, \n",
      "tranquilizers, muscle relaxants , general anesthetics, antipsych otics, other opioids, alc ohol). Because of these \n",
      "risks, reserve concomitant prescribing of these drugs for use i n patients for whom alternative treatment options \n",
      "are inadequate. \n",
      "Observational studies have demonstrated that concomitant use of  opioid analgesics and benzodiazepines \n",
      "increases the risk of drug-related mortality compared to use of  opioid analgesics alone.  Because of similar \n",
      "pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS \n",
      "depressant drugs with opioid analgesics [see Drug Interactions (7)]. \n",
      "If the decision is made to prescrib e a benzodiazepine or other CNS depressant concomitantly with an opioid \n",
      "analgesic, prescribe the lowest  effective dosages and minimum duration of concomitant use.  In patients already \n",
      "receiving an opioid analgesic, pr escribe a lower initial dose o f the benzodiazepine or other CNS depressant than \n",
      "indicated in the ab sence of an opioid, and titrate based on clinical response.  If an opioid analgesic is initiated in \n",
      "a patient already taking a benz odiazepine or other CNS depressant, prescribe a lower initial dose of the opioid \n",
      "analgesic, and titrate based on cli nical response.  Follow pati ents closely for signs and symptoms of respiratory \n",
      "depression and sedation. \n",
      "If concomitant use is warrante d, consider prescribing naloxone for the emergency treatment of opioid overdose \n",
      "[see Dosage and Administration (2.2), Warnings and Precautions (5.3)] . \n",
      "Advise both patients and caregiver s about the risks of respirat ory depression and sedat ion when ZOHYDRO ER \n",
      "is used with benzodiazepines or o ther CNS depressants (including alcohol and illicit drugs ).  Advise patients not \n",
      "to drive or operate heavy machinery until the effects of concom itant use of the benzodiazepine or other CNS \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "Â  \n",
      " depressant have been determin ed.  Screen patients for risk of s ubstance use disorders, including opioid abuse \n",
      "and misuse, and warn them of the risk of overdose and death ass ociated with the use of additional CNS \n",
      "depressants including alcohol and illicit drugs [see Drug Interactions (7) and Pa tient Counseling Information \n",
      "(17)]. \n",
      "Patients must not consume alcoholic beverages, or prescription or non-prescription products  containing alcohol, \n",
      "while on ZOHYDRO ER therapy. The co-ingestion of alcohol with Z OHYDRO ER may result in increased \n",
      "plasma levels and a potentiall y fatal overdose of hydrocodone [see Clinical Pharmacology (12.3)] . \n",
      "5.7 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, \n",
      "Cachectic, or Debilitated Patients \n",
      "The use of ZOHYDRO ER in patients with acute or severe bronchia l asthma in an unmonito red setting or in the \n",
      "absence of resuscitative equi pment is contraindicated.  \n",
      "Patients with Chronic Pulmonar y Disease: ZOHYDRO ER-treated pat ients with significant chronic obstructive \n",
      "pulmonary disease or cor pulmona le, and those with a substantia lly decreased respirato ry reserve, hypoxia, \n",
      "hypercapnia, or pre-existing respi ratory depressi on are at incr eased risk of decreased respi ratory drive including \n",
      "apnea, even at recommended dosages of ZOHYDRO ER.  Elderly, Cachectic, or Debilitate d Patients: Life-threatening r espiratory depression is more likely to occur in \n",
      "elderly, cachectic, or debilitated patients because they may ha ve altered pharmacokinetics or altered clearance \n",
      "compared to younger, hea lthier patients.  \n",
      "Monitor such patients closely, pa rticular when initiating and t itrating ZOHYDRO ER and when ZOHYDRO ER \n",
      "is given concomitantly with other drugs that depress respiration. Alternatively, consider the use of non-opioid \n",
      "analgesics in these patients. \n",
      "5.8 Adrenal Insufficiency \n",
      "Cases of adrenal insufficienc y have been reported with opioid u se, more often following greater than one month \n",
      "of use. Presentation of adrenal i nsufficiency may include non- specific symptoms and signs including nausea, \n",
      "vomiting, anorexia, fatigue, wea kness, dizziness, and low blood pressure.  If adrenal insufficiency is suspected, \n",
      "confirm diagnosis with diagnostic testing as soon as possible.  If adrenal insufficienc y is diagnosed, treat with \n",
      "physiologic replacement doses of c orticosteroids.  Wean the patient off of the opioid to allow adrenal function \n",
      "to recover and continue corticosteroid treatment until adrenal function recovers.  Other opioids may be tried as \n",
      "some cases reported use of a different opioid without recurrenc e of adrenal insufficiency.  The information \n",
      "available does not identify any particular opioid as being more  likely to be associated with adrenal \n",
      "insufficiency. \n",
      "5.9 Severe Hypotension \n",
      "ZOHYDRO ER may cause severe h ypotension including orthostatic hypotension and syncope in ambulatory \n",
      "patients. There is an added ris k in patients whose ability to maintain blood pressure has already been \n",
      "compromised by a reduced blood volum e, or after concurrent administration of certain CNS depressant drugs \n",
      "(e.g., phenothiazines or general anesthetics) [see Drug Interactions (7)] . Monitor these patients for signs of \n",
      "hypotension after initiating or t itrating the dosage of ZOHYDRO ER. In patients with  circulatory shock, \n",
      "ZOHYDRO ER may cause vasodilati on that can further reduce cardi ac output and blood pressure. Avoid the \n",
      "use of ZOHYDRO ER in patient s with circulatory shock. \n",
      "5.10 Risks of Use in Patients with Increased Intracranial Press ure, Brain Tumors, Head Injury, or \n",
      "Impaired Consciousness \n",
      "In patients who may be susceptible to the intracranial effects of CO\n",
      "2 retention (e.g., those with evidence of \n",
      "increased intracranial pressure  or brain tumors), ZOHYDRO ER may reduce respiratory driv e, and the resultant \n",
      "CO 2 retention can further increas e intracranial pr essure.  Monitor  such patients for signs of sedation and \n",
      "respiratory depression, particu larly when initiating therapy wi th ZOHYDRO ER. \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      "  \n",
      " \n",
      "  \n",
      "   \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      " Opioids may also obscure the clinic al course in a patient with a head injury. Avoid the use of ZOHYDRO ER in \n",
      "patients with impaired consciousness or coma. \n",
      "5.11 Risks of Use in Patients with  Gastrointestinal Conditions \n",
      "ZOHYDRO ER is contraindicate d in patients with known or suspect ed gastrointestinal obstruction, including \n",
      "paralytic ileus. Hydrocodone in ZOHYDRO ER may cause spasm of t he sphincter of Oddi. Opioids may cause \n",
      "increases in serum amylase.  Moni tor patients with biliary trac t disease, including acute pancreatitis, for \n",
      "worsening of symptoms. 5.12 Increased Risk of Seizures in Patients with Seizure Disord ers \n",
      "The hydrocodone in ZOHYDRO ER may increase the frequency of sei zures in patients wit h seizure disorders, \n",
      "and may increase the risk occurr ing in other clinical settings associated with seizures\n",
      ".Â Monitor patients with a \n",
      "history of seizure disorders for  worsened seizure control during ZOHYDRO ER therapy.  \n",
      "5.13 Withdrawal Do not abruptly discontinue ZOHYDRO ER in a patient physically dependent on opioids. When discontinuing \n",
      "ZOHYDRO ER in a physically dependent patient, gradually taper t he dosage. Rapid tapering of hydrocodone in \n",
      "a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain [see Dosage \n",
      "and Administration (2.5), Drug Abuse and Dependence (9.3)] . \n",
      "Additionally, avoid the use of mixed agonist /antagonist (e.g., pentazocine, nalbuphine , and butorphanol) or \n",
      "partial agonist (e.g., buprenorphine ) analgesics in patients wh o are receiving a full opioid agonist analgesic, \n",
      "including ZOHYDRO ER. In these patients, mixed agonist/antagonist and partial agonist analgesics may reduce \n",
      "the analgesic effect and/or ma y precipitate withdrawal symptoms [see Drug Interactions (7) ]. \n",
      "5.14 Risks of Driving and Operating Machinery \n",
      "ZOHYDRO ER may impair the ment al and physical abilities needed to perform potentially h azardous activities \n",
      "such as driving a car or operat ing machinery. Warn patients not  to drive or operate dangerous machinery unless \n",
      "they are tolerant to the eff ects of ZOHYDRO ER and know how the y will react to the medication [see Clinical \n",
      "Pharmacology (12.3), Patient Counseling Information (17)] . \n",
      "6 ADVERSE REACTIONS \n",
      "The following serious adverse reactions are disc ussed elsewhere  in the labeling:  \n",
      "ï‚· Addiction, Abuse, and Misuse [see Warnings and Precautions (5.1)] \n",
      "ï‚· Life-Threatening Respiratory Depression [see Warnings and Precautions (5.3)] \n",
      "ï‚· Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions (5.4)] \n",
      "ï‚· Interactions with Benzodiazepin es and Other CNS Depressants [see Warnings and Precautions (5.6)] \n",
      "ï‚· Adrenal Insufficiency  [see Warnings and Precautions (5.8)] \n",
      "ï‚· Severe Hypotension [see Warnings and Precautions (5.9)] \n",
      "ï‚· Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.11)] \n",
      "ï‚· Seizures [see Warnings and Precautions (5.12)] \n",
      "ï‚· Withdrawal [see Warnings and Precautions (5.13)] \n",
      "6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying cond itions, adverse reaction rates observed in the \n",
      "clinical trials of a drug cannot  be directly compared to rates in the clinical trials of  another drug and may not \n",
      "reflect the rates observed in clinical practice.  \n",
      "The safety of ZOHYDRO ER wa s evaluated in a total of 1,148 subj ects in Phase 3 clinical trials.  \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " Table 2 lists the most frequen tly occurring adverse reactions o ccurring at a greater frequency than placebo from \n",
      "the placebo-controlled trial i n subjects with moderate-to-severe chronic lower back pain. \n",
      "Table 2. Treatment-Emergent Adverse Events in â‰¥2% of Subjects During the Open-Label \n",
      "Titration Period and/or the Do uble-Blind Treatment Period, by P referred Term â€” \n",
      "Number (%) of Treated Subjects (Placebo-Controlled Study in Opi oid-Experienced \n",
      "Subjects with Moderate-to-Severe Chronic Lower Back Pain) \n",
      "Open-Label \n",
      "Titration Period Double-Blind Treatment Period \n",
      "ZOHYDRO ER ZOHYDRO ER Placebo \n",
      "Preferred Term (N = 510) (n = 151) (n = 151) \n",
      "Constipation 56 (11%) 12 (8%) 0 (0%) \n",
      "Nausea 50 (10%) 11 (7%) 5 (3%) \n",
      "Somnolence 24 (5%) 1 (1%) 0 (0%) \n",
      "Fatigue 21 (4%) 1 (1%) 2 (1%) \n",
      "Headache 19 (4%) 0 (0%) 2 (1%) \n",
      "Dizziness 17 (3%) 3 (2%) 1 (1%) \n",
      "Dry mouth 16 (3% ) 0 (0%) 0 (0%) \n",
      "Vomiting 14 (3%) 7 (5%) 1 (1%) \n",
      "Pruritus 13 (3%) 0 (0%) 0 (0%) \n",
      "Abdominal pain 8 (2%) 4 (3%) 0 (0%) \n",
      "Edema peripheral 7 (1%) 4 (3%) 0 (0%) \n",
      "Upper respiratory tract \n",
      "infection 7 (1%) 5 (3%) 1 (1%) \n",
      "Muscle spasms 6 (1%) 4 (3%) 2 (1%) \n",
      "Urinary tract infectio n 4 (1%) 8 (5%) 3 (2%) \n",
      "Back pain 4 (1%) 6 (4%) 5 (3%) \n",
      "Tremor 1 (0%) 4 (3%) 1 (1%) \n",
      "The common (â‰¥1% to <10%) advers e drug reactions reported at least once by subjects treated with \n",
      "ZOHYDRO ER in the Phase 3 clinica l trials and not represented in Table 2 were: \n",
      "Gastrointestinal Disorders: abdominal discomfort, abdominal pai n, gastroesophageal reflux disease \n",
      "General Disorders and Administration Site Conditions: non-cardiac chest pain, pain, peripheral edema, pyrexia  \n",
      "Injury, Poisoning and Procedural C omplications: contusion, fall, foot fracture, joint inj ury, joint sprain, muscle \n",
      "strain, skin laceration \n",
      "Investigations: increased blood cholesterol, incr eased gamma-glutamyltransferas e \n",
      "Metabolism and Nutrition Disor ders: dehydration, hypokalemia \n",
      "Musculoskeletal and Connective Ti ssue Disorders: arthralgia, mu sculoskeletal pain, myalgia, neck pain, \n",
      "osteoarthritis, pain in extremity  Nervous System Disorders: lethargy, migraine, paresthesia  Psychiatric Disorders: a nxiety, depression, insomnia  \n",
      "Respiratory, Thoracic, and Media stinal Disorders: cough, dyspne a \n",
      "Skin and Subcutaneous Tissue Di sorders: hyperhidrosis, night sw eats, rash  \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      "   \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " Vascular Disorders: hot flush \n",
      "6.2 Postmarketing Experience \n",
      "The following adverse reactions have been identified during pos t approval use of hydrocodone. Because these \n",
      "reactions are reported voluntar ily from a population of uncertain size, it is not alway s possible to reliably \n",
      "estimate their frequency or estab lish a causal relationship to drug exposure. \n",
      "Serotonin syndrome:  Cases of s erotonin syndrome, a potentially  life-threatening condi tion, have been reported \n",
      "during concomitant use of opioi ds with serotonergic drugs. \n",
      "Adrenal insufficiency: Cases of  adrenal insufficiency have bee n reported with opioid use , more often following \n",
      "greater than one month of use. \n",
      "Anaphylaxis: Anaphylaxis has b een reported with ingredients contained in ZOHYDRO ER. \n",
      "Androgen deficiency: Cases of androgen deficiency have occurre d with chronic use of opioids [see Clinical \n",
      "Pharmacology (12.2)] . \n",
      "7 DRUG INTERACTIONS \n",
      "Alcohol \n",
      "Clinical Impact: Concomitant use of alcohol w ith ZOHYDRO ER can result in an i ncrease of \n",
      "hydrocodone plasma levels and potentiall y fatal overdose of h ydrocodone. \n",
      "Intervention: Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products contai ning alcohol while on ZOHYDRO E R therapy \n",
      "[see Clinical Pharmacolo\n",
      "gy (12.3) ]. \n",
      "Inhibitors of CYP3A4 and CYP2D6 \n",
      "Clinical Impact: The concomitant use of ZOHYDRO ER and CYP3A4 inhibitors can inc rease \n",
      "the plasma concentration of  hydrocodone, resulting in increased  or prolonged \n",
      "opioid effects. These effects could be more pronounced with con comitant use \n",
      "of ZOHYDRO ER and CYP2D6 and CYP3A4 inhibitors, particularly wh en an \n",
      "inhibitor is added after a stabl e dose of ZOHYDRO ER is achieve d [see \n",
      "Warnings and Precautions (5.5)] . \n",
      "After stopping a CYP3A4 inhibitor,  as the effects of the inhibi tor decline, the \n",
      "hydrocodone plasma concentration will decrease [see Clinical Pharmacology \n",
      "(12.3)] , resulting in decreased opioid efficacy or a withdrawal syndro me in \n",
      "patients who had developed ph ysical dependence to h ydrocodone. \n",
      "Intervention: If concomitant use is necessar y, consider dosage reduction of Z OHYDRO ER \n",
      "until stable drug effects are achieved. Monitor patients for re spiratory \n",
      "depression and sedation at  frequent intervals.  \n",
      "If a CYP3A4 inhibitor is discontinued, consider increasing the ZOHYDRO \n",
      "ER dosage until stable drug effects are achieved. Monitor for s igns of opioid \n",
      "withdrawal. \n",
      "Examples: Macrolide antibiotics (e.g., ery thromycin), azole-antifungal ag ents (e.g. \n",
      "ketoconazole), protease inhibitors (e. g., ritonavir) \n",
      "CYP3A4 Inducers \n",
      "Clinical Impact: The concomitant use of ZOHYDRO ER and CYP3A4 inducers can decrease \n",
      "the plasma concentration of hydrocodone [see Clinical Pharmacology (12.3)] , \n",
      "resulting in decreased efficacy or onset of a with drawal syndro me in patients \n",
      "who have developed physical  dependence to hydrocodone [see Warnings and \n",
      "Precautions (5.5)] . \n",
      "After stopping a CYP3A4 inducer, as  the effects of the inducer decline, the \n",
      "hydrocodone plasma concentration will increase [see Clinical Pharmacology \n",
      "(12.3)] , which could increase or prol ong both the therapeutic effects and \n",
      "adverse reactions, and ma y cause serious respirator y depression. \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " Intervention: If concomitant use is necessar y, consider increasing the ZOHYDR O ER \n",
      "dosage until stable drug effects are achieved. Monitor for sign s of opioid \n",
      "withdrawal. If a CYP3A4 inducer i s discontinued, consider ZOHYD RO ER \n",
      "dosage reduction and monitor for si gns of respirator y depression. \n",
      "Examples: Rifampin, carbamazepine, phenytoin \n",
      "Benzodiazepines and other Central Nervous System (CNS) Depressa nts \n",
      "Clinical Impact: Due to additive pharmacologic e ffect, the concomitant use of be nzodiazepines \n",
      "or other CNS depressants includ ing alcohol, can increase the ri sk of \n",
      "hypotension, respirator y depression, profound sedation, coma, and death. \n",
      "Intervention: Reserve concomitant prescribi ng of these drugs for use in patie nts for whom \n",
      "alternative treatment options are inadequate.  Limit dosages an d durations to \n",
      "the minimum required.  Follow patients closely for signs of res piratory \n",
      "depression and sedation [see Warnings and Precautions (5.6)]. If concomitant \n",
      "use is warranted, consider pres cribing naloxone for the emergen cy treatment \n",
      "of opioid overdose [see Dosage and Administra tion (2.2), Warnings and \n",
      "Precautions (5.1, 5.3, 5.6)] . \n",
      "Examples: Benzodiazepines and other seda tives/hypnotics, anxiolytics, tra nquilizers, \n",
      "muscle relaxants, general anesth etics, antipsychotics, other op ioids, alcohol \n",
      "Serotonergic Drugs \n",
      "Clinical Impact: The concomitant use of opioids wit h other drugs that affect the  serotonergic \n",
      "neurotransmitter s ystem has resulted in serotonin s yndrome . \n",
      "Intervention: If concomitant use is warranted, carefully observe the patient, particularly \n",
      "during treatment initiation and dose adjustment. Discontinue ZO HYDRO ER \n",
      "if serotonin s yndrome is suspected. \n",
      "Examples: Selective serotonin reuptake inhi bitors (SSRIs), s erotonin and norepinephrine \n",
      "reuptake inhibitors (SNRIs), tricy clic antidepressants (TCAs), triptans, 5-HT3 \n",
      "receptor antagonists, drugs that affect the serotonin neurotran smitter system \n",
      "(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MA O) \n",
      "inhibitors (those intended to tr eat psychiatric disorders and a lso others, such as \n",
      "linezolid and intravenous meth ylene blue) \n",
      "Monoamine Oxidase Inhibitors (MAOIs) \n",
      "Clinical Impact: MAOI interactions with opioids may  manifest as serotonin syndro me or opioid \n",
      "toxicity (e.g., respira tory depression, coma) [see Drug Interactions (7)]. \n",
      "Intervention: The use of ZOHYDRO ER is not r ecommended for patients taking M AOIs or \n",
      "within 14 da ys of stoppin g such treatment. \n",
      "Examples: Phenelzine, tran ylcypromine, linezolid \n",
      "Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics \n",
      "Clinical Impact: May reduce the analgesic effect  of ZOHYDRO ER and/ or precipitat e \n",
      "withdrawal s ymptoms. \n",
      "Intervention: Avoid concomitant use. \n",
      "Examples: butorphanol, nalbuphine, pe ntazocine, buprenorphine  \n",
      "Muscle Relaxants \n",
      "Clinical Impact: Hydrocodone may enhance the neur omuscular blocking action of sk eletal \n",
      "muscle relaxants and produce an increased de gree of respirator y depression. \n",
      "Intervention: Monitor patients for signs of r espiratory depression that may b e greater than \n",
      "otherwise expected and decrease the dosage  of ZOHYDRO ER and/or  the \n",
      "muscle relaxant as necessary. Due to the risk of respiratory de pression with \n",
      "concomitant use of skeletal musc le relaxants and opioids, consider prescribing \n",
      "naloxone for the emergency treatment of opioid overdose [see Dosage and \n",
      "Administration (2.2), Warnin gs and Precautions (5.3, 5.6)] \n",
      "Diuretics \n",
      "Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the re lease of \n",
      "antidiuretic hormone. \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " Intervention: Monitor patients for signs of di minished diuresis and/or effect s on blood \n",
      "pressure and increase the dosa ge of the diuretic as needed. \n",
      "Anticholinergic Drugs \n",
      "Clinical Impact: The concomitant use of anticholin ergic drugs may increase risk of urinary \n",
      "retention and/or severe  constipation, which ma y lead to paral ytic ileus. \n",
      "Intervention: Monitor patients for signs of ur inary retenti on or reduced gast ric motility \n",
      "when ZOHYDRO ER is used concomitantl y with anticholiner gic dru gs. \n",
      "8 USE IN SPECIFIC POPULATIONS \n",
      "8.1 Pregnancy \n",
      "Risk Summary \n",
      "Prolonged use of opioid analgesics  during pregnancy may cause n eonatal opioid withdrawal syndrome [see \n",
      "Warnings and Precautions (5.4)] . There are no studies of ZOHYDRO E R use in pregnant women. Rats \n",
      "administered oral hydrocodone duri ng gestation and lactation sh owed increases in stillborn pups and decreases \n",
      "in pup survival at doses equiva lent to the human dose of 100 mg /day. Reduced nursing behavior and decreased \n",
      "body weights were observed at 2 times the human dose. Reduced f etal weights were observed in rabbits \n",
      "administered hydrocodone during th e period of organogenesis at doses equivalent to 5 times the human dose of \n",
      "100 mg/day. In this study, increases in the number of umbilical  hernias, irregularly shaped bones, and delays in \n",
      "fetal skeletal maturation were  observed at doses 15 times the h uman dose of 100 mg/day. No fetal \n",
      "malformations were observed in animal reproduction studies with  oral administration of hydrocodone bitartrate \n",
      "during organogenesis in rats and rabbits at doses approximately  2 and 10 times a human dose of 100 mg/day, \n",
      "respectively [see Data] . Based on animal data, advise pr egnant women of the potential risks to a fetus. \n",
      "The estimated background risk of major birth defects and miscar riage for the indicated population is unknown. \n",
      "All pregnancies have a background risk of birth defect, loss, o r other adverse outcomes. In the U.S. general \n",
      "population, the estimated backgr ound risk of major birth defect s and miscarriage in c linically recognized \n",
      "pregnancies is 2-4% and 15-20%, respectively. \n",
      "Clinical Considerations Fetal/neonatal adverse reactions Prolonged use of opioid analgesics  during pregnancy for medical  or nonmedical purposes can result in physical \n",
      "dependence in the newborn and neon atal opioid withdrawal syndro me shortly after birth. Observe newborns for \n",
      "symptoms of neonatal opioid w ithdrawal syndrome, such as poor feeding, diarrhea, irritab ility, tremor , rigidity, \n",
      "and seizures, and manage accordingly [see Warnings and Precautions (5.4)] . \n",
      "Labor or Delivery Opioids cross the placenta and may produce respiratory depressi on and psycho-physiologic effects in neonates. \n",
      "An opioid antagonist such as naloxo ne must be available for rev ersal of opioid induced r espiratory depression in \n",
      "the neonate. ZOHYDRO ER is not  recommended for use in women dur ing and immediately prior to labor, \n",
      "when shorter-acting analgesics or  other analgesic techniques ar e more appropriate. Opioid analgesics, including \n",
      "ZOHYDRO ER, can prolong labor thr ough actions which temporarily  reduce the strength, duration and \n",
      "frequency of uterine contractions . However, this effect is not consistent and may be offset by an increased rate \n",
      "of cervical dilatation, whic h tends to shorten labor. \n",
      "Data Animal Data Oral doses of hydrocodone bitart rate up to 25 mg/kg/day in rats and 50 mg/kg/day in rabb its, equivalent to 2 \n",
      "and 10 times an adult human dose of 100 mg/day, respectively on  a mg/m\n",
      "2 basis, did not res ult in any fetal \n",
      "malformations. Fetuses of rabbits administered oral doses of 75  mg/kg/day hydrocodone bitartrate (15 times an \n",
      "adult human dose of 100 mg/day on a mg/m2 basis) during the period of orga nogenesis exhibited an increas ed \n",
      "number of malformations consisting of umbilical hernia, and irr egularly shaped bones (ulna, femur, tibia and/or \n",
      "fibula). Maternal toxicity was e vident at this dose (decreased body weight).  In addition, oral hydrocodone \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " bitartrate reduced fetal weight s at doses greate r than or equal  to 25 mg/kg/day (equivalent to approximately 5 \n",
      "times an adult human dose of 100 mg/day on a mg/m2 basis). Delays in fetal skeletal maturation (reduced \n",
      "ossification of hyoid bodies and xip hoid bones) were seen follo wing dosing with 75 mg/kg/day (a dose \n",
      "equivalent to 15 times an adult human dose of 100 mg/day on a m g/m2 basis). \n",
      "Hydrocodone bitartrate administere d orally to female rats at or al doses of 10 and 25 mg/kg/da y during gestation \n",
      "and lactation resulted in pups whi ch were noted as cold to touc h and caused a reduction i n fetal viability \n",
      "(increases in the number of stillborn pups and/or pups dying po stpartum). The doses cau sing these effects were \n",
      "equivalent to approximately 1 and 2.4 times an adult human dose  of 100 mg/day, on a mg/m2 basis. Nursing was \n",
      "reduced in pups of mothers administered 25 mg/kg/day which corr elated with decreased body weight/body \n",
      "weight gain and food consumption in male pups.  Minimal materna l toxicity was evident at 25 mg/kg \n",
      "(decreased body weight). \n",
      "8.2 Lactation Risk Summary \n",
      "Hydrocodone is present in human milk. A published lactation stu dy reports variable concentrations of \n",
      "hydrocodone and hydromorphone (an ac tive metabolite) in breast milk with administration of immediate-release \n",
      "hydrocodone to nursing mothers in  the early post-partum period.  This lactation study did not assess breastfed \n",
      "infants for potential adverse  drug reactions. Lactation studies  have not been conducted with extended-release \n",
      "hydrocodone, including ZOHYDRO ER, and no information is availa ble on the effects of the drug on the \n",
      "breastfed infant or the effect s of the drug on milk production. \n",
      "Because of the potential for serious adverse reactions, includi ng excess sedation and respiratory depression in a \n",
      "breastfed infant, advise patient s that breastf eeding is not rec ommended during treatme nt with ZOHYDRO ER. \n",
      "Clinical Considerations\n",
      "\tMonitor infants exposed to ZOHYD RO ER through breast milk for e xcess sedation and res piratory depression. \n",
      "Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is \n",
      "stopped, or when breast-feeding is stopped. \n",
      "8.3 Females and Males of Reproductive Potential \n",
      "Infertility \n",
      "Chronic use of opioids may cause  reduced fertility in females a nd males of reproductive potential.  It is not \n",
      "known whether these effects on f ertility are reversible. \n",
      "In rat fertility studies, no effects on male fertility were obs erved with hydrocodone at doses equivalent to 10 \n",
      "times the human dose of 100 mg/day, however, decreases in the w eight of male reproductive organs were \n",
      "observed in all treated groups a t doses equivalent to 2.4 times the human dose of 100 mg/day and above. \n",
      "Reductions in female fertility indices were observed at doses o f hydrocodone equivalent to 2 times the human \n",
      "dose of 100 mg/day and above. These changes are attributed to a hydrocodone-mediated decrease in prolactin levels in the rat. Unique to rode nts, prolactin is required for  normal estrous cycling and the effects on fertility \n",
      "observed in this study are most likely rodent-specific and not believed to be clin ically relevant [see Nonclinical \n",
      "Toxicology (13)]. \n",
      "8.4 Pediatric Use \n",
      "The safety and effectiveness of  ZOHYDRO ER in pediatric patient s below the age of 18 years have not been \n",
      "established. \n",
      "8.5 Geriatric Use \n",
      "Clinical studies of ZOHYDRO ER d id not include sufficient numbe rs of subjects aged 65 and over to determine \n",
      "whether they respond differentl y from younger subjects. Elderly  patients (aged 65 years or older) may have \n",
      "increased sensitivity to hydrocodone.  In general, use caution when selecting a dosage for an elderly patient, \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " usually starting at th e low end of the dosing range, reflecting  the greater frequency of d ecreased hepatic, renal, \n",
      "or cardiac function, and of the c oncomitant disease or other dr ug therapy.  \n",
      "Respiratory depression is the ch ief risk for elderly patients t reated with opioids, and ha s occurred after large \n",
      "initial doses were administere d to patients who were not opioid -tolerant or when opioids  were co-administered \n",
      "with other agents that depress respiration. Titrate the dosage of ZOHYDRO ER slowly i n geriatric patients and \n",
      "monitor closely for signs of central nervous system and respira tory depression [see Warnings and Precautions \n",
      "(5.7)] . \n",
      "Hydrocodone is known to be substa ntially secreted by the kidney  and the risk adverse reactions to this drug may \n",
      "be greater in patients with imp aired renal function. Because elderly patients are more likely to have decreased \n",
      "renal function, care should be taken in dose selection, and it may be useful to monitor renal function.   \n",
      "8.6 Hepatic Impairment \n",
      "No adjustment in starting dose with ZOHYDRO ER is required in p atients with mild or moderate hepatic \n",
      "impairment. Patients with severe hepatic impairment may have higher plasma concentrations than those with \n",
      "normal hepatic function [see Clinical Pharmacology (12.3)] . Therefore, a dosage redu ction is recommended for \n",
      "patients with severe hepatic impairment [see Dosage and Administration (2.4)] . Monitor patients with severe \n",
      "hepatic impairment closely for  respiratory depression, sedation , and hypotension [see Clinical Pharmacology \n",
      "(12.3)] . \n",
      "8.7 Renal Impairment \n",
      "Patients with renal impairment have higher plasma concentration s than those with norm al function. Use a low \n",
      "initial dose of ZOHYDRO ER in patients with renal impairment an d monitor closely for respiratory depression, \n",
      "sedation, and hypotension [see Clinical Pharmacology (12.3)] . \n",
      "9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance ZOHYDRO ER contains hydrocodone bitartrate, a Schedule II contr olled substance. \n",
      "9.2 Abuse ZOHYDRO ER contains hydrocodone, a  substance with a high potent ial for abuse similar to other opioids \n",
      "including fentanyl, hydromorphone, methadone, morphine, oxycodo ne, oxymorphone, and tapentadol. \n",
      "ZOHYDRO ER can be abused and is subject to misuse, abuse, addic tion, and criminal diversion [see Warnings \n",
      "and Precautions (5.1)].  \n",
      "The high drug content in extended re lease formulations adds to the risk of adverse outcomes from abuse and \n",
      "misuse. \n",
      "All patients treated with opioids require careful monitoring for signs of abuse and addiction as use of opioid \n",
      "analgesic products carries the risk of addiction even under app ropriate medical use.  \n",
      "Prescription drug abuse is the i ntentional non-therapeutic use of a prescription drug, even once, for its \n",
      "rewarding psychological or physio logical effects. Drug addictio n is a cluster of behavioral, cognitive, and \n",
      "physiological phenomena that develop after repeated substance u se and includes: a strong desire to take the \n",
      "drug, difficulties in controlling its use, persisting in its us e despite harmful consequences, a higher priority \n",
      "given to drug use than to other activities and ob ligations, increased tolerance, and sometimes a physical \n",
      "withdrawal. \n",
      "\"Drug-seeking\" behavior is very common in persons with substance use disorders. Drug seeking tactics include \n",
      "emergency calls or visits near  the end of office hours, refusal  to undergo appropriate examination, testing, or \n",
      "referral, repeated â€œlossâ€ of pr escriptions, tampering with pres criptions, and reluctance to provide prior medical \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "   \n",
      " \n",
      " records or contact information for other treating healthcare pr ovider(s). â€œDoctor shoppingâ€ (visiting multiple \n",
      "prescribers to obtain additional prescriptions) is common among  drug abusers, and peopl e with untreated \n",
      "addiction. Preoccupation with achieving adequate pain relief ca n be appropriate behavior in a patient with poor \n",
      "pain control. \n",
      "Abuse and addiction are separate and distinct f rom physical dep endence and tolerance. Healthcare providers \n",
      "should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical \n",
      "dependence in all addicts. In a ddition, abuse of opioids can occur in the absence of true addiction. \n",
      "ZOHYDRO ER, like other opioids, can be diverted for non-medical  use into illicit channels of distribution. \n",
      "Careful record-keeping of prescr ibing information, including qu antity, frequency, and renewal requests, as \n",
      "required by state and federal  law, is strongly advised.  \n",
      "Proper assessment of the patient , proper prescribing practices,  periodic re-evaluati on of therapy, and proper \n",
      "dispensing, storage, and disposal are appropriate measures that help to limit abuse of opioid drugs. \n",
      "Risks Specific to Abuse of ZOHYDRO ER \n",
      "ZOHYDRO ER is for oral use onl y. Abuse of ZOHYDR O ER poses a ri sk of overdose and death. The risk is \n",
      "increased with concurrent use of  ZOHYDRO ER with alcohol and ot her central nervous system depressants. \n",
      "Taking cut, broken, chewed, crush ed, or dissolved ZOHYDRO ER en hances drug release and increases the risk \n",
      "of overdose and death. \n",
      "With intravenous abuse, the inac tive ingredients in ZOHYDRO ER can result in death, lo cal tissue necrosis, \n",
      "infection, pulmonary granulomas, i ncreased risk of endocarditis  and valvular heart injury, embolism, and death. \n",
      "Parenteral drug abuse is comm only associated with transmission of infectious diseases  such as hepatitis and \n",
      "HIV. 9.3 Dependence \n",
      "Both tolerance and physical depe ndence can develop during chron ic opioid therapy. Tolera nce is the need for \n",
      "increasing doses of opioids to maintain a defined effect such a s analgesia (in the absen ce of disease progression \n",
      "or other external factors). To lerance may occur to both the des ired and undesired effects of drugs, and may \n",
      "develop at different rates for different effects.  \n",
      "Physical dependence is a physiolo gical state in which the body adapts to the drug after  a period of regular \n",
      "exposure, resulting in withdrawal symptoms after abrupt discont inuation or a significa nt dosage reduction of a \n",
      "drug. Withdrawal also may be precipitated through the administr ation of drugs with opioi d antagonist activity \n",
      "(e.g., naloxone, nalmefene), mixed agonist/antagonist analgesic s (e.g., pentazocine, butorphanol, nalbuphine), \n",
      "or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinical ly significant degree \n",
      "until after several days to weeks of continued opioid usage. \n",
      "Do not abruptly discontinue ZOHYDRO ER in a patient physically dependent on opioids. Rapid tapering of \n",
      "ZOHYDRO ER in a patient physica lly dependent on opioids may lea d to serious withdrawal symptoms, \n",
      "uncontrolled pain, and suicide. Rap id discontinuation has also been associated with attempts to find other \n",
      "sources of opioid analgesics, which may be confused with drug-s eeking for abuse.  \n",
      "When discontinuing ZOHYDRO ER, gradually taper the dosage using  a patient-specific plan that considers the \n",
      "following: the dose of ZOHYDRO ER  the patient has been taking, the duration of treatment, and the physical \n",
      "and psychological attributes of the patient. To improve the lik elihood of a successful taper and minimize \n",
      "withdrawal symptoms, it is impor tant that the opioid tapering s chedule is agreed upon by the patient. In patients \n",
      "taking opioids for a long durati on at high doses, ensure that a  multimodal approach to pain management, \n",
      "including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [see Dosage \n",
      "and Administration (2.5), Warn ings and Precautions (5.13)] . \n",
      "Infants born to mothers physica lly dependent on opioids will al so be physically dependent and may exhibit \n",
      "respiratory difficulties and withdrawal signs [see Use in Specific Populations (8.1)]. \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  10 OVERDOSAGE \n",
      "Clinical Presentation \n",
      "Acute overdosage with ZOHYDRO ER can be manifested by respirato ry depression, somnolence progressing to \n",
      "stupor or coma, skeletal muscle  flaccidity, cold and clammy ski n, constricted pupils, and, in some cases, \n",
      "pulmonary edema, bradycardia, hypo tension, partial or complete airway obstruction, atypical snoring, and \n",
      "death. Marked mydriasis rather than miosis may be seen with hyp oxia in overdose situations [see Clinical \n",
      "Pharmacology (12.2)] . \n",
      "Treatment of Overdose In case of overdose, priorities  are the reestablishment of a pa tent and protected airway and institution of assisted \n",
      "or controlled ventilation if n eeded. Employ other supportive measures (including oxygen and vasopressors) in \n",
      "the management of circulatory shock and pulmonary edema accompa nying overdose as indicated. Cardiac arrest \n",
      "or arrhythmias will require adva nced life support techniques. \n",
      "Opioid antagonists, such as nal oxone, are specific antidotes to respiratory depression resulting from opioid \n",
      "overdosage. For clinically signi ficant respiratory or circulato ry depression secondary  to hydrocodone overdose, \n",
      "administer an opioid antagonist. \n",
      "Because the duration of reversal is expected to be less than th e duration of action of hydrocodone in \n",
      "ZOHYDRO ER, carefully monitor th e patient until spontaneous res piration is reliably reestablished. \n",
      "ZOHYDRO ER will continue to rel ease hydrocodone and add to the hydrocodone load for 24 to 48 hours or \n",
      "longer following ingestion necessitating prolonged monitoring. If the response to an opioid antagonist is \n",
      "suboptimal or only brief in nature, a dminister additional antag onist as directed by the productâ€™s prescribing \n",
      "information. \n",
      "In an individual physically dependent on opioids, administratio n of the recommended dos e of the antagonist \n",
      "will precipitate an acute withdrawal syndrome. The severity of the withdrawal syndrome produced will depend \n",
      "on the degree of physical dependenc e and the dose of the antago nist administered. If a decision is made to treat \n",
      "serious respiratory depression i n the physicall y dependent pati ent, administration of the antagonist should be \n",
      "initiated with care and by titration with smaller than usual do ses of the antagonist. \n",
      "11 DESCRIPTION ZOHYDRO ER (hydrocodone bitartrate ) extended-release capsules a re hard gelatin capsules for oral \n",
      "administration. Hydrocodone bitart rate is an opioid agonist and  occurs as fine, white crystals, or as a crystalline \n",
      "powder. The chemical name is 4,5(alpha)-e poxy-3-methoxy-17-methylmorphinan-6-one tartrate (1 :1) hydrate (2:5) or \n",
      "morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5 alpha)-, [R  (R*, R*)]-2,3-dihydroxybutanedioate (1:1), \n",
      "hydrate (2:5). It has the fo llowing structural formula:  \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      "Â \n",
      "  \n",
      "  \n",
      "Â  \n",
      "  Each ZOHYDRO ER capsule conta ins either 10 mg, 15 mg, 20 mg, 30  mg, 40 mg, or 50 mg of hydrocodone \n",
      "bitartrate and the following in active ingredients: sugar sphere s NF, hypromellose USP, ammonio methacrylate \n",
      "copolymer NF, silicon dioxide NF, talc USP, polyethylene oxide NF, and povidone USP. The capsule shells \n",
      "collectively contai n titanium dioxide, FD&C Blue #1, FD&C Red #40, FDA Yellow iron oxide, FD&C Red #3, \n",
      "FDA Black iron oxide, FDA Re d iron oxide, and gelatin. \n",
      "12 CLINICAL PHARMACOLOGY \n",
      "12.1 Mechanism of Action \n",
      "Hydrocodone is a full opioid agonis t with relative selectivity for the mu-opioid receptor, although it can interact \n",
      "with other opioid receptors at hi gher doses. The principal ther apeutic action of hydrocodone is analgesia. Like \n",
      "all full opioid agonists, there is no ceiling effect for analge sia with hydrocodone. Clinicall y, dosage is titrated to \n",
      "provide adequate analgesia and m ay be limited by adverse reacti ons, including respiratory and CNS depression.  \n",
      "The precise mechanism of the a nalgesic action is unknown. Howev er, specific CNS opioid receptors for \n",
      "endogenous compounds with opioid-like activity have been identi fied throughout the brai n and spinal cord and \n",
      "are thought to play a role in the  analgesic effects of this dru g.  \n",
      "12.2 Pharmacodynamics Effects on the Central Nervous System \n",
      "Hydrocodone produces respirator y depression by di rect action on  brain stem respiratory centers. The respiratory \n",
      "depression involves a reduction in the respons iveness of the brainstem respiratory centers to both increases in \n",
      "carbon dioxide tension and electri cal stimulation. Hydrocodone causes miosis, even in total darkness. Pinpoint \n",
      "pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or \n",
      "ischemic origin may produce similar findings). Marked mydriasis  rather than miosis may be seen with hypoxia \n",
      "in overdose situations [see Overdosage (10)]. \n",
      "Effects on the Gastrointestinal T ract and Other Smooth Muscle  \n",
      "Hydrocodone causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intest ine is delayed and propul sive contractions are \n",
      "decreased. Propulsive peristaltic  waves in the colon are decrea sed, while tone is increased to the point of spasm, \n",
      "resulting in constipation. Other opioid-induced effects may include a reduction in gastric, in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transien t elevations in serum amylase. \n",
      "Effects on the Cardiovascular System  \n",
      "Hydrocodone produces peripheral va sodilation, which may result in orthostatic hypote nsion or syncope. \n",
      "Manifestations of histamine rel ease and/or periph eral vasodilat ion may include pruritus, flushing, red eyes, \n",
      "sweating, and/or orthostatic hypotension. \n",
      "Effects on the Endocrine System\n",
      "\t\n",
      "Opioids inhibit the secretion of  adrenocorticotropic hormone (A CTH), cortisol, and luteinizing hormone (LH) \n",
      "in humans [see Adverse Reactions (6.2)] . They also stimulate prolacti n, growth hormone (GH) secretion,  and \n",
      "pancreatic secretion of insulin and glucagon.\n",
      "\t\n",
      "Chronic use of opioids may influ ence the hypothalamic-pituitary -gonadal axis, leading t o androgen deficiency \n",
      "that may manifest as low libi do, impotence, erectile dysfunctio n, amenorrhea, or infertility. The causal role of \n",
      "opioids in the clinical sy ndrome of hypogonadism is unknown bec ause the various medical, physical, lifestyle, \n",
      "and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for \n",
      "in studies conducted to date [see Adverse Reactions (6.2)] . \n",
      "Effects on the Immune System \n",
      "In vitro  and animal studies indicate that opioids have a variety of eff ects on immune functions, depending on \n",
      "the context in which they are us ed. The clinical significance o f these findings is unknow n.  Overall, the effects \n",
      "of opioids appear to be modestly immunosuppressive. \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " Concentrationâ€”Efficacy Relationships \n",
      "The minimum effective analgesic concentration will vary widely among patients who have been previously \n",
      "treated with potent agonist opioi ds. The minimum effective anal gesic concentration of  hydrocodone for any \n",
      "individual patient may increas e over time due to an increase in  pain, the development of a new pain syndrome \n",
      "and/or potential developmen t of analgesic tolerance. [see Dosage and Administration (2.1, 2.3)] . \n",
      "Concentrationâ€”Adverse Expe rience Relationships \n",
      "There is a relationship between increasing hydrocodone plasma c oncentration and incr easing frequency of \n",
      "adverse experiences such as na usea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant \n",
      "patients, the situation may be altered by the development of to lerance to opioid-related adverse reactions [see \n",
      "Dosage and Administration (2.1, 2.2, 2.3)] . \n",
      "12.3 Pharmacokinetics \n",
      "Absorption \n",
      "As compared to immediate-release hydrocodone combination products, ZOHYDRO ER at similar daily doses results in similar overall exposure but with lower maximum conc entrations. The half-lif e is also longer due to \n",
      "the prolonged duration of absorption. Based on the half-life of  hydrocodone, steady-stat e should be obtained \n",
      "after 3 days of dosing. Follo wing 7 days of dosing, AUC and C\n",
      "max increase approximately two-fold as compared \n",
      "to the first day of dosing. The pha rmacokinetics of ZOHYDRO ER have been shown to be independent of dose \n",
      "up to a dose of 50 mg. \n",
      "ZOHYDRO ER capsules exhibit pe ak plasma concentrations approxim ately 5 hours after dose administration. \n",
      "Food Effects \n",
      "Food has no significant effect on the extent of absorption of h ydrocodone from ZOHYDRO ER. Although there \n",
      "was no evidence of dose dumping a ssociated with this formulatio n under fasted and fed conditions, peak plasma \n",
      "concentration of hydrocodone incr eased by 27% when a ZOHYDRO ER  20 mg capsule was administered with \n",
      "a high-fat meal. \n",
      "Distribution \n",
      "Although the extent of prot ein binding of hydrocodone in human plasma has not been definitively determined, \n",
      "structural similarities to related opioid analgesics suggest th at hydrocodone is not exten sively protein bound. As \n",
      "most agents in the 5-ring morphinan group of semi-synthetic opioids bind plasma protein to a similar degree \n",
      "(range 19% [hydromorphone] t o 45% [oxycodone]), hydrocodone is expected to fall within this range. \n",
      "Elimination Metabolism Hydrocodone exhibits a complex pa ttern of metabolism, including  N-demethylation, O-demethylation, and 6-\n",
      "keto reduction to the corresponding 6-Î±-and 6-Î²-hydroxy metabol ites. CYP3A4 mediated N-demethylation to \n",
      "norhydrocodone is the primary metabolic pathway of hydrocodone with a lower contribution from CYP2D6 \n",
      "mediated O-demethylation to hydromorphone. Hydromorphone is formed from the O-demethylation of hydrocodone and may contribute to the total analgesic effect of  hydrocodone. Therefore, the formation of these \n",
      "and related metabolites can, in theory, be affected by other dr ugs [see Drug Interactions (7)]. Published in vitro \n",
      "studies have shown that N-demethylation of hydrocodone to form norhydrocodone can be attributed to CYP3A4 \n",
      "while O-demethylation of hydr ocodone to hydromorphone is predominantly catalyzed by CYP2D6 and to a \n",
      "lesser extent by an unknown low affinity CYP enzyme.  \n",
      "Excretion \n",
      "Hydrocodone and its metabolites are eliminated primarily in the kidneys, with a mean apparent plasma half-life after ZOHYDRO ER administr ation of approximately 8 hours. \n",
      "Special Populations Age: Geriatric Patients No significant pharmacokinetic  differences by age were observed  based on population pharmacokinetic \n",
      "analysis. \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " Sex: No significant pharmacokinetic differences by sex were observed based on population pharmacokinetic \n",
      "analysis. \n",
      "Hepatic Impairment \n",
      "After a single dose of 20 mg ZOHYD RO ER in 20 patients with mil d to moderate hepatic impairment based on \n",
      "Child-Pugh classifications, mean hydrocodone C max values were 25 Â± 5, 24 Â± 5, and 22 Â± 3.3 ng/mL for \n",
      "moderate and mild impairment, and normal subjects, respectively . Mean hydrocodone AUC values were 509 Â± \n",
      "157, 440 Â± 124, and 391 Â± 74 ngïƒ—h/mL for moderate and mild impairment, and normal subjects, res pectively. \n",
      "Hydrocodone C max values were 8-10% higher in pa tients with mild or moderate hep atic impairment, \n",
      "respectively, while AUC values were 10% and 26% higher in patie nts with mild and moderate hepatic \n",
      "impairment, respectively. Severel y impaired subje cts were not studied [see Use in Specific Populations (8.6)]. \n",
      "Renal Impairment After a single dose of 20 mg ZOHYD RO ER in 28 patients with mil d, moderate, or severe renal impairment \n",
      "based on Cockcroft-Gault criteria, mean hydrocodone C\n",
      "max values were 26 Â± 6.0, 28 Â± 7.5, 21 Â± 5.1 and 19 Â± 4.4 \n",
      "ng/mL for severe, moderate, mild renal impairment, and normal s ubjects, respectively. Mean hydrocodone AUC \n",
      "values were 487 Â± 123, 547 Â± 184, 391 Â± 122 and 343 Â± 105 ng ïƒ—h/mL for severe, moderate, mild renal \n",
      "impairment, and normal subjects, respectively. Hydrocodone C max values were 15%, 48% , and 41% higher and \n",
      "AUC values were 15%, 57% and 44% higher in patients with mild, moderate, and severe renal impairment, respectively [see Use in Specific Populations (8.7)]. \n",
      "Drug Interaction Studies Interactions with Alcohol The rate of absorption of ZOHYDR O ER 50 mg was affected by co-a dministration with 40% alcohol in the \n",
      "fasted state, as exhibited by an increase in peak hydrocodone concentrations (on average 2.4-fold increase with maximum increase of 3.9-fold in one subject) and a decrease in the time to peak concentrations. The extent of \n",
      "absorption was increased on avera ge 1.2-fold with maximum incre ase of 1.7-fold in one subject with 40% \n",
      "alcohol [see Warnings and Precautions (5.6)]. \n",
      "Cytochrome P450 Enzymes While comprehensive PK drug-drug  interaction studies (other than alcohol) have not been performed in humans \n",
      "receiving hydrocodone, published in vitro  and human PK studies indicat e that conversion of hydrocodone t o its \n",
      "primary metabolite, norhydroc odone and lesser metabolite, hydro morphone, is mediated by the cytochrome \n",
      "P450 enzyme system. N-demethyl ation of hydrocodone to form norhydrocodone is attributed to CYP3A4 and \n",
      "O-demethylation of hydrocodone to hydromorphone is predominantl y catalyzed by CYP2D6 and to a lesser \n",
      "extent by an unknown low affinity CYP enzyme.  \n",
      "CYP3A4 Inhibitors and Inducers \n",
      "An increase in CYP3A 4 activity by initiati on of CYP3A4 inhibiting drugs or discontinuation of CYP3A4 \n",
      "inducing drugs could alter the metabolic profile of hydrocodone causing a slowing of hydrocodone clearance, \n",
      "and lead to elevated hydrocodone con centrations and effects, wh ich could be more pronounced with \n",
      "concomitant use of cytochrome P450 CYP3A4 inhibitors. Initiatio n of a CYP3A4 inducing drug can lower \n",
      "hydrocodone plasma levels and may induce an opioid-withdrawal s yndrome  [see Warnings and Precautions \n",
      "(5.5) and Drug Interactions (7)]. \n",
      "13 NONCLINICAL TOXICOLOGY \n",
      "13.1 Carcinogenesis, Mutagenesis,  Impairment of Fertility \n",
      "Carcinogenesis \n",
      "Hydrocodone was evaluated for carcinogenic potential in rats an d mice. In a two-year bioassay in rats, doses up \n",
      "to 30 mg/kg in males and 100 mg/kg i n females were administered  orally and no treatment-related neoplasms \n",
      "were observed (exposure is equivalent to 0.1 times and 0.6 time s for males and females, respectively, the human \n",
      "hydrocodone dose of 100 mg/day based on AUC exposure comparison s). In a two-year bioassay in mice, doses \n",
      "up to 100 mg/kg in males and females were administered orally and no treatment-related neoplasms were \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      "  \n",
      "observed (exposure is equivalent to 0.8 times and 1.5 times, re spectively, the human hydrocodone dose of 100 \n",
      "mg/day based on AUC exposure comparisons.  \n",
      "Mutagenesis \n",
      "Hydrocodone bitartrate was genotoxic in an in vitro  chromosomal aberration assay in the presence of metabolic \n",
      "activation. No evidence of clast ogenicity was observed in this assay in the absence of m etabolic activation. No \n",
      "evidence of DNA damage was found in an in vivo  comet assay in mouse liver. There was no evidence of \n",
      "genotoxic potential in an in vitro  bacterial reverse mutation assay ( Salmonella typhimurium  and Escherichia \n",
      "coli) or in an assay for chromosomal aberrations ( in vivo  mouse bone marrow micronucleus assay).   \n",
      "Impairment of Fertility In a fertility study, rats were administered once daily by oral  gavage the vehicle or hydrocodone bitartrate at \n",
      "doses of 25, 75, and 100 mg/kg/day (equivalent to approximately  2, 7, and 10 times an adult human dose of 100 \n",
      "mg/day, on a mg/m\n",
      "2 basis). Male and female rats were dosed before cohabitation (u p to 28 days), during the \n",
      "cohabitation and until gestati on day 7 (females) or necropsy (m ales; 2-3 weeks post-cohabitation). Hydrocodone \n",
      "bitartrate did not affect reproductive function in males, altho ugh the weights of male re productive organs were \n",
      "decreased at all doses. Doses of  25 mg/kg/day and greater in fe males reduced the rate at which females became \n",
      "pregnant which correlated wit h suppression of estrous cyclicity , thought to be due to increases in prolactin. In \n",
      "hydrocodone bitartrate-treated rats that became pregnant, at 25  mg/kg early embryonic development was \n",
      "unaffected (approximately 2 tim es the adult human daily dose of  100 mg/day on a mg/m2 basis). In rats, \n",
      "prolactin plays a unique role i n the estrous cycle and the clin ical relevance of the f emale rat reproductive \n",
      "findings is uncertain. \n",
      "14 CLINICAL STUDIES \n",
      "The efficacy and safety of ZOHYDRO  ER have been evaluated in a randomized double-blind, placebo-\n",
      "controlled, multi-center clinical trial in opioid-experienced s ubjects with moderate to severe chronic low back \n",
      "pain. \n",
      "Placebo-Controlled Study in Opioi d-Experienced Subjects with Mo derate to Severe Chronic Lower Back Pain \n",
      "A total of 510 subjects current ly on chronic opio id therapy ent ered an open-label conver sion and titration phase \n",
      "(up to 6 weeks) with ZOHYDRO E R dosed every 12 hours at an appr oximated equianalges ic dose of their pre-\n",
      "study opioid medication. For inadequately controlled pain, ZOHY DRO ER was increased by 10 mg per 12-hour \n",
      "dose, once every 3â€“7 days until a stabilized dose was identifie d, or a maximum dosage of 100 mg every 12 \n",
      "hours. There were 302 subjects (59%) randomized at a ratio of 1 :1 into a 12-week double- blind treatment phase \n",
      "with their fixed stabilize d dose of ZOHYDRO ER (40-200 mg daily  taken as 20-100 mg, every 12 hours) or a \n",
      "matching placebo. Subjects randomized to placebo were given a b linded taper of ZOHYDRO ER according to a \n",
      "pre-specified tapering schedule. During the treatment phase, su bjects were allowed to use rescue medication \n",
      "(hydrocodone 5 mg/500 mg acetam inophen) up to 2 doses (2 tablet s) per day. There were 124 treated subjects \n",
      "(82%) that completed the 12-wee k treatment with ZOHYDRO ER and 59 subjects (39%) with placebo. \n",
      "ZOHYDRO ER provided greater analg esia compared to placebo. Ther e was a significant difference in the mean \n",
      "changes from Baseline to Week 12 in average weekly pain intensi ty Numeric Rating Scale (NRS) scores \n",
      "between the two groups. The percentage of subjects in each group who demonstrated impro vement in their NRS pain score at End-of-\n",
      "Study, as compared to Screening is shown in the figure below. T he figure is cumulative, so subjects whose \n",
      "change from Screening is, for e xample, 30% are also included at every level of improvement below 30%. \n",
      "Subjects who did not complete the study were classified as non-responders. Treatment with ZOHYDRO ER \n",
      "produced a greater number of res ponders, defined as subjects wi th at least a 30% improvement, as compared to \n",
      "placebo (67.5% vs. 31.1%). \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      "  \n",
      "  \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      "  \n",
      " \n",
      "  \n",
      " \n",
      "  \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "              \n",
      "      \n",
      "0 10 20 30 40 50 60 70 80 90 100 \n",
      "â‰¥ 10 â‰¥ 20 â‰¥ 30 â‰¥ 40 â‰¥ 50 â‰¥ 60 â‰¥ 70 â‰¥ 80 â‰¥ 90 â‰¥ 100 Percentage of Subjects Improved \n",
      "Percent Improvement in Pain From Screening Percentage Improvementin Average Pain Intensity From \n",
      "Screening to Final Visit \n",
      "ZOHYDRO ER Placebo \n",
      "16 HOW SUPPLIED/STORAGE AND HANDLING \n",
      "ZOHYDRO ER extended-release capsules are supplied in 60-count b ottles with a child-resistant closure as \n",
      "follows: \n",
      "Strength Capsule Color(s) Capsule Text NDC Number \n",
      "10 mg White opaque â€œZ310 10 mgâ€ in \n",
      "black ink 65224-310-60 \n",
      "15 mg Light green and \n",
      "white opaque â€œZ315 15 mgâ€ in \n",
      "black ink 65224-315-60 \n",
      "20 mg Light green \n",
      "opaque â€œZ320 20 mgâ€ in \n",
      "black ink 65224-320-60 \n",
      "30 mg Dark blue and \n",
      "white opaque â€œZ330 30 mgâ€ in \n",
      "black ink 65224-330-60 \n",
      "40 mg Dark brown and \n",
      "white opaque â€œZ340 40 mgâ€ in \n",
      "black ink 65224-340-60 \n",
      "50 mg Dark brown \n",
      "opaque â€œZ350 50 mgâ€ in \n",
      "black ink 65224-350-60 \n",
      "ZOHYDRO ER contains hydrocodone bitartrate which is a controlled substance and is controlled under \n",
      "Schedule II of the Controlled Substances Act. Hydrocodone, like  all opioids, is liable to diversion and misuse \n",
      "and should be handled accordingly. Patients and their families should be instructed to dispose of any \n",
      "ZOHYDRO ER capsules th at are no longer needed.  \n",
      "ZOHYDRO ER may be targeted for  theft and diversion. Healthcare professionals should contact their State \n",
      "Medical Board, State Board of P harmacy, or State Control Board for information on how to detect or prevent \n",
      "diversion of this product. \n",
      "Healthcare professionals should a dvise patients to store ZOHYDR O ER in a secure place, preferably locked and \n",
      "out of the reach of childre n and other non-caregivers.  \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " Store at 25Â°C (77Â°F); excursions permitted to 15Â°-30Â°C (59Â°-86Â°F) [see USP Controlled Room Temperature].  \n",
      "Dispense in tight container as defined in the USP, with a child -resistant closure. \n",
      "Advise patients to dispose of any unused capsules from a prescr iption as soon as they are no longer needed in \n",
      "accordance with local State guidelines and/or regulations [see Patient Counseling Information (17)]. \n",
      "17 PATIENT COUNSELING INFORMATION \n",
      "Advise the patient to read the  FDA approved patient labeling (M edication Guide). \n",
      "Storage and Disposal \n",
      "Because of the risks associate d with accidental ingestion, misu se, and abuse, advise patients to store \n",
      "ZOHYDRO ER securely, out of sight and reach of children, and in  a location not accessibl e by others, including \n",
      "visitors to the home [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9.2)] . Inform patients \n",
      "that leaving ZOHYDRO ER unsecure d can pose a deadly risk to oth ers in the home. \n",
      "Advise patients and caregivers that when medicines are no longe r needed, they should be disposed of promptly. \n",
      "Expired, unwanted, or unused ZOH YDRO ER should be disposed of by flushing the unused medication down \n",
      "the toilet if a drug t ake-back option is not  readily available.  Inform patients that they can visit \n",
      "www.fda.gov/drugdisposal  for a complete list of medici nes recommended for disposal by flushing, as well as \n",
      "additional information on dis posal of unused medicines. \n",
      "Addiction, Abuse, and Misuse \n",
      "Inform patients that the use of Z OHYDRO ER, even when taken as recommended, can result in addiction, \n",
      "abuse, and misuse, which can lead to overdose or death [see Warnings and Precautions (5.1)]. Instruct patients \n",
      "not to share ZOHYDRO ER with others and to take steps to protec t ZOHYDRO ER from theft or misuse.\n",
      "\t\n",
      "Life-Threatening Respiratory Depression Inform patients of the risk of life-threatening respiratory dep ression, including informati on that the risk is \n",
      "greatest when starting ZOHYDRO ER or when the dosage is increased, and that it can occur even at \n",
      "recommended dosages.  \n",
      "Educate patients and caregivers  on how to recognize respiratory  depression and emphasize the importance of \n",
      "calling 911 or getting emergency med ical help right away in the event of a known or suspected overdose [see \n",
      "Warnings and Precautions (5.3)] . \n",
      "Patient Access to Naloxone for the  Emergency Treatment of Opioid Overdose \n",
      "Discuss with the patient and car egiver the availability of nalo xone for the emergency treatment of opioid \n",
      "overdose, both when initiating a nd renewing treatment with ZOHY DRO ER. Inform patients and caregivers \n",
      "about the various ways to obtain naloxone as permitted by indiv idual state naloxone dis pensing and prescribing \n",
      "requirements or guidelines (e .g., by prescription, directly fro m a pharmacist, or as part of a community-based \n",
      "program) [see Dosage and Administration (2.2), Warnings  and Precautions (5.3)]. \n",
      "Educate patients and caregivers  on how to recognize the signs a nd symptoms of an overdose. \n",
      "Explain to patients and caregiver s that naloxoneâ€™ s effects are temporary, and that they must call 911 or get \n",
      "emergency medical help right a way in all cases of known or susp ected opioid overdose, even if naloxone is \n",
      "administered [see Overdosage (10)] . \n",
      "If naloxone is prescribed, also a dvise patients and caregivers: \n",
      "ï‚· How to treat with naloxone i n the event of an opioid overdose \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "    \n",
      " \n",
      " \n",
      " ï‚·\t To tell family and friends about their naloxone and to keep it in a place where family and friends can \n",
      "access it in an emergency \n",
      "ï‚·\t To read the Patient Information ( or other educational material)  that will come with their naloxone. \n",
      "Emphasize the importance of doing this before an opioid emergen cy happens, so the patient and \n",
      "caregiver will  know what to do. \n",
      "Accidental Ingestion \n",
      "Inform patients that accidenta l ingestion, especially by childr en, may result in respira tory depression or death \n",
      "[see Warnings and Precautions (5.3)] . \n",
      "Interaction with Benzodiazepin es and Other CNS Depressants \n",
      "Inform patients and caregivers th at potentially fatal additive effects may occur if ZOHYDRO ER is used with \n",
      "benzodiazepines or other CNS depr essants, including alcohol, an d not to use these concomitantly unless \n",
      "supervised by a health care provider. Instruct patients not to consume alcoholic beverages, as well as prescription and over-the-counter products that contain alcohol , during treatment with ZOHYDRO ER  [see \n",
      "Warnings and Precautions (5.6 ), Drug Interactions (7)]. \n",
      "Serotonin Syndrome Inform patients that opioids could cause a rare  but potentially  life-threatening condition resulting from \n",
      "concomitant administration of ser otonergic drugs.  Warn patients of the symptoms of ser otonin syndrome and to \n",
      "seek medical attention right a way if symptoms develop.  Instruc t patients to inform thei r physicians if they are \n",
      "taking, or plan to take sero tonergic medications. [see Drug Interactions (7)] . \n",
      "MAOI Interaction Inform patients to avoid taki ng ZOHYDRO ER while using any drug s that inhibit monoamine oxidase. Patients \n",
      "should not start MAOIs while  taking ZOHYDRO ER [see Drug Interactions (7)]. \n",
      "Adrenal Insufficiency Inform patients that opioids could cause adrenal insufficiency,  a potentially life-threatening condition.  Adrenal \n",
      "insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, \n",
      "weakness, dizziness, and low blood pressure.  Advise patients t o seek medical attention if they experience a \n",
      "constellation of t hese symptoms [see Warnings and Precautions (5.8)] . \n",
      "Important Administration Instructions [see Dosage and Administration (2)] \n",
      "Instruct patients how t o properly take ZOHY DRO ER, including th e following: \n",
      "ï‚·\t Use ZOHYDRO ER exactly as prescribed to reduce the risk of life -threatening adverse reactions \n",
      "(e.g., respiratory depression) [see Warnings and Precautions (5.3)] . \n",
      "ï‚·\t Swallow ZOHYDRO ER capsules whole. \n",
      "ï‚·\t Do not crush, chew, or dissolve th e capsule or its contents.   \n",
      "Important Discontinuation Instructions \n",
      "In order to avoid developing withdr awal symptoms, instruct pati ents not to discontinue  ZOHYDRO ER without \n",
      "first discussing a taperin g plan with the prescriber [see Dosage and Administration (2.5)] . \n",
      "Hypotension \n",
      "Inform patients that ZOHYDRO ER may cause orthostatic hypotensi on and syncope. Instru ct patients how to \n",
      "recognize symptoms of low blood pr essure and how to reduce the risk of serious consequences should \n",
      "hypotension occur (e.g., sit or lie  down, carefully rise from a sitting or lying position [see Warnings and \n",
      "Precautions (5.9)] ). \n",
      "Anaphylaxis \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "  Inform patients that anaphylaxis  has been reported with ingredients contained in ZOHYDRO ER. Advise \n",
      "patients how to recognize such a  reaction and when to seek medi cal attention [see Contraindications (4), \n",
      "Adverse Reactions (6)]. \n",
      "Pregnancy \n",
      "Neonatal Opioid Withdrawal Syndrome \n",
      "Inform female patients of reproductive potential that prolonged  use of ZOHYDRO ER during pregnancy \n",
      "can result in neonatal  opioid withdrawal syndrome, which may be  life-threatening if not recognized and \n",
      "treated [see Warnings and Precautions (5.4), Use in Specific Populations (8.1)].  \n",
      "Embryo-Fetal Toxicity Inform female patients of repr oductive potential that ZOHYDRO E R can cause fetal harm and to inform \n",
      "their healthcare provider of a known or suspected pregnancy [see Use in Specific Populations (8.1)]. \n",
      "Lactation Advise patients that breastfeeding is not recommended during tr eatment with ZOHYDRO ER [see Use in \n",
      "Specific Populations (8.2)] . \n",
      "Infertility Inform patients that chronic use of opioids may cause reduced f ertility. It is not known whe ther these effects on \n",
      "fertility are reversible [see Adverse Reactions (6.2), Use in Specific Populations (8.3)]. \n",
      "Driving or Operating Heavy Machinery  Inform patients that ZOHYDRO ER may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Blood levels of hyd rocodone, in some patients, may be high at the \n",
      "end of 24 hours after repeated dos e administration. Advise pati ents not to perform su ch tasks until they know \n",
      "how they will react to the medication [see Warnings and Precautions (5.14)] . \n",
      "Constipation Advise patients of the potential for severe constipation, inclu ding management instructions and when to seek \n",
      "medical attention. Instruct patien ts to monitor their analgesic  response following the use of strong laxatives and \n",
      "to contact the prescriber if changes are noted [see Adverse Reactions (6), C linical Pharmacology (12.2)]. \n",
      "Disposal of Unus ed ZOHYDRO ER \n",
      "Advise patients to flush the unused capsules down the toilet wh en ZOHYDRO ER is no longer needed.  \n",
      "ZOHYDRO\n",
      "Â® ER is distributed by Curraxâ„¢ Pharmaceuticals LLC, Morristown, NJ  07960. \n",
      "ZOHYDROÂ® ER is a registered trademark of Persionâ„¢ Pharmaceuticals LLC. \n",
      "ZOH-LC036.07 \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "  \n",
      "  \n",
      " \n",
      " \n",
      "   \n",
      "   \n",
      " \n",
      " \n",
      "  \n",
      "   \n",
      " \n",
      "  \n",
      "  \n",
      "  \n",
      " \n",
      "  \n",
      " \n",
      "      \n",
      "         \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      "  \n",
      "  \n",
      " \n",
      "    \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      "   \n",
      "   \n",
      " \n",
      " \n",
      "  \n",
      "  \n",
      "  \n",
      " \n",
      "  \n",
      " \n",
      " Medication Guide  \n",
      "ZOHYDROÂ® ER (zoh-hye-droh) \n",
      "(hydrocodone bitartrate) extended-release capsules, CII \n",
      "ZOHYDRO ER is: \n",
      "ï‚· A strong prescription pain medicine that contains an opioid (n arcotic) that is used to tr eat pain severe enough to \n",
      "require daily, around-the-cloc k, long-term treatment with an op ioid, when other pain treatments such as non-opioid \n",
      "pain medicines or immediate-rele ase opioid medicines do not tre at your pain well enough or you cannot tolerate \n",
      "them. \n",
      "ï‚· A long acting (extended-release) opioid pain medicine that can  put you at risk for overdo se and death. Even if you \n",
      "take your dose correctly as pre scribed, you are at risk for opi oid addiction, abuse, and misuse that can lead to death. \n",
      "ï‚· Not for use to treat pain th at is not around-the-clock. \n",
      "Important information about ZOHYDRO ER: \n",
      "ï‚· Get emergency help or call 911 ri ght away if you take too much ZOHYDRO ER (overdose).  When you first \n",
      "start taking ZOHYDRO ER, when your  dose is changed, or if you take too much (overdose), serious or life-\n",
      "threatening breathing problems t hat can lead to death may occur. Talk to your healthcare provider about naloxone, \n",
      "a medicine for the emergency tr eatment of an opioid overdose. \n",
      "ï‚· Taking ZOHYDRO ER with other opioid medicines, benzodiazepines , alcohol, or other central nervous system \n",
      "depressants (including street drugs) can cause severe drowsines s, decreased awareness, breathing problems, \n",
      "coma, and death. \n",
      "ï‚· Never give anyone else your ZOH YDRO ER. They could die from ta king it. Selling or giving away ZOHYDRO ER is \n",
      "against the law. \n",
      "ï‚· Store ZOHYDRO ER securely, ou t of sight and reach of children,  and in a location not accessible by others, \n",
      "including visitors to the home. \n",
      "Do not take ZOHYDRO ER if you have: ï‚· severe asthma, trouble breathi ng, or other lung problems. \n",
      "ï‚· a bowel blocka\n",
      "ge or narrowin g of the stomach or intestines. \n",
      "Before taking ZOHYDRO ER, tell your healthcare provider if you have a history of: \n",
      "ï‚· head injury, seizures  ï‚·   liver, kidney, thyroid problems \n",
      "ï‚· p r o b l e m s u r i n a t i n g ï‚·   pancreas or gallbladder problems \n",
      "ï‚· abuse of street or prescription drugs, alcohol addiction, opio id overdose, or mental health problems.  \n",
      "Tell your healthcare provider if you are: ï‚· pregnant or planning to become pregnant.  Prolonged use of ZOHYDRO ER during pregnancy can cause \n",
      "withdrawal symptoms in your newborn baby that could be life-thr eatening if not recognized and treated. \n",
      "ï‚· breastfeeding. Not recommended during treatmen t with ZOHYDRO ER. It may harm y our baby. \n",
      "ï‚· living in a household where ther e are small children or someone who has abused street or prescription drugs. \n",
      "ï‚· taking prescription or over-t he-counter medicines, vitamins, o r herbal supplements. Taking ZOHYDRO ER with \n",
      "certain other medicine s can cause serious side effects that cou ld lead to death. \n",
      "When taking ZOHYDRO ER: \n",
      "ï‚· Do not change your dose. Take ZO HYDRO ER exactly as prescribed  by your healthcare pr ovider.  Use the lowest \n",
      "dose possible for the shortest time needed. \n",
      "ï‚· Take your prescribed dose eve ry 12 hours, at the same time eve ry day. Do not take mor e than your prescribed \n",
      "dose in 12 hours. If you miss a dose, take your next dose at yo ur usual time. \n",
      "ï‚· Swallow ZOHYDRO ER wh ole. Do not cut, break , chew, crush, dissolve, snort, or inject ZOHYDRO ER because \n",
      "this may cause you to overdose and die. \n",
      "Call your healthcare provider if  the dose you are taking does n ot control your pain.  \n",
      "ï‚· Do not stop taking ZOHYDRO ER without talking to your healthcar e provider. \n",
      "ï‚· Dispose of expired, u nwanted, or unusedZOH YDRO ER by promptly flushing down the toilet, if a drug take-back \n",
      "option is not readily  available. Visit www.fda.gov/drugdisposal  for additional information on disposal of \n",
      "unusedmedicines. \n",
      "While taking ZOHYDRO ER DO NOT: \n",
      "ï‚· Drive or operate heavy machiner y, until you know how ZOHYDRO E R affects you. ZOHYDRO ER can make you \n",
      "sleepy, dizzy, or lightheaded. \n",
      "ï‚· Drink alcohol or use prescrip tion or over-the-counter medicine s that contain alcohol. Using products containing \n",
      "alcohol durin g treatment with ZOHYDRO ER ma y cause you to overdose and die. \n",
      "The possible side effects of ZOHYDRO ER are: ï‚· constipation, nausea, sleepin ess, vomiting, tiredness, headach e, dizziness, abdominal pain. Call your healthcare \n",
      "provider if you have any of these symptoms and they are severe. \n",
      "Get emer\n",
      "gency medical help or call 911 ri ght away if you have: \n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n",
      " \n",
      "   \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " ï‚·\t trouble breathing, shortness o f breath, fast heartbeat, chest pain, swelling of your face, tongue or throat, extreme \n",
      "drowsiness, light-headedness wh en you are changing positions, f eeling faint, agitation, high body temperature, \n",
      "trouble walking, stiff muscles, o r mental changes such as confu sion. \n",
      "These are not all the possible si de effects of ZOHYDRO ER. Call your doctor for medical advice about side effects. You \n",
      "may report side effects  to FDA at 1-800-FDA-1088 . For more information go to dailymed.nlm.nih.gov \n",
      "ZOHYDROÂ® ER is distributed by Curraxâ„¢ P harmaceuticals LLC, Morristown, NJ  07960.  ZOHYDROÂ® ER is a registered trademark of Persionâ„¢ Pharmaceuticals \n",
      "LLC, www.ZohydroER.com , 1-800-793-2145.  ZOH-LC037.07 \n",
      "This Medication Guide has been approved by the U.S. Food and Drug Administration \t Revised: 03/2021\n",
      "\t\n",
      "Reference ID: 4756535 \n",
      "This label may not be the latest approved by FDA.  \n",
      "For current labeling information, please visit https://www.fda.gov/drugsatfda\n"
     ]
    }
   ],
   "source": [
    "from io import BytesIO\n",
    "from PyPDF2 import PdfReader\n",
    "from pdf2image import convert_from_bytes\n",
    "import pytesseract\n",
    "import requests\n",
    "\n",
    "def extract_text_from_pdf_url(url, use_ocr_fallback=True):\n",
    "    try:\n",
    "        if \"#page=\" in url:\n",
    "            url = url.split(\"#\")[0]\n",
    "\n",
    "        headers = {\"User-Agent\": \"Mozilla/5.0\"}\n",
    "        response = requests.get(url, headers=headers, timeout=20)\n",
    "        response.raise_for_status()\n",
    "\n",
    "        # Try parsing as PDF\n",
    "        pdf_bytes = BytesIO(response.content)\n",
    "        reader = PdfReader(pdf_bytes)\n",
    "\n",
    "        text = \"\\n\".join([\n",
    "            p.extract_text() or \"\" for p in reader.pages\n",
    "        ]).strip()\n",
    "\n",
    "        if text:\n",
    "            return text\n",
    "\n",
    "        if use_ocr_fallback:\n",
    "            print(f\"[OCR fallback] {url}\")\n",
    "            images = convert_from_bytes(response.content)\n",
    "            return \"\\n\".join([pytesseract.image_to_string(img) for img in images]).strip()\n",
    "\n",
    "        return \"[Empty PDF]\"\n",
    "\n",
    "    except Exception as e:\n",
    "        return f\"[Error: {e}]\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "2edda8ac",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Page 20: Drug Name Active Ingredient Form; Route Appl. \n",
      "No.\n",
      "Company Date URL\n",
      "RELEASE;ORAL\n",
      "PALYNZIQ PEGVALIASE-PQPZ INJECTABLE;INJECTION 761079 BIOMARIN PHARM 11/20/2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761079s000lbl.pdf#page=23\n",
      "PAMELOR NORTRIPTYLINE HYDROCHLORIDE SOLUTION;ORAL 018012\n",
      "\n",
      "Page 13: Drug Name Active Ingredient Form; Route Appl. \n",
      "No.\n",
      "Company Date URL\n",
      "INFLECTRA INFLIXIMAB-DYYB INJECTABLE;INJECTION 125544 CELL TRION INC 06/17/2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125544s018lbl.pdf#page=61\n",
      "INGREZZA VALBENAZINE CAPSULE;ORAL 209241 NEUROCRINE \n",
      "BIOSCIENCES INC\n",
      "\n"
     ]
    }
   ],
   "source": [
    "#print(f\"{pages[0].metadata}\\n\")\n",
    "#print(pages[0].page_content)\n",
    "from langchain_core.vectorstores import InMemoryVectorStore\n",
    "from langchain_openai import OpenAIEmbeddings\n",
    "\n",
    "vector_store = InMemoryVectorStore.from_documents(pages, OpenAIEmbeddings(openai_api_key=os.getenv(\"OPENAI_KEY\")))\n",
    "docs = vector_store.similarity_search(\"What is LayoutParser?\", k=2)\n",
    "for doc in docs:\n",
    "    print(f'Page {doc.metadata[\"page\"]}: {doc.page_content[:300]}\\n')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "93a53e85",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "id": "a755ee43",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "âœ… Finale Antwort:\n",
      "âš ï¸ Unklare Frage: Wie sollte man Dafalgan lagern?.\n",
      "Hier die Rohantwort:\n",
      "\n",
      "Store Dafalgan at room temperature, away from moisture and heat, and out of children's reach. Follow the specific storage instructions on the product label. Always check the expiry date before use.\n",
      "- https://compendium.ch/de/product/17776-dafalgan-tabl-500-mg\n",
      "- https://compendium.ch/de/product/1473942-dafalgan-grippal-gran\n",
      "- https://compendium.ch/product/87957-demogripal-c-gran/mpub\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'input': 'Wie sollte man Dafalgan lagern?',\n",
       " 'compendium': \"Store Dafalgan at room temperature, away from moisture and heat, and out of children's reach. Follow the specific storage instructions on the product label. Always check the expiry date before use.\\n- https://compendium.ch/de/product/17776-dafalgan-tabl-500-mg\\n- https://compendium.ch/de/product/1473942-dafalgan-grippal-gran\\n- https://compendium.ch/product/87957-demogripal-c-gran/mpub\",\n",
       " 'result': \"âš ï¸ Unklare Frage: Wie sollte man Dafalgan lagern?.\\nHier die Rohantwort:\\n\\nStore Dafalgan at room temperature, away from moisture and heat, and out of children's reach. Follow the specific storage instructions on the product label. Always check the expiry date before use.\\n- https://compendium.ch/de/product/17776-dafalgan-tabl-500-mg\\n- https://compendium.ch/de/product/1473942-dafalgan-grippal-gran\\n- https://compendium.ch/product/87957-demogripal-c-gran/mpub\"}"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "load_dotenv()\n",
    "\n",
    "from tavily import TavilyClient\n",
    "from typing import TypedDict\n",
    "from langgraph.graph import StateGraph, END\n",
    "from langchain_core.runnables import RunnableLambda\n",
    "\n",
    "# === Setup ===\n",
    "client = TavilyClient(api_key=os.getenv(\"TAVILY_API_KEY\"))\n",
    "\n",
    "def get_compendium_info(med: str) -> str:\n",
    "    query = f\"site:compendium.ch {med}\"\n",
    "    results = client.search(query=query, search_depth=\"advanced\", include_answer=True)\n",
    "    answer = results.get(\"answer\")\n",
    "    urls = [r[\"url\"] for r in results.get(\"results\", [])]\n",
    "    return (answer or \"Keine genaue Antwort gefunden.\") + \"\\n\" + \"\\n\".join(f\"- {u}\" for u in urls[:3])\n",
    "\n",
    "def get_wirkung_info(compendium: str) -> str:\n",
    "    return f\"ðŸ”¬ Wirkungsauswertung:\\n{compendium}\"\n",
    "\n",
    "def get_lagerung_info(compendium: str) -> str:\n",
    "    return f\"ðŸ“¦ Lagerungsauswertung:\\n{compendium}\"\n",
    "\n",
    "def get_interaktionen_info(compendium: str) -> str:\n",
    "    return f\"ðŸ’¥ Interaktionsanalyse:\\n{compendium}\"\n",
    "\n",
    "def get_dosierung_info(compendium: str) -> str:\n",
    "    return f\"ðŸ’‰ Dosierungsauswertung:\\n{compendium}\"\n",
    "\n",
    "# === Graph State ===\n",
    "class AgentState(TypedDict):\n",
    "    input: str\n",
    "    compendium: str\n",
    "    result: str\n",
    "\n",
    "# === Nodes ===\n",
    "def compendium_node(state: AgentState) -> AgentState:\n",
    "    compendium = get_compendium_info(state[\"input\"])\n",
    "    return {\"input\": state[\"input\"], \"compendium\": compendium, \"result\": \"\"}\n",
    "\n",
    "def router_node(state: AgentState) -> str:\n",
    "    q = state[\"input\"].lower()\n",
    "    if \"lagerung\" in q:\n",
    "        return \"lagerung\"\n",
    "    elif \"interaktion\" in q:\n",
    "        return \"interaktionen\"\n",
    "    elif \"dosierung\" in q:\n",
    "        return \"dosierung\"\n",
    "    elif \"wirkung\" in q:\n",
    "        return \"wirkung\"\n",
    "    else:\n",
    "        return \"default\"\n",
    "\n",
    "def wirkung_node(state: AgentState) -> AgentState:\n",
    "    return {**state, \"result\": get_wirkung_info(state[\"compendium\"])}\n",
    "\n",
    "def lagerung_node(state: AgentState) -> AgentState:\n",
    "    return {**state, \"result\": get_lagerung_info(state[\"compendium\"])}\n",
    "\n",
    "def interaktionen_node(state: AgentState) -> AgentState:\n",
    "    return {**state, \"result\": get_interaktionen_info(state[\"compendium\"])}\n",
    "\n",
    "def dosierung_node(state: AgentState) -> AgentState:\n",
    "    return {**state, \"result\": get_dosierung_info(state[\"compendium\"])}\n",
    "\n",
    "def default_node(state: AgentState) -> AgentState:\n",
    "    return {**state, \"result\": f\"âš ï¸ Unklare Frage: {state['input']}.\\nHier die Rohantwort:\\n\\n{state['compendium']}\"}\n",
    "\n",
    "def output_node(state: AgentState) -> AgentState:\n",
    "    print(\"âœ… Finale Antwort:\")\n",
    "    print(state[\"result\"])\n",
    "    return state\n",
    "\n",
    "# === Build Graph ===\n",
    "workflow = StateGraph(AgentState)\n",
    "\n",
    "# Add all standard nodes\n",
    "workflow.add_node(\"fetch_compendium\", RunnableLambda(compendium_node))\n",
    "workflow.add_node(\"wirkung\", RunnableLambda(wirkung_node))\n",
    "workflow.add_node(\"lagerung\", RunnableLambda(lagerung_node))\n",
    "workflow.add_node(\"interaktionen\", RunnableLambda(interaktionen_node))\n",
    "workflow.add_node(\"dosierung\", RunnableLambda(dosierung_node))\n",
    "workflow.add_node(\"default\", RunnableLambda(default_node))\n",
    "workflow.add_node(\"output\", RunnableLambda(output_node))\n",
    "\n",
    "workflow.set_entry_point(\"fetch_compendium\")\n",
    "# ðŸš¨ THIS is the correct way to declare the router (don't add it manually above!)\n",
    "workflow.add_conditional_edges(\"fetch_compendium\", router_node, {\n",
    "    \"wirkung\": \"wirkung\",\n",
    "    \"lagerung\": \"lagerung\",\n",
    "    \"interaktionen\": \"interaktionen\",\n",
    "    \"dosierung\": \"dosierung\",\n",
    "    \"default\": \"default\"\n",
    "})\n",
    "\n",
    "# All paths lead to output\n",
    "for name in [\"wirkung\", \"lagerung\", \"interaktionen\", \"dosierung\", \"default\"]:\n",
    "    workflow.add_edge(name, \"output\")\n",
    "\n",
    "workflow.add_edge(\"output\", END)\n",
    "\n",
    "# === Compile & Run ===\n",
    "graph = workflow.compile()\n",
    "graph.invoke({\"input\": \"Wie sollte man Dafalgan lagern?\"})\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "id": "211a9b5e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "âœ… Finale Antwort:\n",
      "âš ï¸ Unklare Frage: Wie sollte man Dafalgan lagern?.\n",
      "Hier die Rohantwort:\n",
      "\n",
      "Store Dafalgan at room temperature, away from moisture and heat, and out of children's reach. Follow the specific storage instructions on the product label. Always check the expiry date before use.\n",
      "- https://compendium.ch/de/product/17776-dafalgan-tabl-500-mg\n",
      "- https://compendium.ch/de/product/1473942-dafalgan-grippal-gran\n",
      "- https://compendium.ch/product/87957-demogripal-c-gran/mpub\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'input': 'Wie sollte man Dafalgan lagern?',\n",
       " 'compendium': \"Store Dafalgan at room temperature, away from moisture and heat, and out of children's reach. Follow the specific storage instructions on the product label. Always check the expiry date before use.\\n- https://compendium.ch/de/product/17776-dafalgan-tabl-500-mg\\n- https://compendium.ch/de/product/1473942-dafalgan-grippal-gran\\n- https://compendium.ch/product/87957-demogripal-c-gran/mpub\",\n",
       " 'result': \"âš ï¸ Unklare Frage: Wie sollte man Dafalgan lagern?.\\nHier die Rohantwort:\\n\\nStore Dafalgan at room temperature, away from moisture and heat, and out of children's reach. Follow the specific storage instructions on the product label. Always check the expiry date before use.\\n- https://compendium.ch/de/product/17776-dafalgan-tabl-500-mg\\n- https://compendium.ch/de/product/1473942-dafalgan-grippal-gran\\n- https://compendium.ch/product/87957-demogripal-c-gran/mpub\"}"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph = workflow.compile()\n",
    "graph.invoke({\"input\": \"Wie sollte man Dafalgan lagern?\"})\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1cd99b1e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from langgraph.graph import StateGraph, END\n",
    "from langchain_core.runnables import RunnableLambda\n",
    "from typing import TypedDict\n",
    "\n",
    "# === Define the state ===\n",
    "class AgentState(TypedDict):\n",
    "    input: str\n",
    "    dropdown_type: str\n",
    "    dropdown_class: str\n",
    "    cleaned_input: str\n",
    "    query: str\n",
    "    result: str\n",
    "    source: str\n",
    "\n",
    "# === Nodes ===\n",
    "\n",
    "def analyze_input(state: AgentState) -> AgentState:\n",
    "    user_input = state[\"input\"].strip().lower()\n",
    "    dropdown = state[\"dropdown_type\"]\n",
    "    drug_class = state[\"dropdown_class\"]\n",
    "    cleaned = user_input.title()  # you can also apply spelling correction\n",
    "    return {**state, \"cleaned_input\": cleaned}\n",
    "\n",
    "def formulate_query(state: AgentState) -> AgentState:\n",
    "    mapping = {\n",
    "        \"wirkung\": \"Was ist die Wirkung von\",\n",
    "        \"lagerung\": \"Wie sollte man lagern\",\n",
    "        \"interaktionen\": \"Welche Interaktionen gibt es bei\",\n",
    "        \"dosierung\": \"Wie lautet die empfohlene Dosierung von\",\n",
    "    }\n",
    "    prefix = mapping.get(state[\"dropdown_type\"], \"Information Ã¼ber\")\n",
    "    full_query = f\"{prefix} {state['cleaned_input']}?\"\n",
    "    return {**state, \"query\": full_query}\n",
    "\n",
    "def query_compendium(state: AgentState) -> AgentState:\n",
    "    result = f\"[compendium result for: {state['query']}]\"\n",
    "    return {**state, \"result\": result, \"source\": \"compendium\"}\n",
    "\n",
    "def check_quality(state: AgentState) -> str:\n",
    "    if \"keine\" in state[\"result\"].lower() or len(state[\"result\"]) < 50:\n",
    "        return \"fallback\"\n",
    "    else:\n",
    "        return \"good\"\n",
    "\n",
    "def query_fallback_sources(state: AgentState) -> AgentState:\n",
    "    # Replace with real FDA/EMA logic\n",
    "    result = f\"[fallback result for: {state['query']}]\"\n",
    "    return {**state, \"result\": result, \"source\": \"fda\"}\n",
    "\n",
    "def print_final_response(state: AgentState) -> AgentState:\n",
    "    print(\"âœ… Antwort:\", state[\"result\"])\n",
    "    print(\"ðŸ“¦ Quelle:\", state[\"source\"])\n",
    "    return state\n",
    "\n",
    "\n",
    "graph_builder = StateGraph(AgentState)\n",
    "\n",
    "graph_builder.add_node(\"analyze_input\", RunnableLambda(analyze_input))\n",
    "graph_builder.add_node(\"formulate_query\", RunnableLambda(formulate_query))\n",
    "graph_builder.add_node(\"query_compendium\", RunnableLambda(query_compendium))\n",
    "graph_builder.add_node(\"query_fallback_sources\", RunnableLambda(query_fallback_sources))\n",
    "graph_builder.add_node(\"print_final_response\", RunnableLambda(print_final_response))\n",
    "\n",
    "graph_builder.add_conditional_edges(\"check_quality\", check_quality, {\n",
    "    \"good\": \"print_final_response\",\n",
    "    \"fallback\": \"query_fallback_sources\"\n",
    "})\n",
    "\n",
    "graph_builder.add_node(\"check_quality\", RunnableLambda(check_quality))\n",
    "\n",
    "# Edges\n",
    "graph_builder.set_entry_point(\"analyze_input\")\n",
    "graph_builder.add_edge(\"analyze_input\", \"formulate_query\")\n",
    "graph_builder.add_edge(\"formulate_query\", \"query_compendium\")\n",
    "graph_builder.add_edge(\"query_compendium\", \"check_quality\")\n",
    "graph_builder.add_edge(\"query_fallback_sources\", \"print_final_response\")\n",
    "graph_builder.add_edge(\"print_final_response\", END)\n",
    "\n",
    "graph = graph_builder.compile()\n",
    "from IPython.display import Image, display\n",
    "from langchain_core.runnables.graph import CurveStyle, MermaidDrawMethod, NodeStyles\n",
    "\n",
    "display(\n",
    "    Image(\n",
    "        graph.get_graph().draw_mermaid_png(\n",
    "            draw_method=MermaidDrawMethod.API,\n",
    "        )\n",
    "    )\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "178b922d",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chat_models import ChatOpenAI\n",
    "from langchain.agents import Tool, initialize_agent, AgentType\n",
    "from selenium.webdriver import Edge, EdgeOptions\n",
    "from selenium.webdriver.edge.service import Service\n",
    "from selenium.webdriver.common.by import By\n",
    "from selenium.webdriver.common.keys import Keys\n",
    "from PIL import Image\n",
    "import pytesseract\n",
    "import os\n",
    "import time\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "# Load environment\n",
    "load_dotenv()\n",
    "os.environ[\"LANGCHAIN_TRACING_V2\"] = \"true\"\n",
    "os.environ[\"LANGCHAIN_PROJECT\"] = \"HCI-Live-Agent\"\n",
    "pytesseract.pytesseract.tesseract_cmd = r\"C:\\Users\\FahRe\\AppData\\Local\\Programs\\Tesseract-OCR\\tesseract.exe\"\n",
    "\n",
    "SCREENSHOT_PATH = \"edge_screenshot.png\"\n",
    "driver_path = r\"C:\\Users\\FahRe\\Downloads\\edgedriver_win64\\msedgedriver.exe\"\n",
    "\n",
    "def slow_type(element, text, delay=0.12):\n",
    "    for char in text:\n",
    "        element.send_keys(char)\n",
    "        time.sleep(delay)\n",
    "\n",
    "def open_edge_and_search(search_term=\"Dafalgan EXTRA\"):\n",
    "    from selenium.common.exceptions import SessionNotCreatedException, WebDriverException\n",
    "\n",
    "    try:\n",
    "        edge_options = EdgeOptions()\n",
    "        edge_options.use_chromium = True\n",
    "        edge_options.add_argument(\"start-maximized\")\n",
    "        edge_options.add_argument(\"--disable-extensions\")\n",
    "\n",
    "        service = Service(executable_path=driver_path)\n",
    "        driver = Edge(service=service, options=edge_options)\n",
    "\n",
    "        driver.get(\"https://compendium.ch\")\n",
    "        time.sleep(4)\n",
    "\n",
    "        search_input = driver.find_element(By.CSS_SELECTOR, \"input[placeholder*='Suche']\")\n",
    "        slow_type(search_input, search_term, delay=0.15)\n",
    "        time.sleep(0.5)\n",
    "        search_input.send_keys(Keys.RETURN)\n",
    "\n",
    "        time.sleep(4)\n",
    "        driver.save_screenshot(SCREENSHOT_PATH)\n",
    "        driver.quit()\n",
    "\n",
    "        return f\"Searched '{search_term}' and saved screenshot to '{SCREENSHOT_PATH}'\"\n",
    "\n",
    "    except (SessionNotCreatedException, WebDriverException) as e:\n",
    "        return f\"âŒ Failed to launch Edge or complete search: {str(e)}\"\n",
    "\n",
    "## OCR function\n",
    "def extract_text_from_screenshot(image_path=SCREENSHOT_PATH):\n",
    "    if isinstance(image_path, str):\n",
    "        image_path = image_path.strip().replace(\"image_path=\", \"\").replace(\"'\", \"\")\n",
    "    image = Image.open(image_path)\n",
    "    text = pytesseract.image_to_string(image)\n",
    "    return f\"OCR Result:\\n{text}\"\n",
    "\n",
    "def safe_search_wrapper(term, retries=2):\n",
    "    for attempt in range(retries):\n",
    "        print(f\"ðŸ” Attempt {attempt + 1}\")\n",
    "        result = open_edge_and_search(term)\n",
    "        print(result)\n",
    "        if \"Screenshot saved\" in result:\n",
    "            return result\n",
    "        time.sleep(1)\n",
    "    return \"âŒ All retries failed.\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "119747af",
   "metadata": {},
   "outputs": [],
   "source": [
    "llm = ChatOpenAI(temperature=0, model=\"gpt-4\", openai_api_key=os.getenv(\"OPENAI_KEY\"))\n",
    "\n",
    "tools = [\n",
    "    Tool(\n",
    "        name=\"SearchInCompendium\",\n",
    "        func=lambda term: safe_search_wrapper(term),\n",
    "        description=\"Searches compendium.ch for a medication like 'Dafalgan EXTRA' and takes a screenshot.\"\n",
    "    ),\n",
    "    Tool(\n",
    "        name=\"ExtractTextFromScreenshot\",\n",
    "        func=extract_text_from_screenshot,\n",
    "        description=\"Extracts visible text from a screenshot using OCR.\"\n",
    "    )\n",
    "]\n",
    "\n",
    "agent = initialize_agent(\n",
    "    tools=tools,\n",
    "    llm=llm,\n",
    "    agent=AgentType.ZERO_SHOT_REACT_DESCRIPTION,\n",
    "    verbose=True\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "f2b462fa",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "ðŸ”„ Step 1\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mI need to search for 'Dafalgan EXTRA' on compendium.ch and then extract the visible text from the screenshot of the results page.\n",
      "\n",
      "Action: SearchInCompendium\n",
      "Action Input: 'Dafalgan EXTRA'\u001b[0mðŸ” Attempt 1\n",
      "Searched ''Dafalgan EXTRA'' and saved screenshot to 'edge_screenshot.png'\n",
      "ðŸ” Attempt 2\n",
      "Searched ''Dafalgan EXTRA'' and saved screenshot to 'edge_screenshot.png'\n",
      "\n",
      "Observation: \u001b[36;1m\u001b[1;3mâŒ All retries failed.\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mThe search for 'Dafalgan EXTRA' on compendium.ch failed. I can't proceed to the next step without this information.\n",
      "Final Answer: The search for 'Dafalgan EXTRA' on compendium.ch failed. I was unable to extract the visible text from the results page.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "The search for 'Dafalgan EXTRA' on compendium.ch failed. I was unable to extract the visible text from the results page.\n",
      "\n",
      "ðŸ”„ Step 2\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
      "\u001b[32;1m\u001b[1;3mI need to search for 'Dafalgan EXTRA' on compendium.ch and then extract the visible text from the screenshot of the results page.\n",
      "Action: SearchInCompendium\n",
      "Action Input: 'Dafalgan EXTRA'\u001b[0mðŸ” Attempt 1\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mKeyboardInterrupt\u001b[39m                         Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[47]\u001b[39m\u001b[32m, line 8\u001b[39m\n\u001b[32m      6\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m i \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mrange\u001b[39m(\u001b[32m3\u001b[39m):\n\u001b[32m      7\u001b[39m     \u001b[38;5;28mprint\u001b[39m(\u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[33mðŸ”„ Step \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mi+\u001b[32m1\u001b[39m\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m\"\u001b[39m)\n\u001b[32m----> \u001b[39m\u001b[32m8\u001b[39m     result = \u001b[43magent\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\u001b[43mgoal\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m      9\u001b[39m     \u001b[38;5;28mprint\u001b[39m(result)\n\u001b[32m     11\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[33m\"\u001b[39m\u001b[33mFilmtabl\u001b[39m\u001b[33m\"\u001b[39m \u001b[38;5;129;01min\u001b[39;00m result \u001b[38;5;129;01mor\u001b[39;00m \u001b[33m\"\u001b[39m\u001b[33m500/65 mg\u001b[39m\u001b[33m\"\u001b[39m \u001b[38;5;129;01min\u001b[39;00m result:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\_api\\deprecation.py:188\u001b[39m, in \u001b[36mdeprecated.<locals>.deprecate.<locals>.warning_emitting_wrapper\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m    186\u001b[39m     warned = \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[32m    187\u001b[39m     emit_warning()\n\u001b[32m--> \u001b[39m\u001b[32m188\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mwrapped\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\chains\\base.py:606\u001b[39m, in \u001b[36mChain.run\u001b[39m\u001b[34m(self, callbacks, tags, metadata, *args, **kwargs)\u001b[39m\n\u001b[32m    604\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(args) != \u001b[32m1\u001b[39m:\n\u001b[32m    605\u001b[39m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[33m\"\u001b[39m\u001b[33m`run` supports only one positional argument.\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m--> \u001b[39m\u001b[32m606\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43margs\u001b[49m\u001b[43m[\u001b[49m\u001b[32;43m0\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mcallbacks\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcallbacks\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtags\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtags\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m)\u001b[49m[\n\u001b[32m    607\u001b[39m         _output_key\n\u001b[32m    608\u001b[39m     ]\n\u001b[32m    610\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m kwargs \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m args:\n\u001b[32m    611\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m(kwargs, callbacks=callbacks, tags=tags, metadata=metadata)[\n\u001b[32m    612\u001b[39m         _output_key\n\u001b[32m    613\u001b[39m     ]\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\_api\\deprecation.py:188\u001b[39m, in \u001b[36mdeprecated.<locals>.deprecate.<locals>.warning_emitting_wrapper\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m    186\u001b[39m     warned = \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[32m    187\u001b[39m     emit_warning()\n\u001b[32m--> \u001b[39m\u001b[32m188\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mwrapped\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\chains\\base.py:389\u001b[39m, in \u001b[36mChain.__call__\u001b[39m\u001b[34m(self, inputs, return_only_outputs, callbacks, tags, metadata, run_name, include_run_info)\u001b[39m\n\u001b[32m    357\u001b[39m \u001b[38;5;250m\u001b[39m\u001b[33;03m\"\"\"Execute the chain.\u001b[39;00m\n\u001b[32m    358\u001b[39m \n\u001b[32m    359\u001b[39m \u001b[33;03mArgs:\u001b[39;00m\n\u001b[32m   (...)\u001b[39m\u001b[32m    380\u001b[39m \u001b[33;03m        `Chain.output_keys`.\u001b[39;00m\n\u001b[32m    381\u001b[39m \u001b[33;03m\"\"\"\u001b[39;00m\n\u001b[32m    382\u001b[39m config = {\n\u001b[32m    383\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mcallbacks\u001b[39m\u001b[33m\"\u001b[39m: callbacks,\n\u001b[32m    384\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mtags\u001b[39m\u001b[33m\"\u001b[39m: tags,\n\u001b[32m    385\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mmetadata\u001b[39m\u001b[33m\"\u001b[39m: metadata,\n\u001b[32m    386\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33mrun_name\u001b[39m\u001b[33m\"\u001b[39m: run_name,\n\u001b[32m    387\u001b[39m }\n\u001b[32m--> \u001b[39m\u001b[32m389\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43minvoke\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    390\u001b[39m \u001b[43m    \u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    391\u001b[39m \u001b[43m    \u001b[49m\u001b[43mcast\u001b[49m\u001b[43m(\u001b[49m\u001b[43mRunnableConfig\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[43mk\u001b[49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mv\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mk\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mv\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m.\u001b[49m\u001b[43mitems\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mv\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mis\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mnot\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m}\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    392\u001b[39m \u001b[43m    \u001b[49m\u001b[43mreturn_only_outputs\u001b[49m\u001b[43m=\u001b[49m\u001b[43mreturn_only_outputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    393\u001b[39m \u001b[43m    \u001b[49m\u001b[43minclude_run_info\u001b[49m\u001b[43m=\u001b[49m\u001b[43minclude_run_info\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    394\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\chains\\base.py:170\u001b[39m, in \u001b[36mChain.invoke\u001b[39m\u001b[34m(self, input, config, **kwargs)\u001b[39m\n\u001b[32m    168\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[32m    169\u001b[39m     run_manager.on_chain_error(e)\n\u001b[32m--> \u001b[39m\u001b[32m170\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m e\n\u001b[32m    171\u001b[39m run_manager.on_chain_end(outputs)\n\u001b[32m    173\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m include_run_info:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\chains\\base.py:160\u001b[39m, in \u001b[36mChain.invoke\u001b[39m\u001b[34m(self, input, config, **kwargs)\u001b[39m\n\u001b[32m    157\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m    158\u001b[39m     \u001b[38;5;28mself\u001b[39m._validate_inputs(inputs)\n\u001b[32m    159\u001b[39m     outputs = (\n\u001b[32m--> \u001b[39m\u001b[32m160\u001b[39m         \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_call\u001b[49m\u001b[43m(\u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    161\u001b[39m         \u001b[38;5;28;01mif\u001b[39;00m new_arg_supported\n\u001b[32m    162\u001b[39m         \u001b[38;5;28;01melse\u001b[39;00m \u001b[38;5;28mself\u001b[39m._call(inputs)\n\u001b[32m    163\u001b[39m     )\n\u001b[32m    165\u001b[39m     final_outputs: Dict[\u001b[38;5;28mstr\u001b[39m, Any] = \u001b[38;5;28mself\u001b[39m.prep_outputs(\n\u001b[32m    166\u001b[39m         inputs, outputs, return_only_outputs\n\u001b[32m    167\u001b[39m     )\n\u001b[32m    168\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1624\u001b[39m, in \u001b[36mAgentExecutor._call\u001b[39m\u001b[34m(self, inputs, run_manager)\u001b[39m\n\u001b[32m   1622\u001b[39m \u001b[38;5;66;03m# We now enter the agent loop (until it returns something).\u001b[39;00m\n\u001b[32m   1623\u001b[39m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28mself\u001b[39m._should_continue(iterations, time_elapsed):\n\u001b[32m-> \u001b[39m\u001b[32m1624\u001b[39m     next_step_output = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_take_next_step\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1625\u001b[39m \u001b[43m        \u001b[49m\u001b[43mname_to_tool_map\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1626\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcolor_mapping\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1627\u001b[39m \u001b[43m        \u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1628\u001b[39m \u001b[43m        \u001b[49m\u001b[43mintermediate_steps\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1629\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1630\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1631\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(next_step_output, AgentFinish):\n\u001b[32m   1632\u001b[39m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m._return(\n\u001b[32m   1633\u001b[39m             next_step_output, intermediate_steps, run_manager=run_manager\n\u001b[32m   1634\u001b[39m         )\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1330\u001b[39m, in \u001b[36mAgentExecutor._take_next_step\u001b[39m\u001b[34m(self, name_to_tool_map, color_mapping, inputs, intermediate_steps, run_manager)\u001b[39m\n\u001b[32m   1321\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m_take_next_step\u001b[39m(\n\u001b[32m   1322\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   1323\u001b[39m     name_to_tool_map: Dict[\u001b[38;5;28mstr\u001b[39m, BaseTool],\n\u001b[32m   (...)\u001b[39m\u001b[32m   1327\u001b[39m     run_manager: Optional[CallbackManagerForChainRun] = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m   1328\u001b[39m ) -> Union[AgentFinish, List[Tuple[AgentAction, \u001b[38;5;28mstr\u001b[39m]]]:\n\u001b[32m   1329\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m._consume_next_step(\n\u001b[32m-> \u001b[39m\u001b[32m1330\u001b[39m         \u001b[43m[\u001b[49m\n\u001b[32m   1331\u001b[39m \u001b[43m            \u001b[49m\u001b[43ma\u001b[49m\n\u001b[32m   1332\u001b[39m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43ma\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_iter_next_step\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1333\u001b[39m \u001b[43m                \u001b[49m\u001b[43mname_to_tool_map\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1334\u001b[39m \u001b[43m                \u001b[49m\u001b[43mcolor_mapping\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1335\u001b[39m \u001b[43m                \u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1336\u001b[39m \u001b[43m                \u001b[49m\u001b[43mintermediate_steps\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1337\u001b[39m \u001b[43m                \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1338\u001b[39m \u001b[43m            \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1339\u001b[39m \u001b[43m        \u001b[49m\u001b[43m]\u001b[49m\n\u001b[32m   1340\u001b[39m     )\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1330\u001b[39m, in \u001b[36m<listcomp>\u001b[39m\u001b[34m(.0)\u001b[39m\n\u001b[32m   1321\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m_take_next_step\u001b[39m(\n\u001b[32m   1322\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   1323\u001b[39m     name_to_tool_map: Dict[\u001b[38;5;28mstr\u001b[39m, BaseTool],\n\u001b[32m   (...)\u001b[39m\u001b[32m   1327\u001b[39m     run_manager: Optional[CallbackManagerForChainRun] = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m   1328\u001b[39m ) -> Union[AgentFinish, List[Tuple[AgentAction, \u001b[38;5;28mstr\u001b[39m]]]:\n\u001b[32m   1329\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m._consume_next_step(\n\u001b[32m-> \u001b[39m\u001b[32m1330\u001b[39m         \u001b[43m[\u001b[49m\n\u001b[32m   1331\u001b[39m \u001b[43m            \u001b[49m\u001b[43ma\u001b[49m\n\u001b[32m   1332\u001b[39m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43ma\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_iter_next_step\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1333\u001b[39m \u001b[43m                \u001b[49m\u001b[43mname_to_tool_map\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1334\u001b[39m \u001b[43m                \u001b[49m\u001b[43mcolor_mapping\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1335\u001b[39m \u001b[43m                \u001b[49m\u001b[43minputs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1336\u001b[39m \u001b[43m                \u001b[49m\u001b[43mintermediate_steps\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1337\u001b[39m \u001b[43m                \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1338\u001b[39m \u001b[43m            \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1339\u001b[39m \u001b[43m        \u001b[49m\u001b[43m]\u001b[49m\n\u001b[32m   1340\u001b[39m     )\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1415\u001b[39m, in \u001b[36mAgentExecutor._iter_next_step\u001b[39m\u001b[34m(self, name_to_tool_map, color_mapping, inputs, intermediate_steps, run_manager)\u001b[39m\n\u001b[32m   1413\u001b[39m     \u001b[38;5;28;01myield\u001b[39;00m agent_action\n\u001b[32m   1414\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m agent_action \u001b[38;5;129;01min\u001b[39;00m actions:\n\u001b[32m-> \u001b[39m\u001b[32m1415\u001b[39m     \u001b[38;5;28;01myield\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_perform_agent_action\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1416\u001b[39m \u001b[43m        \u001b[49m\u001b[43mname_to_tool_map\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mcolor_mapping\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43magent_action\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mrun_manager\u001b[49m\n\u001b[32m   1417\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain\\agents\\agent.py:1437\u001b[39m, in \u001b[36mAgentExecutor._perform_agent_action\u001b[39m\u001b[34m(self, name_to_tool_map, color_mapping, agent_action, run_manager)\u001b[39m\n\u001b[32m   1435\u001b[39m         tool_run_kwargs[\u001b[33m\"\u001b[39m\u001b[33mllm_prefix\u001b[39m\u001b[33m\"\u001b[39m] = \u001b[33m\"\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m   1436\u001b[39m     \u001b[38;5;66;03m# We then call the tool on the tool input to get an observation\u001b[39;00m\n\u001b[32m-> \u001b[39m\u001b[32m1437\u001b[39m     observation = \u001b[43mtool\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1438\u001b[39m \u001b[43m        \u001b[49m\u001b[43magent_action\u001b[49m\u001b[43m.\u001b[49m\u001b[43mtool_input\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1439\u001b[39m \u001b[43m        \u001b[49m\u001b[43mverbose\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mverbose\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1440\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcolor\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcolor\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1441\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcallbacks\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m.\u001b[49m\u001b[43mget_child\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01melse\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[32m   1442\u001b[39m \u001b[43m        \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mtool_run_kwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   1443\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1444\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m   1445\u001b[39m     tool_run_kwargs = \u001b[38;5;28mself\u001b[39m._action_agent.tool_run_logging_kwargs()\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\tools\\base.py:775\u001b[39m, in \u001b[36mBaseTool.run\u001b[39m\u001b[34m(self, tool_input, verbose, start_color, color, callbacks, tags, metadata, run_name, run_id, config, tool_call_id, **kwargs)\u001b[39m\n\u001b[32m    773\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m error_to_raise:\n\u001b[32m    774\u001b[39m     run_manager.on_tool_error(error_to_raise)\n\u001b[32m--> \u001b[39m\u001b[32m775\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m error_to_raise\n\u001b[32m    776\u001b[39m output = _format_output(content, artifact, tool_call_id, \u001b[38;5;28mself\u001b[39m.name, status)\n\u001b[32m    777\u001b[39m run_manager.on_tool_end(output, color=color, name=\u001b[38;5;28mself\u001b[39m.name, **kwargs)\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\tools\\base.py:744\u001b[39m, in \u001b[36mBaseTool.run\u001b[39m\u001b[34m(self, tool_input, verbose, start_color, color, callbacks, tags, metadata, run_name, run_id, config, tool_call_id, **kwargs)\u001b[39m\n\u001b[32m    742\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m config_param := _get_runnable_config_param(\u001b[38;5;28mself\u001b[39m._run):\n\u001b[32m    743\u001b[39m         tool_kwargs = tool_kwargs | {config_param: config}\n\u001b[32m--> \u001b[39m\u001b[32m744\u001b[39m     response = \u001b[43mcontext\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_run\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43mtool_args\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mtool_kwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    745\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m.response_format == \u001b[33m\"\u001b[39m\u001b[33mcontent_and_artifact\u001b[39m\u001b[33m\"\u001b[39m:\n\u001b[32m    746\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(response, \u001b[38;5;28mtuple\u001b[39m) \u001b[38;5;129;01mor\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(response) != \u001b[32m2\u001b[39m:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\Apotheker-Agents\\.venv\\Lib\\site-packages\\langchain_core\\tools\\simple.py:105\u001b[39m, in \u001b[36mTool._run\u001b[39m\u001b[34m(self, config, run_manager, *args, **kwargs)\u001b[39m\n\u001b[32m    103\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m config_param := _get_runnable_config_param(\u001b[38;5;28mself\u001b[39m.func):\n\u001b[32m    104\u001b[39m         kwargs[config_param] = config\n\u001b[32m--> \u001b[39m\u001b[32m105\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mfunc\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    106\u001b[39m msg = \u001b[33m\"\u001b[39m\u001b[33mTool does not support sync invocation.\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m    107\u001b[39m \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mNotImplementedError\u001b[39;00m(msg)\n",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[46]\u001b[39m\u001b[32m, line 6\u001b[39m, in \u001b[36m<lambda>\u001b[39m\u001b[34m(term)\u001b[39m\n\u001b[32m      1\u001b[39m llm = ChatOpenAI(temperature=\u001b[32m0\u001b[39m, model=\u001b[33m\"\u001b[39m\u001b[33mgpt-4\u001b[39m\u001b[33m\"\u001b[39m, openai_api_key=os.getenv(\u001b[33m\"\u001b[39m\u001b[33mOPENAI_KEY\u001b[39m\u001b[33m\"\u001b[39m))\n\u001b[32m      3\u001b[39m tools = [\n\u001b[32m      4\u001b[39m     Tool(\n\u001b[32m      5\u001b[39m         name=\u001b[33m\"\u001b[39m\u001b[33mSearchInCompendium\u001b[39m\u001b[33m\"\u001b[39m,\n\u001b[32m----> \u001b[39m\u001b[32m6\u001b[39m         func=\u001b[38;5;28;01mlambda\u001b[39;00m term: \u001b[43msafe_search_wrapper\u001b[49m\u001b[43m(\u001b[49m\u001b[43mterm\u001b[49m\u001b[43m)\u001b[49m,\n\u001b[32m      7\u001b[39m         description=\u001b[33m\"\u001b[39m\u001b[33mSearches compendium.ch for a medication like \u001b[39m\u001b[33m'\u001b[39m\u001b[33mDafalgan EXTRA\u001b[39m\u001b[33m'\u001b[39m\u001b[33m and takes a screenshot.\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m      8\u001b[39m     ),\n\u001b[32m      9\u001b[39m     Tool(\n\u001b[32m     10\u001b[39m         name=\u001b[33m\"\u001b[39m\u001b[33mExtractTextFromScreenshot\u001b[39m\u001b[33m\"\u001b[39m,\n\u001b[32m     11\u001b[39m         func=extract_text_from_screenshot,\n\u001b[32m     12\u001b[39m         description=\u001b[33m\"\u001b[39m\u001b[33mExtracts visible text from a screenshot using OCR.\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m     13\u001b[39m     )\n\u001b[32m     14\u001b[39m ]\n\u001b[32m     16\u001b[39m agent = initialize_agent(\n\u001b[32m     17\u001b[39m     tools=tools,\n\u001b[32m     18\u001b[39m     llm=llm,\n\u001b[32m     19\u001b[39m     agent=AgentType.ZERO_SHOT_REACT_DESCRIPTION,\n\u001b[32m     20\u001b[39m     verbose=\u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[32m     21\u001b[39m )\n",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[45]\u001b[39m\u001b[32m, line 68\u001b[39m, in \u001b[36msafe_search_wrapper\u001b[39m\u001b[34m(term, retries)\u001b[39m\n\u001b[32m     66\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m attempt \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mrange\u001b[39m(retries):\n\u001b[32m     67\u001b[39m     \u001b[38;5;28mprint\u001b[39m(\u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33mðŸ” Attempt \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mattempt\u001b[38;5;250m \u001b[39m+\u001b[38;5;250m \u001b[39m\u001b[32m1\u001b[39m\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m\"\u001b[39m)\n\u001b[32m---> \u001b[39m\u001b[32m68\u001b[39m     result = \u001b[43mopen_edge_and_search\u001b[49m\u001b[43m(\u001b[49m\u001b[43mterm\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     69\u001b[39m     \u001b[38;5;28mprint\u001b[39m(result)\n\u001b[32m     70\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[33m\"\u001b[39m\u001b[33mScreenshot saved\u001b[39m\u001b[33m\"\u001b[39m \u001b[38;5;129;01min\u001b[39;00m result:\n",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[45]\u001b[39m\u001b[32m, line 48\u001b[39m, in \u001b[36mopen_edge_and_search\u001b[39m\u001b[34m(search_term)\u001b[39m\n\u001b[32m     45\u001b[39m time.sleep(\u001b[32m0.5\u001b[39m)\n\u001b[32m     46\u001b[39m search_input.send_keys(Keys.RETURN)\n\u001b[32m---> \u001b[39m\u001b[32m48\u001b[39m \u001b[43mtime\u001b[49m\u001b[43m.\u001b[49m\u001b[43msleep\u001b[49m\u001b[43m(\u001b[49m\u001b[32;43m4\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[32m     49\u001b[39m driver.save_screenshot(SCREENSHOT_PATH)\n\u001b[32m     50\u001b[39m driver.quit()\n",
      "\u001b[31mKeyboardInterrupt\u001b[39m: "
     ]
    }
   ],
   "source": [
    "goal = \"\"\"\n",
    "Search for 'Dafalgan EXTRA' on compendium.ch, extract the visible text from the results page.\n",
    "Use tools step-by-step. Screenshot filename is 'edge_screenshot.png'.\n",
    "\"\"\"\n",
    "\n",
    "for i in range(3):\n",
    "    print(f\"\\nðŸ”„ Step {i+1}\")\n",
    "    result = agent.run(goal)\n",
    "    print(result)\n",
    "\n",
    "    if \"Filmtabl\" in result or \"500/65 mg\" in result:\n",
    "        print(\"âœ… Found product.\")\n",
    "        break\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
